,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,192,1,1,,441206,2726,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
1,248,1,1,,441206,2726,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
2,330,1,1,,441206,2726,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
3,357,2,1,,11110990,2726,Inconclusive,,,,,AP1 Signaling Pathway,Confirmatory,,
4,357,2,1,,11110991,2726,Inconclusive,,,,,AP1 Signaling Pathway,Confirmatory,,
5,410,1,5,,11110990,2726,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
6,410,1,5,,11110991,2726,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
7,411,2,1,,11110990,2726,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
8,411,2,1,,11110991,2726,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
9,444,1,1,,11110990,2726,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
10,444,1,1,,11110991,2726,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
11,445,3,1,,11110990,2726,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
12,445,3,1,,11110991,2726,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
13,446,1,1,,11110990,2726,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
14,446,1,1,,11110991,2726,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
15,447,1,1,,11110990,2726,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
16,447,1,1,,11110991,2726,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
17,448,1,2,,11110990,2726,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
18,448,1,2,,11110991,2726,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
19,450,1,2,,11110990,2726,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
20,450,1,2,,11110991,2726,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
21,451,1,2,,11110990,2726,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
22,451,1,2,,11110991,2726,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
23,526,1,1,,11110990,2726,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
24,526,1,1,,11110991,2726,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
25,530,1,1,,11110990,2726,Inconclusive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
26,530,1,1,,11110991,2726,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
27,584,1,3,,11110990,2726,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
28,584,1,3,,11110991,2726,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
29,585,1,4,,11110990,2726,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
30,585,1,4,,11110991,2726,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
31,587,1,5,,11110990,2726,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
32,587,1,5,,11110991,2726,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
33,588,1,4,,11110990,2726,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
34,588,1,4,,11110991,2726,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
35,589,1,3,,11110990,2726,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
36,589,1,3,,11110991,2726,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
37,590,1,3,,11110990,2726,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
38,590,1,3,,11110991,2726,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
39,591,1,4,,11110990,2726,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
40,591,1,4,,11110991,2726,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
41,592,1,6,,11110990,2726,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
42,592,1,6,,11110991,2726,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
43,593,1,4,,11110990,2726,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
44,593,1,4,,11110991,2726,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
45,594,1,4,,11110990,2726,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
46,594,1,4,,11110991,2726,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
47,595,1,3,,11110990,2726,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
48,595,1,3,,11110991,2726,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
49,596,1,2,,11110990,2726,Active,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
50,596,1,2,,11110991,2726,Active,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
51,597,1,3,,11110990,2726,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
52,597,1,3,,11110991,2726,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
53,603,1,2,,11110990,2726,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
54,603,1,2,,11110991,2726,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
55,605,1,2,,11110990,2726,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
56,605,1,2,,11110991,2726,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
57,607,1,3,,11110990,2726,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
58,607,1,3,,11110991,2726,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
59,662,1,1,,11110990,2726,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
60,662,1,1,,11110991,2726,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
61,875,1,2,,11110990,2726,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
62,875,1,2,,11110991,2726,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
63,879,1,2,,11110990,2726,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
64,879,1,2,,11110990,2726,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
65,880,2,1,,11110991,2726,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
66,880,2,1,,11110991,2726,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
67,880,2,1,,26747094,2726,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
68,880,2,1,,26747094,2726,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
69,880,2,1,,26751621,2726,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
70,880,2,1,,26751621,2726,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
71,881,2,2,,11110990,2726,Inactive,317373425.0,247.0,10.0,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
72,881,2,2,,11110991,2726,Inactive,317373425.0,247.0,12.5893,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
73,883,1,3,,11110990,2726,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
74,883,1,3,,11110991,2726,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
75,884,1,2,,11110990,2726,Inconclusive,13435386.0,1576.0,1.0,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
76,884,1,2,,11110991,2726,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
77,885,1,2,,11110990,2726,Inactive,13435386.0,1576.0,1.0,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
78,885,1,2,,11110991,2726,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
79,886,1,2,,11110990,2726,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
80,886,1,2,,11110990,2726,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
81,886,1,2,,11110991,2726,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
82,886,1,2,,11110991,2726,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
83,887,1,2,,11110990,2726,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
84,887,1,2,,11110991,2726,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
85,889,1,3,,11110990,2726,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
86,889,1,3,,11110991,2726,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
87,891,1,2,,11110990,2726,Active,40805836.0,1565.0,0.3981,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
88,891,1,2,,11110991,2726,Active,40805836.0,1565.0,0.1585,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
89,892,1,2,,11110990,2726,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
90,892,1,2,,11110991,2726,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
91,893,1,2,,11110990,2726,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
92,893,1,2,,11110990,2726,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
93,893,1,2,,11110991,2726,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
94,893,1,2,,11110991,2726,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
95,894,2,1,,11110991,2726,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
96,894,2,1,,26747094,2726,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
97,895,1,2,,11110990,2726,Inconclusive,21620132.0,4790.0,28.1838,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
98,899,1,2,,11110990,2726,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
99,899,1,2,,11110991,2726,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
100,900,1,3,,11110990,2726,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
101,900,1,3,,11110991,2726,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
102,901,1,2,,11110990,2726,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
103,901,1,2,,11110991,2726,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
104,902,1,2,,11110990,2726,Active,120407068.0,7157.0,10.0,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
105,902,1,2,,11110991,2726,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
106,912,1,2,,11110990,2726,Inconclusive,21392848.0,,19.9526,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
107,912,1,2,,11110991,2726,Inconclusive,21392848.0,,10.0,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
108,914,1,3,,11110990,2726,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
109,914,1,3,,11110991,2726,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
110,915,1,3,,11110990,2726,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
111,915,1,3,,11110991,2726,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
112,917,1,3,,11110990,2726,Inconclusive,120660324.0,7066.0,12.5893,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
113,918,1,3,,11110990,2726,Active,120660324.0,7066.0,12.5893,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
114,923,1,2,,11110990,2726,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
115,923,1,2,,11110991,2726,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
116,924,1,2,,11110990,2726,Inconclusive,120407068.0,7157.0,19.9526,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
117,924,1,2,,11110991,2726,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
118,925,1,2,,11110990,2726,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
119,925,1,2,,11110991,2726,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
120,926,1,2,,11110990,2726,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
121,926,1,2,,11110991,2726,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
122,927,1,3,,11110990,2726,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
123,927,1,3,,11110991,2726,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
124,928,1,2,,11110990,2726,Inconclusive,21620132.0,4790.0,28.1838,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
125,938,1,2,,11110990,2726,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
126,938,1,2,,11110991,2726,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
127,940,1,2,,26611657,2726,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
128,943,1,2,,11110990,2726,Active,18249941.0,25229.0,0.5623,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
129,944,1,2,,11110990,2726,Active,18249941.0,25229.0,1.5849,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
130,945,1,4,,11110990,2726,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
131,954,1,2,,11110990,2726,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
132,957,1,2,,11110990,2726,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
133,958,1,2,,11110990,2726,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
134,959,1,4,,11110990,2726,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
135,992,1,3,,11110990,2726,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
136,995,1,2,,11110990,2726,Inconclusive,66932916.0,5594.0,15.8489,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
137,995,1,2,,11110991,2726,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
138,997,1,2,,11110990,2726,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
139,998,1,2,,11110990,2726,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
140,1030,2,1,,11110991,2726,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
141,1030,2,1,,26747094,2726,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
142,1030,2,1,,26751621,2726,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
143,1195,1,2,,48415768,2726,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
144,1332,1,1,,49698686,2726,Active,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
145,1379,1,2,,11110991,2726,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
146,1379,1,2,,26747094,2726,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
147,1422,1,1,,26611657,2726,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
148,1452,1,1,,11110990,2726,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
149,1452,1,1,,11110991,2726,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
150,1454,1,1,,11110991,2726,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
151,1454,1,1,,26747094,2726,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
152,1457,1,1,,11110991,2726,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
153,1457,1,1,,26747094,2726,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
154,1457,1,1,,26751621,2726,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
155,1458,1,1,,11110991,2726,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
156,1458,1,1,,26747094,2726,Inactive,10937869.0,6607.0,10.0,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
157,1458,1,1,,26751621,2726,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
158,1460,1,3,,26747094,2726,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
159,1460,1,3,,26751621,2726,Inconclusive,92096784.0,4137.0,28.1838,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
160,1463,1,1,,26747094,2726,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
161,1463,1,1,,26751621,2726,Inconclusive,,,28.1838,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
162,1467,1,3,,11110991,2726,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
163,1467,1,3,,26747094,2726,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
164,1468,1,1,,26747094,2726,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
165,1468,1,1,,26751621,2726,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
166,1469,1,1,,11110991,2726,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
167,1469,1,1,,26747094,2726,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
168,1469,1,1,,26751621,2726,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
169,1471,2,1,,11110990,2726,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
170,1471,2,1,,11110991,2726,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
171,1471,2,1,,26747094,2726,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
172,1471,2,1,,26751621,2726,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
173,1476,2,1,,11110991,2726,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
174,1476,2,1,,26747094,2726,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
175,1477,1,1,,11110991,2726,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
176,1477,1,1,,26747094,2726,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
177,1477,1,1,,26751621,2726,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
178,1478,2,1,,11110991,2726,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
179,1478,2,1,,26747094,2726,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
180,1479,1,2,,11110991,2726,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
181,1479,1,2,,26747094,2726,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
182,1479,1,2,,26751621,2726,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
183,1487,1,1,,11110991,2726,Inconclusive,27436948.0,4000.0,7.0795,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
184,1487,1,1,,26751621,2726,Inconclusive,27436948.0,4000.0,0.2239,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
185,1490,2,1,,11110991,2726,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
186,1490,2,1,,26747094,2726,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
187,1490,2,1,,26751621,2726,Active,10954339.0,,79.4328,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
188,1519,1,3,,11110991,2726,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
189,1519,1,3,,26747094,2726,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
190,1580,1,1,,8149253,2726,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
191,1581,1,1,,8149253,2726,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
192,1582,1,1,,8149253,2726,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
193,1583,1,1,,8149253,2726,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
194,1584,1,1,,8149253,2726,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
195,1585,1,1,,8149253,2726,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
196,1586,1,1,,8149253,2726,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
197,1587,1,1,,8149253,2726,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
198,1588,1,1,,8149253,2726,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
199,1589,1,1,,8149253,2726,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
200,1590,1,1,,8149253,2726,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
201,1593,1,1,,8149253,2726,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
202,1594,1,1,,8149253,2726,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
203,1595,1,1,,8149253,2726,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
204,1596,1,1,,8149253,2726,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
205,1597,1,1,,8149253,2726,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
206,1598,1,1,,8149253,2726,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
207,1599,1,1,,8149253,2726,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
208,1600,1,1,,8149253,2726,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
209,1601,1,1,,8149253,2726,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
210,1602,1,1,,8149253,2726,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
211,1603,1,1,,8149253,2726,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
212,1604,1,1,,8149253,2726,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
213,1605,1,1,,8149253,2726,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
214,1606,1,1,,8149253,2726,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
215,1607,1,1,,8149253,2726,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
216,1608,1,1,,8149253,2726,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
217,1609,1,1,,8149253,2726,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
218,1610,1,1,,8149253,2726,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
219,1612,1,1,,8149253,2726,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
220,1613,1,1,,8149253,2726,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
221,1614,1,1,,8149253,2726,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
222,1616,1,1,,8149253,2726,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
223,1688,1,1,,26751621,2726,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
224,1766,1,1,,11110991,2726,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
225,1766,1,1,,11110991,2726,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
226,1766,1,1,,26747094,2726,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
227,1766,1,1,,26747094,2726,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
228,1766,1,1,,26751621,2726,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
229,1766,1,1,,26751621,2726,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
230,1768,1,1,,11110991,2726,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
231,1768,1,1,,11110991,2726,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
232,1768,1,1,,26747094,2726,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
233,1768,1,1,,26747094,2726,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
234,1768,1,1,,26751621,2726,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
235,1768,1,1,,26751621,2726,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
236,1851,1,2,,11110990,2726,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
237,1851,1,2,,11110991,2726,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
238,1851,1,2,1.0,11110990,2726,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
239,1851,1,2,1.0,11110991,2726,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
240,1851,1,2,2.0,11110990,2726,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
241,1851,1,2,2.0,11110991,2726,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
242,1851,1,2,3.0,11110990,2726,Inconclusive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
243,1851,1,2,3.0,11110991,2726,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
244,1851,1,2,4.0,11110990,2726,Active,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
245,1851,1,2,4.0,11110991,2726,Active,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
246,1851,1,2,5.0,11110990,2726,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
247,1851,1,2,5.0,11110991,2726,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
248,1865,1,1,,11110991,2726,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
249,1865,1,1,,26747094,2726,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
250,1865,1,1,,26751621,2726,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
251,1948,1,1,,11110991,2726,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
252,1948,1,1,,26747094,2726,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
253,2062,1,2,,85209020,2726,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
254,2101,1,1,,11110991,2726,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
255,2101,1,1,,26747094,2726,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
256,2101,1,1,,26751621,2726,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
257,2107,1,1,,11110991,2726,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
258,2107,1,1,,26747094,2726,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
259,2107,1,1,,26751621,2726,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
260,2112,1,1,,11110991,2726,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
261,2112,1,1,,26747094,2726,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
262,2112,1,1,,26751621,2726,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
263,2147,1,1,,11110991,2726,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
264,2147,1,1,,26747094,2726,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
265,2451,1,2,,11110991,2726,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
266,2451,1,2,,26747094,2726,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
267,2472,1,2,,11110991,2726,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
268,2472,1,2,,26747094,2726,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
269,2517,2,1,,11110991,2726,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
270,2517,2,1,,26747094,2726,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
271,2517,2,1,,26751621,2726,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
272,2528,1,2,,11110991,2726,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
273,2528,1,2,,26747094,2726,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
274,2528,1,2,,26751621,2726,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
275,2546,1,1,,11110991,2726,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
276,2546,1,1,,26747094,2726,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
277,2546,1,1,,26751621,2726,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
278,2549,1,1,,11110991,2726,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
279,2549,1,1,,26747094,2726,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
280,2549,1,1,,26751621,2726,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
281,2551,1,1,,11110991,2726,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
282,2551,1,1,,26747094,2726,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
283,2551,1,1,,26751621,2726,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
284,2660,1,1,,90340916,2726,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
285,2666,1,1,,90340916,2726,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
286,2667,1,1,,90340916,2726,Inconclusive,4826730.0,2475.0,16.4816,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
287,2668,1,1,,90340916,2726,Inconclusive,4826730.0,2475.0,26.1216,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
288,2808,1,2,,57287810,2726,Inactive,83699673.0,27035.0,17.0,IC50,Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Purchased analogs,Confirmatory,,
289,3479,7,1,,103169389,2726,Active,,,0.6729999999999999,Ki,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Confirmatory,8097537.0,
290,3663,7,1,,103169389,2726,Unspecified,,,1.0,IC50,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Confirmatory,2542551.0,
291,3699,7,1,,103169389,2726,Unspecified,,,1.0,Ki,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,Confirmatory,1346653.0,
292,3717,7,1,,103169389,2726,Active,,,0.37200000000000005,IC50,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,Confirmatory,2542551.0,
293,4363,7,1,,103169389,2726,Active,,,0.179,Ki,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,Confirmatory,1346653.0,
294,5042,7,2,,103169389,2726,Active,,,0.00331,Ki,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,Confirmatory,7907148.0,
295,5055,7,1,,103169389,2726,Active,,,0.0088,IC50,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,Confirmatory,2542551.0,
296,5123,9,2,,103169389,2726,Active,,,0.0033,Ki,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,Confirmatory,8101877.0,
297,5229,7,2,,103169389,2726,Active,,,0.0007,Ki,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,Confirmatory,1346653.0,
298,6563,7,2,,103169389,2726,Active,,,0.004,Ki,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Confirmatory,12825922.0,
299,6648,7,2,,103169389,2726,Active,,,0.021,Ki,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,Confirmatory,12825922.0,
300,7783,3,4,,103169389,2726,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
301,8002,5,2,,103169389,2726,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
302,19262,5,1,,103169389,2726,Unspecified,,,,,Aqueous solubility,Other,10866370.0,
303,19424,3,4,,103169389,2726,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
304,22293,4,4,,103169389,2726,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
305,23957,3,3,,103169389,2726,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
306,23958,3,3,,103169389,2726,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
307,23960,3,3,,103169389,2726,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
308,23962,4,3,,103169389,2726,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
309,23964,4,3,,103169389,2726,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
310,23966,4,3,,103169389,2726,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
311,23968,4,3,,103169389,2726,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
312,23970,4,3,,103169389,2726,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
313,23973,4,3,,103169389,2726,Unspecified,,,,,"Partition coefficient (logD, measured by HPLC, log k')",Other,6167716.0,
314,23976,4,3,,103169389,2726,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
315,25603,4,4,,103169389,2726,Unspecified,,,,,Dissociation constant was reported,Other,7310811.0,
316,26296,4,4,,103169389,2726,Unspecified,,,,,Partition coefficient (logD7.4),Other,6167716.0,
317,26304,4,4,,103169389,2726,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
318,26310,4,4,,103169389,2726,Unspecified,,,,,Partition coefficient (logD7.4),Other,6167716.0,
319,26311,3,3,,103169389,2726,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
320,26362,4,3,,103169389,2726,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
321,26396,3,4,,103169389,2726,Unspecified,,,,,Partition coefficient (logD7.4),Other,6167716.0,
322,27370,6,2,,103169389,2726,Unspecified,,,,,Lethal dose after peroral administration in mouse,Other,2869146.0,
323,28233,3,3,,103169389,2726,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
324,28234,3,4,,103169389,2726,Unspecified,,,,,% absorbed in human GI-tract,Other,11300874.0,
325,28235,3,3,,103169389,2726,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
326,28236,3,3,,103169389,2726,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
327,28679,3,4,,103169389,2726,Unspecified,,,,,Partition coefficient (logD6.8),Other,11300874.0,
328,28921,3,3,,103169389,2726,Unspecified,,,,,Partition coefficient (logP) (hexadecane),Other,11300874.0,
329,28923,3,4,,103169389,2726,Unspecified,,,,,Effective permeability measured with Caco-2 cells,Other,11300874.0,
330,28924,3,3,,103169389,2726,Unspecified,,,,,Effective permeability (Pe) across a hexadecane membrane (pH 6.8),Other,11300874.0,
331,28925,3,3,,103169389,2726,Unspecified,,,,,Highest effective permeability across hexadecane membrane (pH 4-8),Other,11300874.0,
332,28926,3,3,,103169389,2726,Unspecified,,,,,Effective permeability corrected for ionization,Other,11300874.0,
333,28928,3,3,,103169389,2726,Unspecified,,,,,Intrinsic permeability of the compound,Other,11300874.0,
334,29139,4,3,,103169389,2726,Unspecified,,,,,"Calculated dissociation constant (pKa, calculated with ACD/pKa)",Other,12477351.0,
335,29140,4,3,,103169389,2726,Unspecified,,,,,Apparent value (pKa) calculated with ACD/pKa (experimental pKa value),Other,12477351.0,
336,29359,3,3,,103169389,2726,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
337,29423,3,4,,103169389,2726,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
338,29811,4,3,,103169389,2726,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
339,29925,5,2,,103169389,2726,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
340,34442,6,5,,103169389,2726,Active,,,1.3,IC50,Inhibitory concentration against Dopamine sensitive adenylate cyclase in rats,Confirmatory,6106062.0,
341,34454,9,3,,103169389,2726,Active,,,0.11800000000000001,Ki,Inhibitory activity against Dopamine sensitive adenylate cyclase in rats,Confirmatory,6106062.0,
342,35436,7,1,,103169389,2726,Active,,,0.0055,Ki,The compound was tested for its binding affinity towards alpha-1 adrenergic receptor by displacing [3H]WB-4101 radioligand in rat cerebral cortexc,Confirmatory,1346653.0,
343,36588,7,2,,103169389,2726,Active,,,0.031,IC50,Ability to bind at Alpha-1 adrenergic receptor by displacing [3H]WB-4101,Confirmatory,2542551.0,
344,36847,7,2,,103169389,2726,Active,,,0.031,IC50,In vitro affinity for cortical alpha-1 adrenergic receptor labelled with [3H]WB-4101,Confirmatory,2869146.0,
345,42112,3,3,,103169389,2726,Unspecified,,,,,BSA binding (log K),Other,6167716.0,
346,45980,6,3,,103169389,2726,Active,,,0.01,Ki,Compound was evaluated for the inhibition of [3H]haloperidol binding in calf brain homogenates,Confirmatory,7252977.0,
347,49902,4,3,,103169389,2726,Unspecified,,,,,Reduction of the integrated electromyographic response by 50% in cat after intravenous administration,Other,7392031.0,
348,49904,4,3,,103169389,2726,Unspecified,,,,,Reduction of the integrated electromyographic response by 50% in cat after peroral administration,Other,7392031.0,
349,51937,5,6,,103169389,2726,Active,7531135.0,3757.0,1.47,IC50,K+ channel blocking activity in Chinese hamster ovary cells expressing HERG Kv11.1,Confirmatory,12190308.0,
350,59858,6,2,,103169389,2726,Unspecified,,,,,Inhibition of apomorphine induced emesis in dogs when administered perorally,Other,2891853.0,
351,60528,3,3,,103169389,2726,Unspecified,,,,,Inhibition of apomorphine induced emesis in dogs at 2 mg/kg of dose.,Other,2891853.0,
352,61079,7,2,,103169389,2726,Active,,,0.002,Ki,Binding affinity against dopamine D2 receptor,Confirmatory,7907148.0,
353,61197,8,5,,103169389,2726,Active,118229.0,24316.0,0.00215,IC50,Binding affinity against Dopamine receptor D1 by using [3H]SCH-23390 as radioligand,Confirmatory,7830274.0,
354,61326,7,2,,103169389,2726,Active,,,0.04,IC50,Compound was tested in vitro for its affinity towards rat striatal Dopamine receptor D2 labeled with [3H]- spiperone,Confirmatory,2869146.0,
355,61348,5,3,,103169389,2726,Inconclusive,,,,,Binding affinity of compound towards dopamine receptor D1 was determined in rat striatal homogenate using [3H]SCH-23390 as radioligand; '-' means not tested,Other,8558526.0,
356,61381,7,3,,103169389,2726,Active,,,0.04,IC50,Ability to bind at dopamine receptor D2 of rat corpus striatum by displacing [3H]spiperone,Confirmatory,2542551.0,
357,61503,8,5,,103169389,2726,Active,118229.0,24316.0,0.05,Ki,"Inhibition of [3H]SCH-23,390 binding to Dopamine receptor D1 at 0.25 nM",Confirmatory,3050089.0,
358,61521,9,1,,103169389,2726,Active,,,0.035,Ki,In vitro binding affinity against Dopamine receptor D1 in rat striatal tissue,Confirmatory,8101877.0,
359,62164,9,1,,103169389,2726,Active,,,0.08,IC50,"Competition in vitro with the dopamine receptor D2 antagonist [3H]spiperone, for binding sites on calf caudate membranes.",Confirmatory,8096548.0,
360,62431,11,1,,103169389,2726,Active,,,0.025,IC50,Compound was tested for inhibition of [3H]spiperone binding in membrane preparations obtained from calf caudate.,Confirmatory,6105219.0,
361,62443,8,2,,103169389,2726,Active,,,0.034,IC50,Inhibition of binding of 1.6 nM [3H]haloperidol to dopamine receptor by 50%,Confirmatory,7288826.0,
362,62444,8,2,,103169389,2726,Active,,,2.5,IC50,Inhibition of binding of 5 nM [3H]dopamine to dopamine receptor by 50%,Confirmatory,7288826.0,
363,62445,9,2,,103169389,2726,Active,,,2.5,IC50,Inhibition of [3H]dopamine binding to Dopamine receptor in calf caudate nuclei.,Confirmatory,6106063.0,
364,62446,9,2,,103169389,2726,Active,,,0.034,IC50,Inhibition of [3H]haloperidol binding to Dopamine receptor in calf caudate nuclei.,Confirmatory,6106063.0,
365,62454,11,1,,103169389,2726,Active,,,0.025,IC50,compound was tested for its ability to displace [3H]- spiroperidol from dopamine receptor.,Confirmatory,6123599.0,
366,62465,3,8,,103169389,2726,Unspecified,,,,,Ratio of IC50 evaluated by using [3H]DA to [3H]-HP,Other,7288826.0,
367,62581,7,1,,103169389,2726,Active,,,,,Dopamine receptor antagonist activity in the superfused rabbit ear artery preparation,Other,7252977.0,
368,62723,7,1,,103169389,2726,Active,,,0.077,IC50,Ability to inhibit the binding of [3H]spiroperidol in rat striatal tissue,Confirmatory,2861286.0,
369,62730,11,1,,103169389,2726,Active,,,0.11199999999999999,IC50,Compound was tested for inhibition of [3H]spiperone binding in membrane preparations obtained from rat corpus striatum.,Confirmatory,6105219.0,
370,62736,7,3,,103169389,2726,Active,,,0.051,IC50,Affinity for Dopamine receptors in the rat striatum using [3H]spiroperidol displacement.,Confirmatory,2876102.0,
371,62737,7,2,,103169389,2726,Active,,,0.051,IC50,Ability to displace [3H]spiroperidol from labeled Dopamine receptor of corpus striatum,Confirmatory,2876105.0,
372,62859,9,2,,103169389,2726,Active,,,0.031,IC50,Concentration inhibiting the specific binding of [3H]spiroperidol by 50%,Confirmatory,6198519.0,
373,62860,7,1,,103169389,2726,Active,,,0.111,IC50,Concentration of compound for 50% displacement of [3H]spiperone from Dopamine receptor in rat brain,Confirmatory,6249933.0,
374,62879,7,2,,103169389,2726,Active,,,0.0389,IC50,Tested for displacement of rat caudate dopamine receptors by using [3H]apomorphine as radioligand,Confirmatory,6132009.0,
375,62880,7,2,,103169389,2726,Active,,,0.00988,IC50,Tested for displacement of rat caudate dopamine receptors by using [3H]spiperone as radioligand,Confirmatory,6132009.0,
376,62883,7,5,,103169389,2726,Active,118211.0,29238.0,0.051,IC50,Displacement of [3H]spiroperidol from dopamine receptor of rat corpus striatum homogenate,Confirmatory,6104732.0,
377,62883,7,5,,103169389,2726,Active,118229.0,24316.0,0.051,IC50,Displacement of [3H]spiroperidol from dopamine receptor of rat corpus striatum homogenate,Confirmatory,6104732.0,
378,62883,7,5,,103169389,2726,Active,118251.0,25195.0,0.051,IC50,Displacement of [3H]spiroperidol from dopamine receptor of rat corpus striatum homogenate,Confirmatory,6104732.0,
379,62883,7,5,,103169389,2726,Active,6226851.0,25432.0,0.051,IC50,Displacement of [3H]spiroperidol from dopamine receptor of rat corpus striatum homogenate,Confirmatory,6104732.0,
380,62883,7,5,,103169389,2726,Active,47117674.0,24318.0,0.051,IC50,Displacement of [3H]spiroperidol from dopamine receptor of rat corpus striatum homogenate,Confirmatory,6104732.0,
381,63020,7,2,,103169389,2726,Active,,,0.013999999999999999,Ki,In vitro ability to displace [3H]spiroperidol from rat dopamine receptor,Confirmatory,7154006.0,
382,63036,3,8,,103169389,2726,Unspecified,,,,,Compound was evaluated for its binding affinity towards Dopamine receptor,Other,2579238.0,
383,63371,7,2,,103169389,2726,Active,,,0.035480000000000005,Ki,Binding affinity against dopamine receptor D1,Confirmatory,7907148.0,
384,63500,6,2,,103169389,2726,Unspecified,,,,,"Antagonistic activity against apomorphine-induced emesis, after 5 hour of peroral administration in dogs",Other,2571727.0,
385,64154,9,1,,103169389,2726,Active,,,0.00201,Ki,In vitro binding affinity against Dopamine D2 receptor in rat striatal tissue.,Confirmatory,8101877.0,
386,64165,4,6,,103169389,2726,Unspecified,,,,,Intrinsic activity from GTP shift using membranes from CHO cells transfected with mammalian dopamine receptor D2.,Other,8097537.0,
387,64781,3,6,,103169389,2726,Active,,,,,Binding affinity of compound towards Dopamine receptor D2 was determined in rat striatal homogenate using [3H]- spiperone as radioligand,Other,8558526.0,
388,64785,3,6,,103169389,2726,Active,,,,,"The compound is evaluated for the affinity towards Dopamine receptor D2, using [3H]-spiperone as ligand on rat striatal membranes.",Other,9216832.0,
389,65133,8,5,,103169389,2726,Active,1169206.0,1814.0,0.003,Ki,Displacement of [125I]iodosulpiride from human Dopamine receptor D3 expressed in CHO cells,Confirmatory,14521403.0,
390,65257,8,5,,103169389,2726,Active,47117674.0,24318.0,0.0049700000000000005,Ki,Inhibition of [3H]spiperone binding to Dopamine receptor D2 at 0.02 nM,Confirmatory,3050089.0,
391,65261,9,1,,103169389,2726,Active,,,0.0017699999999999999,Ki,"Compound was evaluated for binding affinity towards Dopamine receptor D2 in striatal membranes, using [3H]- spiperone as radioligand in the absence of sodium chloride",Confirmatory,1827843.0,
392,65267,9,1,,103169389,2726,Active,,,0.0021899999999999997,Ki,"Compound was evaluated for binding affinity towards Dopamine receptor D2 in striatal membranes, using [3H]- spiperone as radioligand in the presence of sodium chloride",Confirmatory,1827843.0,
393,65405,7,1,,103169389,2726,Active,,,0.003,Ki,"Compound was evaluated for the binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells",Confirmatory,8097537.0,
394,65421,7,2,,103169389,2726,Active,,,0.0012,Ki,Compound was tested for inhibitory activity against the binding of [3H]spiperone to Dopamine receptor D2 in rat striatal membranes,Confirmatory,2887659.0,
395,65726,11,1,,103169389,2726,Active,,,0.01,Ki,In vitro binding affinity for dopamine receptor D2 of rat nucleus accumbens labeled with [3H]spiperone,Confirmatory,2884314.0,
396,65827,6,2,,103169389,2726,Active,,,0.079,Ki,Inhibition of dopamine-stimulated adenylate cyclase obtained from rat corpus striatum was determined by the conversion of [32P]ATP to [32P]-cAMP,Confirmatory,3050089.0,
397,65886,9,2,,103169389,2726,Active,,,0.05,Ki,Tested for Competitive binding inhibition of [3H]spiperone to Dopamine receptor D2 in rat striatal membrane.,Confirmatory,,
398,65908,7,2,,103169389,2726,Active,,,0.0078,Ki,Binding affinity towards dopamine receptor D2 by displacing [3H]spiperone radioligand in rat striatum,Confirmatory,1346653.0,
399,75299,5,4,,103169389,2726,Inactive,,,,,Inhibitory activity against human erythrocyte glutathione reductase; '*' indicates No inhibition,Other,9457238.0,
400,75426,3,9,,103169389,2726,Inactive,,,,,Compound at 1 mM was tested for the inhibition of human erythrocyte glutathione reductase; No inhibition,Other,10956223.0,
401,88403,3,4,,103169389,2726,Unspecified,,,,,In Vitro evaluation on percentage inhibition in Heme Oxygenase at concentration 100 (uM) of Cell-free parasite Plasmodium yoelii,Other,10978190.0,
402,88410,3,4,,103169389,2726,Unspecified,,,,,In Vitro inhibition of Heme Oxygenase in Cell-free parasite Plasmodium yoelii at concentration 50 uM,Other,10978190.0,
403,91481,4,7,,103169389,2726,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
404,92844,6,2,,103169389,2726,Unspecified,,,155.7,IC50,Concentration required to inhibit ADP-induced platelet aggregation by 50%,Confirmatory,1501222.0,
405,103232,4,4,,103169389,2726,Unspecified,,,,,Anti MDR activity was expressed as MDR ratio or MDR fold reversal in doxorubicin resistant human breast carcinoma tumor cell line MCF-7/DOX,Other,9599232.0,
406,108860,3,3,,103169389,2726,Active,,,,,Relative CNS activity of compound was measured in mice (+++ =for activity in > 6 assays),Other,6106063.0,
407,111333,4,2,,103169389,2726,Active,,,,,Relative central nervous system(CNS) activity was measured in mice; Activity in >=6 assays,Other,7288826.0,
408,111824,3,3,,103169389,2726,Unspecified,,,,,"Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 0.31 mg/kg",Other,6716406.0,
409,111825,3,3,,103169389,2726,Unspecified,,,,,"Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 0.63 mg/kg",Other,6716406.0,
410,111826,3,3,,103169389,2726,Unspecified,,,,,"Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 1.25 mg/kg",Other,6716406.0,
411,111830,3,3,,103169389,2726,Unspecified,,,,,"Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 2.5 mg/kg",Other,6716406.0,
412,111841,3,3,,103169389,2726,Unspecified,,,,,"Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 5 mg/kg",Other,6716406.0,
413,112708,4,3,,103169389,2726,Unspecified,,,,,Hypothermia in mice after perorla administration,Other,6105217.0,
414,112952,6,2,,103169389,2726,Unspecified,,,,,Compound was tested for inhibition of norepinephrine lethality in mouse when administered perorally,Other,2869146.0,
415,112955,6,2,,103169389,2726,Unspecified,,,,,Compound was tested for inhibition of spontaneous motor activity in mouse when administered perorally,Other,2869146.0,
416,113146,7,2,,103169389,2726,Unspecified,,,,,Compound was tested orally (po) in rats for antagonism of stereotypies induced by amphetamine,Other,6134833.0,
417,113543,7,2,,103169389,2726,Unspecified,,,,,Induction of catalepsy in mice,Other,9513593.0,
418,113713,7,2,,103169389,2726,Unspecified,,,,,Inhibition of the APO-induced stereotyped behavior in mice,Other,9513593.0,
419,113716,5,2,,103169389,2726,Inactive,,,,,Inhibition of the GBL-induced increase in DOPA accumulation in mice(DA auto receptor agonist activity); IA = inactive,Other,9513593.0,
420,113718,5,2,,103169389,2726,Inactive,,,,,Inhibition of the GBL-induced increase in DOPA synthesis in mice; IA = inactive,Other,9513593.0,
421,113719,7,8,,103169389,2726,Unspecified,3023234.0,11548.0,,,Inhibition of noradrenaline lethal effects in mice as alpha-1 induced adrenoceptor antagonist activity,Other,9513593.0,
422,113719,7,8,,103169389,2726,Unspecified,3121722.0,11550.0,,,Inhibition of noradrenaline lethal effects in mice as alpha-1 induced adrenoceptor antagonist activity,Other,9513593.0,
423,113719,7,8,,103169389,2726,Unspecified,341940608.0,11549.0,,,Inhibition of noradrenaline lethal effects in mice as alpha-1 induced adrenoceptor antagonist activity,Other,9513593.0,
424,113874,6,2,,103169389,2726,Unspecified,,,,,Intraperitoneal dose required for antagonism of d-amphetamine lethality in grouped mice (GAL),Other,6103960.0,
425,114076,7,3,,103169389,2726,Unspecified,,,,,post-synaptic dopamine autoreceptor antagonist activity evaluated by inhibition of the apomorphine-induced stereotyped behavior in mice.,Other,9513593.0,
426,114407,6,2,,103169389,2726,Unspecified,,,,,Anticonvulsant activity to prevent pentamethylenetetrazole (MTZ) induced lethality in mice after oral administration,Other,6103962.0,
427,114415,6,2,,103169389,2726,Unspecified,,,,,Antipsychotic activity to prevent amphetamine induced lethality in mice after oral administration,Other,6103962.0,
428,114482,7,2,,103169389,2726,Unspecified,,,,,Compound (administered intraperitoneally) was assessed for neuroleptic activity to antagonize methyl phenidate induced stereotypes in mice,Other,6134833.0,
429,115755,5,2,,103169389,2726,Inactive,,,,,Minimum effective dose was measured orally by antagonism of tetrabenazine-induced depression in mice(po); inact means compound is inactive.,Other,6103960.0,
430,116898,7,2,,103169389,2726,Unspecified,,,,,Lethal dose in mice after perorla administration,Other,6105217.0,
431,118787,3,3,,103169389,2726,Unspecified,,,,,Retention for passive avoidance learning in mice at dose 1.25 mg/kg,Other,7265121.0,
432,118789,3,3,,103169389,2726,Unspecified,,,,,Retention for passive avoidance learning in mice at dose 2.5 mg/kg,Other,7265121.0,
433,118793,3,3,,103169389,2726,Unspecified,,,,,Retention for passive avoidance learning in mice at dose 5 mg/kg,Other,7265121.0,
434,128162,6,2,,103169389,2726,Unspecified,,,,,"Activity of inclined screen in mouse, after 1 hour of peroral administration in mouse",Other,2571727.0,
435,128163,6,2,,103169389,2726,Unspecified,,,,,"Activity of inclined screen in mouse, after 5 hour of peroral administration in mouse",Other,2571727.0,
436,128818,6,2,,103169389,2726,Unspecified,,,,,"Antagonistic activity against amphetamine-induced hypermotility, after 1 hour of peroral administration in mouse",Other,2571727.0,
437,128819,6,2,,103169389,2726,Unspecified,,,,,"Antagonistic activity against amphetamine-induced hypermotility, after 5 hour of peroral administration in mouse",Other,2571727.0,
438,128984,6,2,,103169389,2726,Unspecified,,,,,"Anticonvulsant activity against electroshock-induced convulsions, after 1 hour of peroral administration in mouse",Other,2571727.0,
439,128985,6,2,,103169389,2726,Unspecified,,,,,"Anticonvulsant activity against electroshock-induced convulsions, after 5 hours of peroral administration in mouse",Other,2571727.0,
440,128987,6,2,,103169389,2726,Unspecified,,,,,"Anticonvulsant activity against tryptamine-induced convulsions, after 1 hour of peroral administration in mouse",Other,2571727.0,
441,129286,6,2,,103169389,2726,Unspecified,,,,,"Antiexploratory activity (EXPL) of mice determined by an antimex activity meter, when administered perorally",Other,2891853.0,
442,129461,6,2,,103169389,2726,Unspecified,,,,,Cataleptogenic action in mice on peroral administration,Other,6131132.0,
443,130133,6,2,,103169389,2726,Unspecified,,,,,Neuroleptic activity in vivo by ability to antagonise climbing in apomorphine dosed mice after intraperitoneal administration.,Other,2861286.0,
444,130391,4,3,,103169389,2726,Unspecified,,,,,Hypothermia in mice after peroral administration,Other,6105216.0,
445,130860,4,2,,103169389,2726,Unspecified,,,,,"3,4 -Dihydroxy phenylacetic acid (DOPAC) levels in mouse brain at 10 mg/kg dose.",Other,2891853.0,
446,130873,6,2,,103169389,2726,Unspecified,,,,,"Inhibition against apomorphine-induced climbing, after 1 hour of peroral administration in mouse",Other,2571727.0,
447,130874,6,2,,103169389,2726,Unspecified,,,,,"Inhibition against apomorphine-induced climbing, after 5 hour of peroral administration in mouse",Other,2571727.0,
448,130877,6,2,,103169389,2726,Unspecified,,,,,"Inhibition against apomorphine-induced turning, after 1 hr of peroral administration in mouse",Other,2571727.0,
449,130885,6,2,,103169389,2726,Unspecified,,,,,Inhibition of conditioned avoidance response in mice when administered perorally,Other,2891853.0,
450,130906,6,2,,103169389,2726,Unspecified,,,,,"Inhibition of spontaneous locomotor activity, after 1 hour of peroral administration in mouse",Other,2571727.0,
451,130907,6,2,,103169389,2726,Unspecified,,,,,"Inhibition of spontaneous locomotor activity, after 5 hour of peroral administration in mouse",Other,2571727.0,
452,131051,6,2,,103169389,2726,Unspecified,,,,,"Inhibitory activity against tremorine-induced salivation, after 1 hour of peroral administration in mouse",Other,2571727.0,
453,131052,7,2,,103169389,2726,Unspecified,,,,,"Inhibitory activity against tremorine-induced salivation, after 5 hour of peroral administration in mouse",Other,2571727.0,
454,131198,6,2,,103169389,2726,Unspecified,,,,,Concentration of compound that causes catalepsy in the mice when administered perorally,Other,2891853.0,
455,131199,6,2,,103169389,2726,Unspecified,,,,,Concentration of compound that causes ptosis in the mice when administered perorally,Other,2891853.0,
456,131204,6,3,,103169389,2726,Unspecified,,,,,"Contractile activity in skeletal muscles, after 1 hour of peroral administration in mouse",Other,2571727.0,
457,131206,6,3,,103169389,2726,Unspecified,,,,,"Contractile activity in skeletal muscles, after 5 hour of peroral administration in mouse",Other,2571727.0,
458,131214,6,2,,103169389,2726,Unspecified,,,,,Lethal dose in mice by administered the compound intraperitoneally,Other,2571727.0,
459,131364,6,3,,103169389,2726,Unspecified,,,,,"Effect on skeletal muscle tone, after 1 hour of peroral administration in mouse",Other,2571727.0,
460,131365,6,3,,103169389,2726,Unspecified,,,,,"Effect on skeletal muscle tone, after 5 hour of peroral administration in mouse",Other,2571727.0,
461,131419,6,2,,103169389,2726,Unspecified,,,,,"Potentiation against pentobarbital-induced sleeping, after 1 hour of peroral administration in mouse",Other,2571727.0,
462,131420,6,2,,103169389,2726,Unspecified,,,,,"Potentiation against pentobarbital-induced sleeping, after 5 hour of peroral administration in mouse",Other,2571727.0,
463,131589,6,2,,103169389,2726,Unspecified,,,,,"Suppression of aggressive behavior, after 5 hour of peroral administration in mouse",Other,2571727.0,
464,133400,4,2,,103169389,2726,Unspecified,,,,,The homovanillic acid (HVA)levels in mouse brain at 10 mg/kg of dose.,Other,2891853.0,
465,133401,4,2,,103169389,2726,Unspecified,,,,,The homovanillic acid (HVA)levels in mouse brain at 50 mg/kg of dose.,Other,2891853.0,
466,133656,4,2,,103169389,2726,Unspecified,,,,,"3,4 -Dihydroxy phenylacetic acid (DOPAC) levels in mouse brain at 50 mg/kg dose.",Other,2891853.0,
467,133853,3,3,,103169389,2726,Unspecified,,,,,"Anticonvulsant activity against pentylenetetrazole-induced convulsions, after 1 hour of peroral administration in mouse at a dose of 15 mg/kg",Other,2571727.0,
468,133856,3,3,,103169389,2726,Unspecified,,,,,"Anticonvulsant activity against pentylenetetrazole-induced convulsions, after 1 hour of peroral administration in mouse at a dose of 50 mg/kg",Other,2571727.0,
469,133865,3,3,,103169389,2726,Unspecified,,,,,"Antiexploratory activity (EXPL) of mice determined by an antimex activity meter, 10 mg/kg of dose was administered perorally",Other,2891853.0,
470,134001,3,3,,103169389,2726,Unspecified,,,,,"Antiexploratory activity (EXPL) of mice determined by an antimex activity meter, 50 mg/kg of dose was administered perorally",Other,2891853.0,
471,134417,7,2,,103169389,2726,Unspecified,,,,,Lethal dose in mice after perorla administration,Other,6105216.0,
472,135326,5,2,,103169389,2726,Unspecified,,,,,BBB penetration classification,Other,10841799.0,
473,135366,3,3,,103169389,2726,Unspecified,,,,,"Inhibitory activity against tremorine-induced tremors, after 1 hour of peroral administration in mouse at dose 7.5 mg/kg",Other,2571727.0,
474,135369,3,3,,103169389,2726,Unspecified,,,,,"Inhibitory activity against tremorine-induced tremors, after 5 hour of peroral administration in mouse at dose 7.5 mg/kg",Other,2571727.0,
475,135601,4,3,,103169389,2726,Unspecified,,,,,Reduction of locomotor activity count to 50% of the control in mouse after oral administration,Other,7392031.0,
476,140417,3,3,,103169389,2726,Unspecified,,,,,Sedative activity measured after ip administration to female mice and checked for their horizontal movement at a dose of 1 mg/Kg,Other,6876081.0,
477,140476,8,1,,103169389,2726,Active,,,4.9,ED50,Effective dose against Leishmania donovani (Leishmania donovani) amastigotes in mouse peritoneal macrophages,Confirmatory,9457238.0,
478,140477,8,1,,103169389,2726,Active,,,3.69,ED50,Effective dose against Trypanosoma brucei) trypomastigotes in mouse peritoneal macrophages,Confirmatory,9457238.0,
479,140479,8,1,,103169389,2726,Unspecified,,,10.0,ED50,Effective dose against Trypanosoma cruzi (Trypanosoma cruzi) trypomastigotes in mouse peritoneal macrophages,Confirmatory,9457238.0,
480,140702,5,2,,103169389,2726,Unspecified,,,,,Evaluated for hypothermic activity in mice at 30 mg/kg on peroral administration,Other,6131132.0,
481,140974,10,1,,103169389,2726,Active,,,0.0607,Ki,In vitro binding affinity against Muscarinic acetylcholine receptors in rat brain.,Confirmatory,8101877.0,
482,142687,7,2,,103169389,2726,Active,,,0.06026,Ki,Binding affinity against muscarinic (M) receptor,Confirmatory,7907148.0,
483,143008,5,4,,103169389,2726,Unspecified,,,,,Binding affinity against PCP binding site associated with N-methyl-D-aspartate glutamate receptor from rat synaptic plasma membrane(SPM) determined using [3H]TCP as radioligand.,Other,1433216.0,
484,143909,9,1,,103169389,2726,Active,,,0.6,IC50,Inhibition of [3H]1 binding to dextromethorpin binding site of guinea pig microsomal pellet P3 N-methyl-D-aspartate glutamate receptor,Confirmatory,1433216.0,
485,143910,9,2,,103169389,2726,Active,,,1.1,IC50,Binding affinity against dextromethorpin binding site associated with N-methyl-D-aspartate glutamate receptor from guinea pig mitochondrial pellet P2 determined using [3H]1 as radioligand.,Confirmatory,1433216.0,
486,144475,9,5,,103169389,2726,Active,548372.0,24410.0,1.3,IC50,Binding affinity against dextromethorpin binding site of N-methyl-D-aspartate glutamate receptor from rat brain using [3H]1,Confirmatory,1433216.0,
487,144475,9,5,,103169389,2726,Active,548374.0,24411.0,1.3,IC50,Binding affinity against dextromethorpin binding site of N-methyl-D-aspartate glutamate receptor from rat brain using [3H]1,Confirmatory,1433216.0,
488,144475,9,5,,103169389,2726,Active,548379.0,24408.0,1.3,IC50,Binding affinity against dextromethorpin binding site of N-methyl-D-aspartate glutamate receptor from rat brain using [3H]1,Confirmatory,1433216.0,
489,144475,9,5,,103169389,2726,Active,3915771.0,24409.0,1.3,IC50,Binding affinity against dextromethorpin binding site of N-methyl-D-aspartate glutamate receptor from rat brain using [3H]1,Confirmatory,1433216.0,
490,144475,9,5,,103169389,2726,Active,18202594.0,24412.0,1.3,IC50,Binding affinity against dextromethorpin binding site of N-methyl-D-aspartate glutamate receptor from rat brain using [3H]1,Confirmatory,1433216.0,
491,144475,9,5,,103169389,2726,Active,51701630.0,170796.0,1.3,IC50,Binding affinity against dextromethorpin binding site of N-methyl-D-aspartate glutamate receptor from rat brain using [3H]1,Confirmatory,1433216.0,
492,144475,9,5,,103169389,2726,Active,51701631.0,191573.0,1.3,IC50,Binding affinity against dextromethorpin binding site of N-methyl-D-aspartate glutamate receptor from rat brain using [3H]1,Confirmatory,1433216.0,
493,144597,8,7,,103169389,2726,Inactive,548372.0,24410.0,,,Binding affinity against glycine binding site of N-methyl-D-aspartate glutamate receptor from rat synaptic plasma membrane(SPM) using [3H]glycine; NA = No effect,Other,1433216.0,
494,144597,8,7,,103169389,2726,Inactive,548374.0,24411.0,,,Binding affinity against glycine binding site of N-methyl-D-aspartate glutamate receptor from rat synaptic plasma membrane(SPM) using [3H]glycine; NA = No effect,Other,1433216.0,
495,144597,8,7,,103169389,2726,Inactive,548379.0,24408.0,,,Binding affinity against glycine binding site of N-methyl-D-aspartate glutamate receptor from rat synaptic plasma membrane(SPM) using [3H]glycine; NA = No effect,Other,1433216.0,
496,144597,8,7,,103169389,2726,Inactive,3915771.0,24409.0,,,Binding affinity against glycine binding site of N-methyl-D-aspartate glutamate receptor from rat synaptic plasma membrane(SPM) using [3H]glycine; NA = No effect,Other,1433216.0,
497,144597,8,7,,103169389,2726,Inactive,18202594.0,24412.0,,,Binding affinity against glycine binding site of N-methyl-D-aspartate glutamate receptor from rat synaptic plasma membrane(SPM) using [3H]glycine; NA = No effect,Other,1433216.0,
498,144597,8,7,,103169389,2726,Inactive,51701630.0,170796.0,,,Binding affinity against glycine binding site of N-methyl-D-aspartate glutamate receptor from rat synaptic plasma membrane(SPM) using [3H]glycine; NA = No effect,Other,1433216.0,
499,144597,8,7,,103169389,2726,Inactive,51701631.0,191573.0,,,Binding affinity against glycine binding site of N-methyl-D-aspartate glutamate receptor from rat synaptic plasma membrane(SPM) using [3H]glycine; NA = No effect,Other,1433216.0,
500,146870,5,1,,103169389,2726,Unspecified,,,,,The compound was tested for its ability to inhibit Na+/K+ ATPase in rat brain.,Other,6167716.0,
501,150609,6,7,,103169389,2726,Active,84028191.0,1565.0,7.0,Ki,Inhibitory constant for cytochrome P450 2D6,Confirmatory,8487254.0,
502,150616,9,2,,103169389,2726,Active,,,12.2,Ki,Concentration giving half of the maximal ATPase activity calculated for the high-affinity binding site of the CHO P-Glycoprotein (P-gp) in two-affinity model,Confirmatory,12477351.0,
503,150735,9,2,,103169389,2726,Active,,,0.6,Ki,High affinity constant at binding site of human P-Glycoprotein (P-gp) in two-affinity model,Confirmatory,12477351.0,
504,150736,3,8,,103169389,2726,Unspecified,,,,,Fraction of high affinity at binding site of human P-Glycoprotein (P-gp) in two-affinity model,Other,12477351.0,
505,161281,10,5,,103169389,2726,Active,7531135.0,3757.0,1.4791100000000001,IC50,Inhibition of human Potassium channel HERG expressed in mammalian cells,Confirmatory,12873512.0,
506,161300,4,4,,103169389,2726,Active,,,0.012,Ki,Tested for displacement of [3H]prazosin from Prazosin receptor site of calf cerebral cortex,Confirmatory,6132009.0,
507,161627,9,2,,103169389,2726,Active,,,2.0,EC50,Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells,Confirmatory,12904059.0,
508,167130,8,1,,103169389,2726,Active,,,,,In vitro inhibition of iron-dependent peroxidation of rabbit brain vesicular membrane lipids,Other,1542098.0,
509,169417,3,3,,103169389,2726,Unspecified,,,,,Antipsychotic activity was assessed by ability to block response of rats trained to avoid an electrical shock (inhibition of self-jump and/or discrete trial conditioned avoidance response(CAR) upon ip administration; value ranges from 2-7,Other,2884314.0,
510,169424,3,3,,103169389,2726,Unspecified,,,,,Antipsychotic activity was assessed by ability to block response of rats trained to avoid an electrical shock (inhibition of self-jump and/or discrete trial conditioned avoidance response(CAR) upon po administration; value ranges from 2-3,Other,2884314.0,
511,169809,3,3,,103169389,2726,Unspecified,,,,,Compound was assessed for its ability to block a conditioned avoidance response; Dose administered perorally is 10 mg/kg; 51-75%block,Other,6105216.0,
512,169954,3,3,,103169389,2726,Unspecified,,,,,Compound was assessed for its ability to produce catalepsy in rats; Dose administered perorally is 10 mg/kg; Group score is 4-7,Other,6105216.0,
513,170116,3,3,,103169389,2726,Unspecified,,,,,Compound was evaluated for its ability to block conditioned avoidance response (CAR) in rats; Dose administered perorally is 10 mg/kg; 51-75% block,Other,6105217.0,
514,171952,3,3,,103169389,2726,Unspecified,,,,,compound was evaluated for its ability to produce catalepsy activity in rats,Other,6105217.0,
515,175353,3,3,,103169389,2726,Unspecified,,,,,Compound's potency to increase the level of the dopamine metabolite DOPAC levels in male wistar rats at 2.62 ug/g dose,Other,6123599.0,
516,175354,3,3,,103169389,2726,Unspecified,,,,,Compound's potency to increase the level of the dopamine metabolite DOPAC levels in male wistar rats at 2.7 ug/g dose,Other,6123599.0,
517,175360,3,3,,103169389,2726,Unspecified,,,,,"Compound's potency to increase the level of the dopamine metabolite homovanillic acid (HVA), levels in male wistar rats at 1.62 ug/g dose",Other,6123599.0,
518,175361,3,3,,103169389,2726,Unspecified,,,,,"Compound's potency to increase the level of the dopamine metabolite homovanillic acid (HVA), levels in male wistar rats at 2.5 ug/g dose",Other,6123599.0,
519,176179,6,4,,103169389,2726,Unspecified,118211.0,29238.0,,,Ability to antagonize the stereotypy in rats induced by d-amphetamine sulfate 1 hr later of the treatment,Other,2876105.0,
520,176179,6,4,,103169389,2726,Unspecified,118229.0,24316.0,,,Ability to antagonize the stereotypy in rats induced by d-amphetamine sulfate 1 hr later of the treatment,Other,2876105.0,
521,176179,6,4,,103169389,2726,Unspecified,118251.0,25195.0,,,Ability to antagonize the stereotypy in rats induced by d-amphetamine sulfate 1 hr later of the treatment,Other,2876105.0,
522,176179,6,4,,103169389,2726,Unspecified,6226851.0,25432.0,,,Ability to antagonize the stereotypy in rats induced by d-amphetamine sulfate 1 hr later of the treatment,Other,2876105.0,
523,176179,6,4,,103169389,2726,Unspecified,47117674.0,24318.0,,,Ability to antagonize the stereotypy in rats induced by d-amphetamine sulfate 1 hr later of the treatment,Other,2876105.0,
524,176182,7,3,,103169389,2726,Unspecified,,,,,Ability to antagonize the stereotypy in rats induced by d-amphetamine sulfate 24 hr later of the treatment,Other,2876105.0,
525,176184,6,4,,103169389,2726,Unspecified,118211.0,29238.0,,,Ability to antagonize the stereotypy in rats induced by d-amphetamine sulfate 5 hr later of the treatment,Other,2876105.0,
526,176184,6,4,,103169389,2726,Unspecified,118229.0,24316.0,,,Ability to antagonize the stereotypy in rats induced by d-amphetamine sulfate 5 hr later of the treatment,Other,2876105.0,
527,176184,6,4,,103169389,2726,Unspecified,118251.0,25195.0,,,Ability to antagonize the stereotypy in rats induced by d-amphetamine sulfate 5 hr later of the treatment,Other,2876105.0,
528,176184,6,4,,103169389,2726,Unspecified,6226851.0,25432.0,,,Ability to antagonize the stereotypy in rats induced by d-amphetamine sulfate 5 hr later of the treatment,Other,2876105.0,
529,176184,6,4,,103169389,2726,Unspecified,47117674.0,24318.0,,,Ability to antagonize the stereotypy in rats induced by d-amphetamine sulfate 5 hr later of the treatment,Other,2876105.0,
530,176235,6,2,,103169389,2726,Unspecified,,,,,"Inhibitory activity in apomorphine antagonism test at a dose of 20 mg/kg, sc",Other,7907148.0,
531,176253,7,2,,103169389,2726,Unspecified,,,,,Intraperitoneal dose producing a block of avoidance response in 50% of the rats.,Other,6198519.0,
532,176322,6,2,,103169389,2726,Unspecified,,,,,Blockade of apomorphine-induced stereotypy in rats when administered perorally,Other,2542551.0,
533,176327,6,2,,103169389,2726,Unspecified,,,,,"Body weight gain, after 2 hour period of conditioned feeding in rats",Other,2571727.0,
534,176331,6,2,,103169389,2726,Unspecified,,,,,Inhibition of d-amphetamine induced stereotypy in rats; i.p. treatment 1 hr before amphetamine.,Other,2876102.0,
535,176333,6,2,,103169389,2726,Unspecified,,,,,Inhibition of d-amphetamine induced stereotypy in rats; i.p. treatment 24 hr before amphetamine.,Other,2876102.0,
536,176335,6,2,,103169389,2726,Unspecified,,,,,Inhibition of d-amphetamine induced stereotypy in rats; i.p. treatment 5 hr before amphetamine.,Other,2876102.0,
537,176353,7,2,,103169389,2726,Unspecified,,,,,"Ability to induce catalepsy in rats perorally, an effect normally related to clinical extrapyramidal side effects",Other,6134833.0,
538,176368,6,2,,103169389,2726,Unspecified,,,,,Conditioned avoidance response (CAR) when administered perorally,Other,2542551.0,
539,176404,6,2,,103169389,2726,Unspecified,,,,,Evaluated for neuroleptic-like property using anti-methamphetamine test in rats on peroral administration,Other,6131132.0,
540,176406,6,2,,103169389,2726,Unspecified,,,,,Evaluated for neuroleptic-like property using open-field test in rats(increase in ambulation at 3 to 20 mg/kg on peroral administration,Other,6131132.0,
541,176643,5,2,,103169389,2726,Inactive,,,,,Reversal of trifluoperazine-induced catalepsy in rats when administered perorally; Inactive,Other,2542551.0,
542,176908,6,2,,103169389,2726,Unspecified,,,,,Dose producing 50% of the theoretically obtained maximum catalepsy in rats (value in parentheses indicates 95%confidence limits),Other,6198519.0,
543,177108,6,2,,103169389,2726,Unspecified,,,,,ED50 value for catalepsy indicates the dose required to produce a 50% of maximum catalepsy score. parentheses value indicate 95% confidence limit.,Other,1346653.0,
544,177235,7,2,,103169389,2726,Unspecified,,,,,Compound was evaluated for its ability to stimulate the synthesis of homovanillic acid (HVA).,Other,6105219.0,
545,177508,6,2,,103169389,2726,Unspecified,,,,,In vivo inhibition of apomorphine-mediated stereotypy in rats administered subcutaneously at 20 mg/kg expressed as ED50 (mg/kg),Other,8101877.0,
546,177666,6,2,,103169389,2726,Unspecified,,,,,Effective Dose for avoidance acquisition in naive rats when administered intraperitoneal,Other,6106062.0,
547,177667,6,2,,103169389,2726,Unspecified,,,,,Effective Dose for catalepsy production in naive rats when administered intraperitoneal,Other,6106062.0,
548,177727,6,2,,103169389,2726,Unspecified,,,,,Induction of catalepsy in rats when administered perorally (2.4-7.1),Other,2542551.0,
549,177731,6,2,,103169389,2726,Unspecified,,,,,"Inhibition against conditioned avoidance response, after 1 hour of peroral administration in rats",Other,2571727.0,
550,177732,6,2,,103169389,2726,Unspecified,,,,,"Inhibition against conditioned avoidance response, after 5 hour of peroral administration in rats",Other,2571727.0,
551,177741,6,2,,103169389,2726,Unspecified,,,,,"Activity to evoke catalepsy, after 1 hour of peroral administration in rats",Other,2571727.0,
552,177948,6,2,,103169389,2726,Unspecified,,,,,"Antagonistic activity against amphetamine-induced stereotypy, after 1 hour of peroral administration in rats",Other,2571727.0,
553,177949,6,2,,103169389,2726,Unspecified,,,,,"Antagonistic activity against amphetamine-induced stereotypy, after 5 hour of peroral administration in rats",Other,2571727.0,
554,177954,6,2,,103169389,2726,Unspecified,,,,,"Antagonistic activity against apomorphine-induced stereotypy, after 1 hour of peroral administration in rats",Other,2571727.0,
555,177955,6,2,,103169389,2726,Unspecified,,,,,"Antagonistic activity against apomorphine-induced stereotypy, after 5 hour of peroral administration in rats",Other,2571727.0,
556,178197,6,2,,103169389,2726,Unspecified,,,,,Effective dose in blocking conditioned avoidance responding (CAR) in the rat when administered intraperitoneally,Other,2565400.0,
557,178235,6,2,,103169389,2726,Unspecified,,,,,Inhibition of self stimulation response in rats when administered perorally.,Other,2891853.0,
558,178517,6,2,,103169389,2726,Unspecified,,,,,Inhibition of conditioned avoidance response (CAR),Other,2869146.0,
559,178537,6,2,,103169389,2726,Unspecified,,,,,Compound was tested for inhibition of spontaneous motor activity in rat when administered perorally,Other,2869146.0,
560,178541,6,2,,103169389,2726,Unspecified,,,,,Compound was tested for its ability to induce catalepsy in rats.,Other,2869146.0,
561,178824,6,2,,103169389,2726,Unspecified,,,,,"Antipsychotic activity was assessed by ability to antagonize the stereotypy induced in rats by d-amphetamine (5 mg / kg, ip) after 1 h; Range is 3.2-10",Other,6104734.0,
562,178826,6,2,,103169389,2726,Unspecified,,,,,"Antipsychotic activity was assessed by ability to antagonize the stereotypy induced in rats by d-amphetamine (5 mg / kg, ip) after 24 h",Other,6104734.0,
563,178829,6,2,,103169389,2726,Unspecified,,,,,"Antipsychotic activity was assessed by ability to antagonize the stereotypy induced in rats by d-amphetamine (5 mg / kg, ip) after 5 h",Other,6104734.0,
564,178842,7,2,,103169389,2726,Unspecified,,,,,Antipsychotic activity was evaluated by the antagonism of amphetamine in rats when administered subcutaneously after 24 hr r,Other,6105220.0,
565,178843,7,2,,103169389,2726,Unspecified,,,,,Antipsychotic activity was evaluated by the antagonism of amphetamine in rats when administered subcutaneously after 5 hr,Other,6105220.0,
566,178844,7,2,,103169389,2726,Unspecified,,,,,Antipsychotic activity was evaluated by the antagonism of amphetamine in rats when administered subcutaneously after 1 hr,Other,6105220.0,
567,178868,6,2,,103169389,2726,Unspecified,,,,,Compound was tested for the inhibition of apomorphine-induced stereotype,Other,2869146.0,
568,180162,6,2,,103169389,2726,Unspecified,,,,,Antipsychotic activity at a dose 10 times the ED50 value for CAR block for production of catalepsy in the rat (following i.p. dosing),Other,1346653.0,
569,180439,4,3,,103169389,2726,Unspecified,,,,,Levels of homovanillic acid (HVA) in rat brain 2 hour after an intraperitoneal injection dose,Other,6198519.0,
570,181263,6,2,,103169389,2726,Unspecified,,,,,"tested for neuroleptic activity by measuring antagonism of d-amphetamine sulfate at intraperitoneal dosage of 5 mg/kg, after 1 hour in rat",Other,6104732.0,
571,181264,6,2,,103169389,2726,Unspecified,,,,,"tested for neuroleptic activity by measuring antagonism of d-amphetamine sulfate at intraperitoneal dosage of 5 mg/kg, after 24 hours in rat",Other,6104732.0,
572,181265,6,2,,103169389,2726,Unspecified,,,,,"tested for neuroleptic activity by measuring antagonism of d-amphetamine sulfate at intraperitoneal dosage of 5 mg/kg, after 5 hours in rat",Other,6104732.0,
573,181422,3,3,,103169389,2726,Unspecified,,,,,Conditioned avoidance response in rats after oral administration,Other,8096548.0,
574,181425,3,3,,103169389,2726,Unspecified,,,,,Compound was tested for the presence of catalepsy (CAT) in rats after oral administration,Other,8096548.0,
575,181661,4,3,,103169389,2726,Active,,,0.18,IC50,Binding affinity against rat striatal membranes using [3H]spiroperidol as the radioligand after 2 hours of conditioned feeding,Confirmatory,2571727.0,
576,184476,3,3,,103169389,2726,Unspecified,,,,,Estimated oral dose depressing motor activity by 50% in rats(po),Other,6103960.0,
577,185207,3,3,,103169389,2726,Unspecified,,,,,Blockade of Sidman-avoidance activity in rats when administered perorally,Other,2542551.0,
578,185209,3,3,,103169389,2726,Unspecified,,,,,Blockade of apomorphine-induced climbing in mice when administered perorally,Other,2542551.0,
579,186207,3,3,,103169389,2726,Unspecified,,,,,Log (1/ED50*10e-3) was measured as histamine releasing activity in rat mast cells. c,Other,6167716.0,
580,186417,3,3,,103169389,2726,Unspecified,,,,,Effect on the spontaneous locomotor activity of rats at 0-15 min upon ip administration of the compounds at a dose of 15 mg/kg,Other,1846917.0,
581,186425,3,3,,103169389,2726,Unspecified,,,,,Effect on the spontaneous locomotor activity of rats at 0-60 min upon ip administration of the compounds at a dose of 100 mg/kg.,Other,1846917.0,
582,189474,3,3,,103169389,2726,Unspecified,,,,,Apparent partition coefficient was measured as histamine releasing activity in rat mast cells.,Other,6167716.0,
583,194153,3,4,,103169389,2726,Unspecified,,,,,The percent loss of escape responding was determined for the estimated effective dose 50 values for CAR block,Other,2565400.0,
584,196427,4,4,,103169389,2726,Active,,,0.051,IC50,Inhibition of [3H]spiroperidol binding to rat striatal membrane using 0.5 nM ligand.,Confirmatory,6105220.0,
585,205267,9,2,,103169389,2726,Active,,,4.3,IC50,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex,Confirmatory,2579237.0,
586,205268,4,7,,103169389,2726,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
587,214487,10,5,,103169389,2726,Active,136620.0,,10.8,Ki,Inhibitory activity against Trypanosoma cruzi trypanothione reductase,Confirmatory,10956223.0,
588,214488,10,5,,103169389,2726,Active,136620.0,,35.4,IC50,Inhibitory activity against recombinant Trypanosoma cruzi (Trypanosoma cruzi) Trypanothione reductase,Confirmatory,9457238.0,
589,214649,3,10,,103169389,2726,Unspecified,136620.0,,,,Natural log of the value in (uM) of inhibition constant was tested against Trypanothione Reductase,Other,9240356.0,
590,214654,10,5,,103169389,2726,Active,136620.0,,10.8,Ki,Inhibitory activity against recombinant Trypanosoma cruzi (Trypanosoma cruzi) Trypanothione reductase (linear competitive type),Confirmatory,9457238.0,
591,214939,7,3,,103169389,2726,Unspecified,,,93.0,Km,Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4),Confirmatory,12699380.0,
592,218770,7,1,,103169389,2726,Active,,,0.012,IC50,"Ability to displace [3H]haloperidol from rat striatal membranes, in order to measure its intrinsic affinity for the dopamine (DA) receptor",Confirmatory,6134833.0,
593,227718,7,1,,103169389,2726,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
594,231522,3,6,,103169389,2726,Unspecified,,,,,Ratio of binding affinity towards 5-HT2 to D2 receptor was measured,Other,7907148.0,
595,231526,3,6,,103169389,2726,Unspecified,,,,,Ratio of binding affinity towards D2 to D1 receptor was measured,Other,7907148.0,
596,231528,3,5,,103169389,2726,Unspecified,,,,,Ratio of binding affinity towards D2 to muscarinic receptor (M) was measured,Other,7907148.0,
597,231653,3,10,,103169389,2726,Unspecified,112808.0,29595.0,,,Binding ratio of -log Ki between 5-HT2 and D2 receptors,Other,8101877.0,
598,231653,3,10,,103169389,2726,Unspecified,112817.0,25187.0,,,Binding ratio of -log Ki between 5-HT2 and D2 receptors,Other,8101877.0,
599,231653,3,10,,103169389,2726,Unspecified,398970.0,29581.0,,,Binding ratio of -log Ki between 5-HT2 and D2 receptors,Other,8101877.0,
600,231653,3,10,,103169389,2726,Unspecified,47117674.0,24318.0,,,Binding ratio of -log Ki between 5-HT2 and D2 receptors,Other,8101877.0,
601,231654,3,9,,103169389,2726,Unspecified,118229.0,24316.0,,,Binding ratio of -log Ki between D2 and D1 receptors,Other,8101877.0,
602,231654,3,9,,103169389,2726,Unspecified,47117674.0,24318.0,,,Binding ratio of -log Ki between D2 and D1 receptors,Other,8101877.0,
603,231655,3,5,,103169389,2726,Unspecified,,,,,Binding ratio of -log Ki between D2 and M receptors,Other,8101877.0,
604,232327,3,3,,103169389,2726,Unspecified,,,,,Ratio of APO Sterotype ED50 vs catalepsy ED50,Other,2869146.0,
605,232353,3,3,,103169389,2726,Unspecified,,,,,Ratio of CAR ED50 vs catalepsy ED50,Other,2869146.0,
606,233474,3,7,,103169389,2726,Inconclusive,,,,,Hill slope was determined for the compound in D1 receptor binding assay; '-' means not tested,Other,8558526.0,
607,233475,3,7,,103169389,2726,Unspecified,,,,,Hill slope was determined for the compound in D2 receptor binding assay,Other,8558526.0,
608,233503,3,3,,103169389,2726,Unspecified,,,,,Ionisation constant (pKa),Other,12061889.0,
609,233664,4,9,,103169389,2726,Unspecified,118229.0,24316.0,,,Selectivity ratio of binding affinity towards dopamine D2 and D1 receptors,Other,3050089.0,
610,233664,4,9,,103169389,2726,Unspecified,47117674.0,24318.0,,,Selectivity ratio of binding affinity towards dopamine D2 and D1 receptors,Other,3050089.0,
611,234393,4,3,,103169389,2726,Unspecified,,,,,ratio between ED50 values of DA receptor antagonist activity and catalepsy.,Other,9513593.0,
612,237685,4,3,,103169389,2726,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
613,238747,4,9,,103169389,2726,Active,1703010.0,3362.0,0.05,Ki,Binding affinity for human 5-hydroxytryptamine 6 receptor,Confirmatory,15771424.0,
614,243151,7,2,,103169389,2726,Active,,,1.4791100000000001,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
615,243189,7,4,,103169389,2726,Active,7531135.0,3757.0,1.4791100000000001,IC50,Inhibition of partially open human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel),Confirmatory,15745831.0,
616,272392,8,5,,103169389,2726,Inconclusive,1706296.0,100144487.0,,Ki,Displacement of [3H]SCH-23390 from dopamine D1-like receptor in porcine striata homogenate,Confirmatory,17154515.0,
617,272393,7,1,,103169389,2726,Active,,,0.008,Ki,Displacement of [3H]spiperone from dopamine D2-like receptor in porcine striata homogenate,Confirmatory,17154515.0,
618,272394,5,6,,103169389,2726,Inconclusive,118228.0,1812.0,,EC50,Activity at human dopamine D1 receptor expressed in HEK293 cells assessed as stimulation of cAMP production,Confirmatory,17154515.0,
619,272395,4,10,,103169389,2726,Inconclusive,118228.0,1812.0,,,Intrinsic activity at human dopamine D1 receptor expressed in HEK293 cells assessed as stimulation of cAMP production relative to dopamine,Other,17154515.0,
620,272396,9,2,,103169389,2726,Inconclusive,47117674.0,24318.0,,EC50,Activity at rat dopamine D2L receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production,Confirmatory,17154515.0,
621,272397,4,10,,103169389,2726,Inconclusive,47117674.0,24318.0,,,Intrinsic activity at rat dopamine D2L receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production relative to dopamine,Other,17154515.0,
622,272398,5,6,,103169389,2726,Inconclusive,1345939.0,1815.0,,EC50,Activity at human dopamine D4.4 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production,Confirmatory,17154515.0,
623,272399,4,11,,103169389,2726,Inconclusive,1345939.0,1815.0,,,Intrinsic activity at human dopamine D4.4 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production relative to dopamine,Other,17154515.0,
624,275284,6,2,,103169389,2726,Inconclusive,,,,EC50,Reduction of PrPSC accumulation in ScN2a cells,Confirmatory,17201410.0,
625,275285,8,1,,103169389,2726,Inconclusive,,,,LD50,Cytotoxicity against ScN2a cells,Confirmatory,17201410.0,
626,275286,6,2,,103169389,2726,Unspecified,,,,,Solubility in phosphate buffer at pH 6.5 at 500 uM,Other,17201410.0,
627,275287,3,4,,103169389,2726,Unspecified,,,,,Permeability across DOPC lipid membrane by PAMPA,Other,17201410.0,
628,289349,8,5,,103169389,2726,Active,71164787.0,83810.0,1.3,Ki,Displacement of [3H]RTX from rat TRPV1 receptor expressed in CHO cells,Confirmatory,17629487.0,
629,289350,4,10,,103169389,2726,Unspecified,71164787.0,83810.0,,,Agonist activity at rat TRPV1 receptor expressed in CHO cells by Ca2+ uptake assay,Other,17629487.0,
630,289351,5,6,,103169389,2726,Active,71164787.0,83810.0,0.52,Ki,Antagonist activity at rat TRPV1 receptor expressed in CHO cells by Ca2+ uptake assay,Confirmatory,17629487.0,
631,294090,10,1,,103169389,2726,Active,,,8.2,EC50,Antiviral activity against Sindbis virus replication in BHK cells after 12 hrs by XTT assay,Confirmatory,17287124.0,
632,294091,10,1,,103169389,2726,Unspecified,,,100.0,CC50,Cytotoxicity against BHK cells by XTT assay,Confirmatory,17287124.0,
633,298031,3,5,,103169389,2726,Unspecified,,,,,"Lipophilicity, log D at pH7.4",Other,17725338.0,
634,298032,3,3,,103169389,2726,Unspecified,,,,,"Acid dissociation constant, pKa of the compound",Other,17725338.0,
635,298478,4,1,,103169389,2726,Active,118206.0,1813.0,0.01,Ki,Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells,Confirmatory,17880057.0,
636,298479,4,1,,103169389,2726,Active,1169206.0,1814.0,0.00158,Ki,Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells,Confirmatory,17880057.0,
637,298480,4,1,,103169389,2726,Active,1345939.0,1815.0,0.02512,Ki,Displacement of [3H]spiperone from human dopamine D4.4 receptor expressed in CHO cells,Confirmatory,17880057.0,
638,298481,4,1,,103169389,2726,Inactive,231454.0,3350.0,,Ki,Displacement of [3H]8-OH-DPAT from human 5HT1A receptor expressed in CHO cells,Confirmatory,17880057.0,
639,298482,4,1,,103169389,2726,Active,543727.0,3356.0,0.0063100000000000005,Ki,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHO cells,Confirmatory,17880057.0,
640,298484,4,1,,103169389,2726,Active,1168220.0,3357.0,0.039810000000000005,Ki,Displacement of [3H]DOI from 5HT2B receptor expressed in CHO cells,Confirmatory,17880057.0,
641,298485,4,1,,103169389,2726,Active,112816.0,3358.0,0.039810000000000005,Ki,Displacement of [3H]mesulergine from 5HT2C receptor expressed in CHO cells,Confirmatory,17880057.0,
642,298486,4,1,,103169389,2726,Active,1703010.0,3362.0,0.05012,Ki,Displacement of [3H]LSD from human 5HT6 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
643,298487,4,1,,103169389,2726,Active,8488960.0,3363.0,0.03162,Ki,Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells,Confirmatory,17880057.0,
644,298488,4,1,,103169389,2726,Inactive,1168222.0,3359.0,,Ki,Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
645,298488,4,1,,103169389,2726,Inactive,74705987.0,9177.0,,Ki,Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
646,298488,4,1,,103169389,2726,Inactive,162416113.0,285242.0,,Ki,Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
647,298488,4,1,,103169389,2726,Inactive,166198366.0,170572.0,,Ki,Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
648,298488,4,1,,103169389,2726,Inactive,338817899.0,200909.0,,Ki,Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
649,298489,4,1,,103169389,2726,Active,400630.0,6532.0,0.0631,Ki,Displacement of [3H]paraxetine from human 5HT transporter expressed in HEK293 cells,Confirmatory,17880057.0,
650,298490,4,1,,103169389,2726,Active,113118.0,1128.0,0.12589,Ki,Displacement of [3H]pirenzepine from human M1 receptor expressed in CHO cells,Confirmatory,17880057.0,
651,298491,4,1,,103169389,2726,Active,23503039.0,1132.0,0.15849000000000002,Ki,Displacement of [3H]4-DAMP from human M4 receptor expressed in CHO cells,Confirmatory,17880057.0,
652,298492,4,1,,103169389,2726,Active,543734.0,24173.0,0.00158,Ki,Displacement of [3H]prazosin from adrenergic alpha1 receptor in rat cerebral cortex,Confirmatory,17880057.0,
653,298492,4,1,,103169389,2726,Active,1168244.0,29413.0,0.00158,Ki,Displacement of [3H]prazosin from adrenergic alpha1 receptor in rat cerebral cortex,Confirmatory,17880057.0,
654,298492,4,1,,103169389,2726,Active,1168247.0,29412.0,0.00158,Ki,Displacement of [3H]prazosin from adrenergic alpha1 receptor in rat cerebral cortex,Confirmatory,17880057.0,
655,298493,4,1,,103169389,2726,Active,231461.0,25083.0,0.5011899999999999,Ki,Displacement of [3H]RX 821002 from adrenergic alpha-2 receptor in rat cerebral cortex,Confirmatory,17880057.0,
656,298493,4,1,,103169389,2726,Active,231464.0,24175.0,0.5011899999999999,Ki,Displacement of [3H]RX 821002 from adrenergic alpha-2 receptor in rat cerebral cortex,Confirmatory,17880057.0,
657,298493,4,1,,103169389,2726,Active,47117345.0,24174.0,0.5011899999999999,Ki,Displacement of [3H]RX 821002 from adrenergic alpha-2 receptor in rat cerebral cortex,Confirmatory,17880057.0,
658,298494,4,1,,103169389,2726,Active,399889.0,100730517.0,0.05012,Ki,Displacement of [3H]pyrilamine from histaminergic H1 receptor guinea pig cerebellum,Confirmatory,17880057.0,
659,311524,4,3,,103169389,2726,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
660,311932,3,10,,103169389,2726,Unspecified,224471897.0,6609.0,,,Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM,Other,18027916.0,
661,311934,3,3,,103169389,2726,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,18027916.0,
662,311935,3,4,,103169389,2726,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,18027916.0,
663,327169,3,3,,103169389,2726,Unspecified,,,,,Apparent permeability across parallel artificial membrane,Other,18348514.0,
664,327170,4,6,,103169389,2726,Unspecified,113576.0,213.0,54.9541,Kd,Binding affinity to human serum albumin by PAMPA method,Confirmatory,18348514.0,
665,330907,10,1,,103169389,2726,Unspecified,,,,,Displacement of quinaldine red from human AAG by fluorescence method,Other,18289858.0,
666,339863,6,2,,103169389,2726,Unspecified,,,,,Antibacterial activity against wild type Staphylococcus aureus ATCC 25923 by microdilution technique,Other,18578473.0,
667,339867,3,10,,103169389,2726,Unspecified,60392839.0,,,,Inhibition of NorA pump-mediated ethidium bromide efflux in Staphylococcus aureus K1199B at 50 uM by fluorimetric analysis,Other,18578473.0,
668,339869,3,3,,103169389,2726,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,18578473.0,
669,339870,3,4,,103169389,2726,Unspecified,,,,,Intrinsic solubility in water,Other,18578473.0,
670,339872,3,10,,103169389,2726,Unspecified,60392839.0,,,,Inhibition of NorA deficient Staphylococcus aureus K2378 assessed as fold reduction of ciprofloxacin MIC at 25 ug/mL by microdilution technique,Other,18578473.0,
671,339876,3,10,,103169389,2726,Unspecified,60392839.0,,,,Inhibition of NorA overexpressing Staphylococcus aureus K2378 assessed as fold reduction of ciprofloxacin MIC at 25 ug/mL by microdilution technique,Other,18578473.0,
672,343384,10,1,,103169389,2726,Active,136620.0,,,IC50,Inhibition of Trypanosoma cruzi recombinant trypanothione reductase,Confirmatory,18558492.0,
673,343386,3,10,,103169389,2726,Unspecified,136620.0,,,,Inhibition of Trypanosoma cruzi recombinant trypanothione reductase at 12.2 uM,Other,18558492.0,
674,349880,8,1,,103169389,2726,Unspecified,,,,,Permeability across porcine brain lipid coated polyvinylidene fluoride membrane by PAMPA,Other,19374444.0,
675,354425,6,2,,103169389,2726,Active,,,10.2,IC50,Inhibition of calmodulin-dependent cAMP phosphodiesterase in bovine brain by SDS-PAGE,Confirmatory,12608853.0,
676,355715,6,2,,103169389,2726,Active,,,9.8,IC50,Inhibition of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase after 30 min,Confirmatory,12713403.0,
677,373867,6,3,,103169389,2726,Unspecified,,,,,Hepatic clearance in human hepatocytes in absence of fetal calf serum,Other,18768239.0,
678,374351,6,2,,103169389,2726,Active,,,7.6,EC50,Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay,Confirmatory,17893158.0,
679,374353,6,3,,103169389,2726,Active,,,10.34,CC50,Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay,Confirmatory,17893158.0,
680,374355,3,3,,103169389,2726,Unspecified,,,,,"Selectivity index, ratio of CC50 for human WI38 cells preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay to EC50 for BKV Gardner ATCC VR837",Other,17893158.0,
681,380160,3,3,,103169389,2726,Active,,,,,"Protective effect against amphetamine-induced lethality in mouse at 4 mg/kg, ip administered 30 mins prior to amphetamine challenge measured after 24 hrs",Other,16562831.0,
682,380162,3,3,,103169389,2726,Active,,,,,"Inhibition of apomorphine-induced climbing behavior in mouse at 4 mg/kg, ip administered 30 mins prior to apomorphine challenge",Other,16562831.0,
683,380961,3,4,,103169389,2726,Active,,,,,"Effect on gross behavioral activity in Swiss albino mouse assessed as spontaneous motor activity at 5 mg/kg, ip after 45 mins using smoked drum",Other,,
684,386623,4,8,,103169389,2726,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
685,386625,9,5,,103169389,2726,Active,313104181.0,6580.0,27.0,IC50,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy,Confirmatory,18788725.0,
686,392463,8,5,,103169389,2726,Unspecified,17367264.0,11255.0,1.0,Ki,Displacement of [125I]iodoproxyfan from human histamine H3 receptor expressed in CHO/HEK293 cells,Confirmatory,19091563.0,
687,392464,8,5,,103169389,2726,Active,547645.0,3269.0,0.00425,Ki,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Confirmatory,19091563.0,
688,392465,8,5,,103169389,2726,Active,118228.0,1812.0,0.096,Ki,Displacement of [3H]SCH23390 from human dopamine D1 receptor expressed in HEK cells,Confirmatory,19091563.0,
689,392466,8,5,,103169389,2726,Active,118214.0,1816.0,0.172,Ki,Displacement of [3H]SCH23390 from human dopamine D5 receptor expressed in HEK cells,Confirmatory,19091563.0,
690,392467,8,5,,103169389,2726,Active,118206.0,1813.0,0.00406,Ki,Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells,Confirmatory,19091563.0,
691,392468,8,5,,103169389,2726,Active,1169206.0,1814.0,0.0069,Ki,Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells,Confirmatory,19091563.0,
692,395325,3,3,,103169389,2726,Unspecified,,,,,"Lipophilicity, log P by microemulsion electrokinetic chromatography",Other,19256501.0,
693,395328,3,3,,103169389,2726,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,19256501.0,
694,395887,9,1,,103169389,2726,Active,,,7.26,IC50,Inhibition of recombinant calmodulin mediated bovine brain PDE1 activation assessed as effect on inorganic phosphate release by spectrophotometry,Confirmatory,19013822.0,
695,395888,9,1,,103169389,2726,Active,,,19.28,Ki,Inhibition of recombinant calmodulin mediated bovine brain PDE1 activation assessed as effect on inorganic phosphate release using variable calmodulin level by spectrophotometry,Confirmatory,19013822.0,
696,399545,6,2,,103169389,2726,Active,,,0.18,IC50,Spasmolytic activity in guinea pig ileum assessed as inhibition of spontaneous contraction,Confirmatory,14987052.0,
697,399546,3,4,,103169389,2726,Unspecified,,,,,Spasmolytic activity in guinea pig ileum assessed as inhibition of spontaneous contraction relative to papaverine,Other,14987052.0,
698,399550,6,2,,103169389,2726,Active,,,10.2,IC50,Inhibition of bovine brain CaM-dependent PDE assessed as inorganic phosphate release in presence of bovine brain calmodulin,Confirmatory,14987052.0,
699,402358,6,2,,103169389,2726,Active,,,6.8,IC50,Inhibition of calmodulin-dependent PDE1 activation,Confirmatory,15974630.0,
700,404304,3,10,,103169389,2726,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
701,408340,8,5,,103169389,2726,Active,7531135.0,3757.0,1.4791100000000001,IC50,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Confirmatory,18448342.0,
702,411793,6,2,,103169389,2726,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as intrinsic clearance per mg of protein,Other,19108654.0,
703,420668,8,5,,103169389,2726,Active,7531135.0,3757.0,1.4791100000000001,IC50,Inhibition of human ERG in MCF7 cells,Confirmatory,19110341.0,
704,420669,3,4,,103169389,2726,Unspecified,,,,,"Lipophilicity, log D at pH 7.0",Other,19110341.0,
705,425652,7,2,,103169389,2726,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
706,425653,7,2,,103169389,2726,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
707,427196,8,1,,103169389,2726,Unspecified,,,,,Membrane permeability by PAMPA-BBB assay,Other,19663388.0,
708,427197,8,1,,103169389,2726,Unspecified,,,,,Membrane permeability dissolved in PBS/EtOH (70:30) mixture by PAMPA-BBB assay,Other,19663388.0,
709,427198,8,1,,103169389,2726,Unspecified,,,,,Membrane permeability dissolved in PBS/EtOH (80:20) mixture by PAMPA-BBB assay,Other,19663388.0,
710,444050,7,1,,103169389,2726,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
711,444051,6,2,,103169389,2726,Unspecified,,,,,Total clearance in human,Other,20070106.0,
712,444052,6,2,,103169389,2726,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
713,444053,6,2,,103169389,2726,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
714,444054,6,1,,103169389,2726,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
715,444055,3,3,,103169389,2726,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
716,444056,3,3,,103169389,2726,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
717,444057,3,3,,103169389,2726,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
718,444058,6,2,,103169389,2726,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
719,453203,3,4,,103169389,2726,Unspecified,,,,,"Lipophilicity, log D of the compound",Other,19963379.0,
720,453204,3,6,,103169389,2726,Unspecified,,,,,Permeability in human skin after 48 hrs by Franz cell permeability assay,Other,19963379.0,
721,455986,3,5,,103169389,2726,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
722,463106,1,2,,90340916,2726,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
723,469403,5,1,,103169389,2726,Unspecified,,,,,Permeability across PAMPA membrane,Other,19856923.0,
724,485281,1,1,,11110991,2726,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
725,485290,1,1,,11110991,2726,Inactive,20150581.0,,17.7828,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
726,485290,1,1,,26747094,2726,Inactive,20150581.0,,79.4328,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
727,485290,1,1,,26751621,2726,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
728,485295,1,2,,90340916,2726,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
729,485297,1,1,,90340916,2726,Inactive,4759012.0,9367.0,91.9997,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
730,485298,1,1,,90340916,2726,Inactive,,,20.5962,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
731,485313,1,2,,90340916,2726,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
732,485342,1,2,,90340916,2726,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
733,485345,1,2,,90340916,2726,Inconclusive,,,10.3225,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
734,485350,1,2,,92124167,2726,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
735,485366,1,2,,90340916,2726,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
736,485368,1,2,,90340916,2726,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
737,488772,1,1,,90340916,2726,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
738,488773,1,2,,90340916,2726,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
739,488816,1,1,,90340916,2726,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
740,488837,1,1,,90340916,2726,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
741,488949,1,2,,90340916,2726,Inconclusive,41055989.0,54737.0,23.7781,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
742,488953,1,1,,90340916,2726,Inconclusive,187960037.0,10951.0,50.1187,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
743,488978,1,1,,90340916,2726,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
744,488981,1,1,,90340916,2726,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
745,488982,1,1,,90340916,2726,Inactive,4503383.0,1812.0,0.4109,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
746,488983,1,1,,90340916,2726,Inconclusive,4503383.0,1812.0,0.4467,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
747,490180,3,3,,103169389,2726,Unspecified,,,,,"Toxicity in rat assessed as time spent on rotarod at 4 mg/kg, ip by rotarod test",Other,20392546.0,
748,492967,1,2,,99301712,2726,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
749,493033,1,2,,92124167,2726,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
750,493106,1,1,,90340916,2726,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
751,493107,1,1,,90340916,2726,Inconclusive,116283940.0,79915.0,29.081,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
752,493153,1,1,,90340916,2726,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
753,493153,1,1,,90340916,2726,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
754,493162,1,2,,99301712,2726,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
755,493164,1,2,,90340916,2726,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
756,493164,1,2,,90340916,2726,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
757,493164,1,2,,90340916,2726,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
758,496817,4,2,,103169389,2726,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
759,496818,4,2,,103169389,2726,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
760,496819,4,2,,103169389,2726,Active,,,28.0,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
761,496820,4,2,,103169389,2726,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
762,496821,4,2,,103169389,2726,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
763,496823,4,2,,103169389,2726,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
764,496824,4,2,,103169389,2726,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
765,496825,4,2,,103169389,2726,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
766,496826,4,2,,103169389,2726,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
767,496827,4,2,,103169389,2726,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
768,496828,4,2,,103169389,2726,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
769,496829,4,2,,103169389,2726,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
770,496830,4,2,,103169389,2726,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
771,496831,4,2,,103169389,2726,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
772,496832,4,2,,103169389,2726,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
773,497005,4,2,,103169389,2726,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
774,502877,2,3,,103169389,2726,Active,,,0.0032,Ki,Displacement of [3H]spiperone from D2 like receptor in pig striatal tissue by topcount scintillation counting,Confirmatory,20709559.0,
775,504327,1,1,,11110991,2726,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
776,504327,1,1,,90340916,2726,Inconclusive,153791535.0,2648.0,39.8107,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
777,504332,1,1,,11110991,2726,Inconclusive,168985070.0,,8.9125,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
778,504332,1,1,,90340916,2726,Inconclusive,168985070.0,,21.1923,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
779,504536,1,1,,90340916,2726,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
780,504547,1,1,,90340916,2726,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
781,504548,1,2,,90340916,2726,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
782,504749,1,3,,26751621,2726,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
783,504749,1,3,,104171139,2726,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
784,504749,1,3,1.0,26751621,2726,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
785,504749,1,3,2.0,104171139,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
786,504749,1,3,3.0,104171139,2726,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
787,504749,1,3,4.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
788,504749,1,3,5.0,104171139,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
789,504749,1,3,6.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
790,504749,1,3,7.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
791,504749,1,3,8.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
792,504749,1,3,9.0,104171139,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
793,504749,1,3,10.0,26751621,2726,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
794,504749,1,3,11.0,26751621,2726,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
795,504749,1,3,12.0,104171139,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
796,504749,1,3,13.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
797,504749,1,3,14.0,104171139,2726,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
798,504749,1,3,15.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
799,504749,1,3,16.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
800,504749,1,3,17.0,26751621,2726,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
801,504749,1,3,18.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
802,504749,1,3,19.0,26751621,2726,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
803,504749,1,3,20.0,104171139,2726,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
804,504749,1,3,21.0,26751621,2726,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
805,504749,1,3,22.0,104171139,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
806,504749,1,3,23.0,104171139,2726,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
807,504749,1,3,24.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
808,504749,1,3,25.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
809,504749,1,3,26.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
810,504749,1,3,27.0,104171139,2726,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
811,504749,1,3,28.0,104171139,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
812,504749,1,3,29.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
813,504749,1,3,30.0,104171139,2726,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
814,504749,1,3,31.0,104171139,2726,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
815,504749,1,3,32.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
816,504749,1,3,33.0,104171139,2726,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
817,504749,1,3,34.0,26751621,2726,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
818,504749,1,3,35.0,26751621,2726,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
819,504749,1,3,36.0,104171139,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
820,504749,1,3,37.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
821,504749,1,3,38.0,104171139,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
822,504749,1,3,39.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
823,504749,1,3,40.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
824,504749,1,3,41.0,104171139,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
825,504749,1,3,42.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
826,504749,1,3,43.0,26751621,2726,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
827,504749,1,3,44.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
828,504749,1,3,45.0,104171139,2726,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
829,504749,1,3,46.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
830,504749,1,3,47.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
831,504749,1,3,48.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
832,504749,1,3,49.0,26751621,2726,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
833,504749,1,3,50.0,104171139,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
834,504749,1,3,51.0,26751621,2726,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
835,504749,1,3,52.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
836,504749,1,3,53.0,104171139,2726,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
837,504749,1,3,54.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
838,504749,1,3,55.0,104171139,2726,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
839,504749,1,3,56.0,26751621,2726,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
840,504749,1,3,57.0,26751621,2726,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
841,504749,1,3,58.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
842,504749,1,3,59.0,104171139,2726,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
843,504749,1,3,60.0,104171139,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
844,504749,1,3,61.0,26751621,2726,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
845,504770,1,2,,92124167,2726,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
846,504810,1,2,,90340916,2726,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
847,504812,1,2,,90340916,2726,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
848,504832,1,1,,104171139,2726,Inconclusive,,,19.0115,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
849,504834,1,1,,104171139,2726,Inactive,,,21.3313,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
850,504836,1,2,,90340916,2726,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
851,504845,1,1,,90340916,2726,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
852,504845,1,1,,104171139,2726,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
853,504847,1,1,,11110991,2726,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
854,504847,1,1,,90340916,2726,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
855,504847,1,1,,104171139,2726,Inconclusive,63054845.0,7421.0,50.1187,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
856,504865,1,1,,11110991,2726,Inconclusive,118600387.0,7398.0,39.8107,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
857,504865,1,1,,90340916,2726,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
858,504865,1,1,,104171139,2726,Inconclusive,118600387.0,7398.0,50.1187,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
859,515780,5,1,,103169389,2726,Unspecified,,,,,Intrinsic solubility of the compound in water,Other,20810286.0,
860,526528,2,5,,103169389,2726,Unspecified,,,,,Metabolic stability of the compound in ICR mouse liver microsome assessed as compound remaining at 1 uM,Other,20850971.0,
861,526529,2,5,,103169389,2726,Unspecified,,,,,Metabolic stability of the compound in ICR mouse liver microsome assessed as compound remaining at 1 uM in presence of NADPH,Other,20850971.0,
862,532573,5,2,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 by broth dilution method,Other,18694955.0,
863,532574,5,2,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing acrB::aph mutant by broth dilution method,Other,18694955.0,
864,532575,5,2,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing acrD::aph mutant by broth dilution method,Other,18694955.0,
865,532576,5,2,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing acrF::aph mutant by broth dilution method,Other,18694955.0,
866,532577,5,2,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing tolC::aph mutant by broth dilution method,Other,18694955.0,
867,532578,5,2,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing marA::aph mutant by broth dilution method,Other,18694955.0,
868,532579,5,2,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing soxS::aph mutant by broth dilution method,Other,18694955.0,
869,532580,5,2,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph mutant by broth dilution method,Other,18694955.0,
870,532763,2,4,,103169389,2726,Inconclusive,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph mutant by broth dilution method in presence of chlorpromazine,Other,18694955.0,
871,532764,5,2,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph-pTRC hisA:ramA mutant by broth dilution method,Other,18694955.0,
872,532765,5,2,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph-pTRC hisA:ramA mutant by broth dilution method in presence of IPTG,Other,18694955.0,
873,532774,2,5,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 assessed as ramA expression at 200 ug/ml,Other,18694955.0,
874,532775,2,5,,103169389,2726,Inconclusive,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph mutant assessed as ramA expression at 200 ug/ml,Other,18694955.0,
875,532776,2,5,,103169389,2726,Inconclusive,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph-pTRC hisA:ramA mutant assessed as ramA expression at 200 ug/ml,Other,18694955.0,
876,532777,2,5,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing acrB::aph mutant assessed as ramA expression at 200 ug/ml,Other,18694955.0,
877,532778,2,5,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 assessed as acrB expression at 200 ug/ml,Other,18694955.0,
878,532779,2,5,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph mutant assessed as acrB expression at 200 ug/ml,Other,18694955.0,
879,532780,2,5,,103169389,2726,Inconclusive,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph-pTRC hisA:ramA mutant assessed as acrB expression at 200 ug/ml,Other,18694955.0,
880,532781,2,5,,103169389,2726,Inconclusive,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing acrB::aph mutant assessed as acrB expression at 200 ug/ml,Other,18694955.0,
881,534131,4,1,,103169389,2726,Unspecified,,,,,Antiparasitic activity against Naegleria fowleri ATCC 30215 trophozoites after 6 days,Other,18765686.0,
882,534132,4,1,,103169389,2726,Unspecified,,,,,Antiparasitic activity against Naegleria fowleri ATCC 30215 trophozoites after 2 days,Other,18765686.0,
883,534133,4,1,,103169389,2726,Unspecified,,,,,Antiparasitic activity against Naegleria fowleri ATCC 30215 trophozoites after 4 days,Other,18765686.0,
884,534134,2,5,,103169389,2726,Unspecified,,,,,Antiparasitic activity against Naegleria fowleri ATCC 30215 trophozoites at 25 ug/ml on day 6 by LDH release assay,Other,18765686.0,
885,534144,2,5,,103169389,2726,Unspecified,,,,,Antiparasitic activity against Naegleria fowleri ATCC 30215 trophozoites at 100 ug/ml on day 4 by LDH release assay,Other,18765686.0,
886,534146,6,1,,103169389,2726,Unspecified,,,,,"Blood urea nitrogen level in BALB/c mouse serum at 10 mg/kg, ip",Other,18765686.0,
887,534147,6,1,,103169389,2726,Unspecified,,,,,"Blood urea nitrogen level in BALB/c mouse serum at 20 mg/kg, ip",Other,18765686.0,
888,534148,6,1,,103169389,2726,Unspecified,,,,,"Blood urea nitrogen level in BALB/c mouse serum at 50 mg/kg, ip",Other,18765686.0,
889,534149,2,5,,103169389,2726,Unspecified,,,,,"Hepatotoxicity in BALB/c mouse hepatocytes assessed as change in cell morphology at 20 mg/kg, ip by histopathological analysis",Other,18765686.0,
890,534150,2,3,,103169389,2726,Unspecified,,,,,"Renal toxicity in BALB/c mouse assessed as degeneration of renal tubules at 20 mg/kg, ip by histopathological analysis",Other,18765686.0,
891,534151,2,4,,103169389,2726,Unspecified,,,,,"Renal toxicity in BALB/c mouse assessed as necrosis in kidney cortex at 20 mg/kg, ip by histopathological analysis",Other,18765686.0,
892,534152,2,3,,103169389,2726,Unspecified,,,,,"Renal toxicity in BALB/c mouse assessed as change in renal cortical tubule morphology at 20 mg/kg, ip by histopathological analysis",Other,18765686.0,
893,534357,2,6,,103169389,2726,Unspecified,,,,,"Antiparasitic activity against Naegleria fowleri ATCC 30215 trophozoites infected in BALB/c mouse assessed as mouse survival at 20 mg/kg, ip administered on days 3 and 7 postinfection",Other,18765686.0,
894,534358,2,6,,103169389,2726,Unspecified,,,,,"Antiparasitic activity against Naegleria fowleri ATCC 30215 trophozoites infected in BALB/c mouse assessed as mouse survival at 20 mg/kg, ip administered on days 3, 7 and 11 postinfection",Other,18765686.0,
895,534359,2,6,,103169389,2726,Unspecified,,,,,"Antiparasitic activity against Naegleria fowleri ATCC 30215 trophozoites infected in BALB/c mouse assessed as mean time to death at 20 mg/kg, ip administered on days 3, 7 and 11 postinfection",Other,18765686.0,
896,534360,2,5,,103169389,2726,Active,,,,,Antiparasitic activity against Naegleria fowleri ATCC 30215 trophozoites infected in BALB/c mouse brain by histopathology analysis,Other,18765686.0,
897,537763,6,5,,103169389,2726,Active,1168220.0,3357.0,0.052000000000000005,Ki,Displacement of [3H]LSD from human cloned 5HT2B receptor expressed in CHO cells by liquid scintillation counting,Confirmatory,20958049.0,
898,540209,4,3,,103169389,2726,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
899,540210,4,3,,103169389,2726,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
900,540211,2,5,,103169389,2726,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
901,540212,4,3,,103169389,2726,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
902,540213,4,3,,103169389,2726,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
903,540222,4,3,,103169389,2726,Unspecified,,,,,Clearance in rat after iv administration,Other,16621936.0,
904,540223,3,2,,103169389,2726,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,16621936.0,
905,540224,4,3,,103169389,2726,Unspecified,,,,,Clearance in dog after iv administration,Other,16621936.0,
906,540225,4,3,,103169389,2726,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,16621936.0,
907,540226,4,3,,103169389,2726,Unspecified,,,,,Clearance in monkey after iv administration,Other,16621936.0,
908,540227,4,3,,103169389,2726,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,16621936.0,
909,540228,4,3,,103169389,2726,Unspecified,,,,,Clearance in human after iv administration,Other,16621936.0,
910,540229,4,3,,103169389,2726,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,16621936.0,
911,540234,2,5,,103169389,2726,Unspecified,,,,,Cerep Phospholipidosis assay (HepG2 cells),Other,,
912,540237,2,3,,103169389,2726,Active,,,,,Phospholipidosis-positive literature compound observed in rat,Other,17428028.0,
913,540239,2,3,,103169389,2726,Active,,,,,Phospholipidosis-positive literature compound observed in dog,Other,17428028.0,
914,540256,1,2,,90340916,2726,Active,,,23.0999,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
915,540276,1,2,,11110990,2726,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
916,540276,1,2,,11110991,2726,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
917,540276,1,2,,26747094,2726,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
918,540276,1,2,,26747095,2726,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
919,540276,1,2,,26751620,2726,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
920,540276,1,2,,26751621,2726,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
921,540276,1,2,,50100209,2726,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
922,540276,1,2,,50104291,2726,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
923,540276,1,2,,90340916,2726,Inconclusive,420597.0,,9.1962,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
924,540276,1,2,,104171139,2726,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
925,540299,1,2,,92124167,2726,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
926,547838,4,7,,103169389,2726,Active,215273968.0,316.0,,IC50,Inhibition of human aldehyde oxidase,Confirmatory,20853847.0,
927,547841,4,2,,103169389,2726,Active,,,,IC50,Inhibition of guinea pig aldehyde oxidase,Confirmatory,20853847.0,
928,547842,4,7,,103169389,2726,Active,20981678.0,100008601.0,20.0,IC50,Inhibition of rabbit aldehyde oxidase,Confirmatory,20853847.0,
929,554098,2,11,,103169389,2726,Unspecified,60392839.0,,,,Inhibition of NorA in Staphylococcus aureus 1199B assessed as reduction in ethidium bromide efflux at 50 uM by fluorimetry after 5 mins,Other,21141825.0,
930,564968,1,4,,103169389,2726,Unspecified,,,,,Upregulation of p27 gene expression in Mycobacterium tuberculosis by microarray,Other,19564371.0,
931,564969,1,4,,103169389,2726,Unspecified,,,,,Upregulation of p55 gene expression Mycobacterium tuberculosis by microarray,Other,19564371.0,
932,564970,1,4,,103169389,2726,Unspecified,,,,,Downregulation of p27 gene expression Mycobacterium tuberculosis by microarray,Other,19564371.0,
933,564971,1,4,,103169389,2726,Unspecified,,,,,Downregulation of p55 gene expression Mycobacterium tuberculosis by microarray,Other,19564371.0,
934,564972,4,2,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Mycobacterium bovis BCG by twofold dilution method,Other,19564371.0,
935,564977,5,2,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring inactivated p55 gene by twofold dilution method,Other,19564371.0,
936,564987,4,2,,103169389,2726,Inconclusive,,,,,Antimicrobial activity against Mycobacterium bovis BCG harboring pPAZ23 carrying p27-p55 operon by twofold dilution method,Other,19564371.0,
937,568159,2,6,,103169389,2726,Unspecified,,,,,Metabolic stability in ICR mouse liver microsomes assessed as compound remaining at 1 uM after 60 mins in absence of NADPH,Other,21256006.0,
938,568160,2,6,,103169389,2726,Unspecified,,,,,Metabolic stability in ICR mouse liver microsomes assessed as compound remaining at 1 uM after 60 mins in presence of NADPH,Other,21256006.0,
939,576612,7,5,,103169389,2726,Active,7531135.0,3757.0,1.4791100000000001,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
940,581672,7,1,,103169389,2726,Active,,,4.5,IC50,Inhibition of Pdr5p-mediated rhodamine 6G transport in Saccharomyces cerevisiae MKPDR5h plasma membrane by spectrofluorometric assay,Confirmatory,19188399.0,
941,581806,4,1,,103169389,2726,Unspecified,,,,,Inhibition of Saccharomyces cerevisiae MKPDR5h multidrug transporter Pdr5p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening spectrofluorometric assay,Other,19188399.0,
942,581807,4,1,,103169389,2726,Unspecified,,,,,Inhibition of Saccharomyces cerevisiae MKCDR1h multidrug transporter Cdr1p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening spectrofluorometric assay,Other,19188399.0,
943,581808,4,1,,103169389,2726,Active,,,,,Inhibition of Saccharomyces cerevisiae MKSNQ2h multidrug transporter Snq2p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening spectrofluorometric assay,Other,19188399.0,
944,588208,2,3,,103169389,2726,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
945,588209,2,3,,103169389,2726,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
946,588210,2,4,,103169389,2726,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
947,588211,2,3,,103169389,2726,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
948,588212,2,3,,103169389,2726,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
949,588213,2,3,,103169389,2726,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
950,588220,2,3,,103169389,2726,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
951,588346,1,1,,124879757,2726,Inconclusive,168985070.0,,25.1189,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a: Hit Confirmation in b-rIgG Counterscreen,Confirmatory,,
952,588349,1,1,,90340916,2726,Inconclusive,,,25.1189,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
953,588378,1,1,,90340916,2726,Inconclusive,171543895.0,6311.0,14.1254,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
954,588453,1,1,,90340916,2726,Inactive,8659577.0,58819.0,1.9953,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
955,588453,1,1,,124879754,2726,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
956,588453,1,1,,124879757,2726,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
957,588456,1,1,,90340916,2726,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
958,588456,1,1,,124879754,2726,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
959,588456,1,1,,124879757,2726,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
960,588519,1,2,,92124167,2726,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
961,588579,1,1,,11110991,2726,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
962,588579,1,1,,90340916,2726,Inconclusive,7705344.0,51426.0,37.6858,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
963,588579,1,1,,104171139,2726,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
964,588579,1,1,,124879752,2726,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
965,588579,1,1,,124879754,2726,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
966,588579,1,1,,124879757,2726,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
967,588590,1,1,,124879754,2726,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
968,588590,1,1,,124879757,2726,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
969,588795,1,1,,90340916,2726,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
970,588795,1,1,,124879754,2726,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
971,588795,1,1,,124879757,2726,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
972,588834,2,1,,26751621,2726,Active,325651834.0,3757.0,14.1254,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
973,588855,1,1,,124879754,2726,Inconclusive,18418623.0,4088.0,35.4813,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
974,588856,1,1,,124879754,2726,Active,,,15.8489,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
975,589024,1,10,,103169389,2726,Unspecified,49066046.0,9970.0,,,Constitutive androstane receptor inverse agonist,Other,,
976,589030,1,10,,103169389,2726,Unspecified,341941191.0,12355.0,,,Constitutive androstane receptor agonist,Other,,
977,589038,1,10,,103169389,2726,Unspecified,84028191.0,1565.0,,,"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP2D6",Other,,
978,592681,1,4,,103169389,2726,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
979,602310,1,2,,124879754,2726,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
980,602314,1,2,,92124167,2726,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
981,602332,1,1,,11110991,2726,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
982,602332,1,1,,90340916,2726,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
983,602332,1,1,,104171139,2726,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
984,602332,1,1,,124879752,2726,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
985,602332,1,1,,124879754,2726,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
986,603866,6,2,,103169389,2726,Active,,,10.3,IC50,Inhibition of Calmodulin-dependent PDE1 activity assessed as inorganic phosphate release after 30 min,Confirmatory,21514702.0,
987,603867,2,1,,103169389,2726,Active,,,5.55,Km,Binding affinity to human Calmodulin M124C mutant assessed as extrinsic fluorescence quenching in phosphate buffer at pH 5.1 by mBBr fluorescence assay,Confirmatory,21514702.0,
988,603955,1,3,,103169389,2726,Unspecified,,,,,"In-vivo blood to lung partition coefficients of the compound, logP(lung) in rat",Other,17544548.0,
989,611557,1,4,,103169389,2726,Inconclusive,,,,Ki,Displacement of [3H]SCH-23390 from dopamine D1 like receptor in porcine striatal membranes after 30 mins by scintillation counting,Confirmatory,21714510.0,
990,611558,1,4,,103169389,2726,Active,,,0.008,Ki,Displacement of [3H]spiperone from dopamine D2 like receptor in porcine striatal membranes after 30 mins by scintillation counting,Confirmatory,21714510.0,
991,611559,1,4,,103169389,2726,Inconclusive,,,,,Selectivity ratio Ki for dopamine D2 like receptor in porcine striatal membranes to Ki for dopamine D1 like receptor in porcine striatal membranes,Other,21714510.0,
992,617955,1,5,,103169389,2726,Active,,,0.00267,Ki,Displacement of [3H]-N-methylspiperone from dopamine D2-like receptor in pig striatal tissue homogenates after 30 mins by scintillation counting,Confirmatory,21862338.0,
993,619744,8,1,,103169389,2726,Active,,,,IC50,Displacement of [3H]mesulergine from 5-HT2C receptor after 1.5 hrs by scintillation counting,Confirmatory,21907583.0,
994,619748,5,2,,103169389,2726,Active,,,,IC50,Displacement of [3H]LSD from 5-HT7 receptor after 1.5 hrs by scintillation counting,Confirmatory,21907583.0,
995,620399,3,1,,103169389,2726,Unspecified,,,,,Permeability of the compound by PAMPA,Other,21871694.0,
996,624030,1,2,,104171139,2726,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
997,624031,1,2,,104171139,2726,Active,,,8.0875,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
998,624032,1,2,,104171139,2726,Inconclusive,8393992.0,24660.0,40.5334,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
999,624044,1,2,,104171139,2726,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
1000,624146,1,1,,90340916,2726,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
1001,624147,1,1,,90340916,2726,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
1002,624148,1,2,,90340916,2726,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
1003,624149,1,1,,90340916,2726,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
1004,624170,1,1,,104171139,2726,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1005,624172,1,1,,104171139,2726,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1006,624173,1,3,,104171139,2726,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1007,624178,1,1,,124879754,2726,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1008,624178,1,1,,124879757,2726,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1009,624180,1,1,,135650088,2726,Active,12621102.0,65032.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT7,Other,7908055.0,
1010,624181,1,1,,135650088,2726,Active,10880131.0,3363.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT7,Other,15821958.0,
1011,624183,1,1,,135650088,2726,Active,113865998.0,15566.0,,,Antagonists at Mouse 5-Hydroxytryptamine receptor 5-HT7,Other,8394987.0,
1012,624190,1,1,,135650088,2726,Active,13242259.0,64354.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT6,Other,7908055.0,
1013,624192,1,1,,135650088,2726,Active,4504545.0,3362.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT6,Other,8522988.0,
1014,624192,1,1,,135650088,2726,Active,4504545.0,3362.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT6,Other,15821958.0,
1015,624202,1,1,,124879754,2726,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1016,624202,1,1,,124879757,2726,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1017,624209,1,1,,135650088,2726,Active,377520139.0,3358.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2C,Other,10991983.0,
1018,624209,1,1,,135650088,2726,Active,377520139.0,3358.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2C,Other,12629531.0,
1019,624215,1,1,,135650088,2726,Active,55956923.0,3350.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1A,Other,9760039.0,
1020,624222,1,1,,135650088,2726,Active,8393583.0,29595.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT2A,Other,9655845.0,
1021,624223,1,1,,135650088,2726,Active,260099679.0,3356.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A,Other,12629531.0,
1022,624263,1,1,,124879754,2726,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1023,624263,1,1,,124879754,2726,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1024,624263,1,1,,124879757,2726,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1025,624263,1,1,,124879757,2726,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1026,624296,1,1,,26751621,2726,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1027,624296,1,1,,104171139,2726,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1028,624297,1,1,,26751621,2726,Inconclusive,7705682.0,51053.0,29.0929,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1029,624297,1,1,,104171139,2726,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1030,624349,1,2,,92124167,2726,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1031,624349,1,2,,92307276,2726,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1032,624349,1,2,,92308728,2726,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1033,624414,1,1,,124879754,2726,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1034,624414,1,1,,124879757,2726,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1035,624455,1,1,,90340916,2726,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
1036,624607,1,9,,103169389,2726,Unspecified,549152.0,54659.0,,,Specific activity of expressed human recombinant UGT1A3,Other,10836148.0,
1037,624608,3,2,,103169389,2726,Unspecified,136731.0,54657.0,,,Specific activity of expressed human recombinant UGT1A4,Other,10836148.0,
1038,624622,3,1,,103169389,2726,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
1039,624623,3,1,,103169389,2726,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells,Other,11602674.0,
1040,624626,1,9,,103169389,2726,Unspecified,238054374.0,5243.0,,,Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
1041,624628,1,9,,103169389,2726,Unspecified,238054374.0,5243.0,,,Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM,Other,11602674.0,
1042,624629,1,9,,103169389,2726,Unspecified,238054374.0,5243.0,,,Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay,Other,11602674.0,
1043,625144,5,5,,103169389,2726,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1044,625145,4,7,,103169389,2726,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1045,625146,5,5,,103169389,2726,Active,126397.0,100009114.0,15.950999999999999,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1046,625147,4,7,,103169389,2726,Active,395398606.0,4159.0,24.343000000000004,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1047,625148,4,7,,103169389,2726,Active,60392672.0,4160.0,15.204,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1048,625149,4,7,,103169389,2726,Active,729996.0,4161.0,7.617000000000001,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1049,625150,5,5,,103169389,2726,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1050,625151,4,7,,103169389,2726,Active,113118.0,1128.0,0.083,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1051,625152,4,7,,103169389,2726,Active,113122.0,1129.0,0.652,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1052,625153,4,7,,103169389,2726,Active,113125.0,1131.0,0.20600000000000002,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1053,625154,4,7,,103169389,2726,Active,23503039.0,1132.0,0.149,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1054,625155,4,7,,103169389,2726,Active,543761.0,1133.0,0.025,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1055,625156,1,9,,103169389,2726,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1056,625157,6,2,,103169389,2726,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1057,625158,3,4,,103169389,2726,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1058,625159,5,5,,103169389,2726,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1059,625160,1,9,,103169389,2726,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1060,625161,4,7,,103169389,2726,Active,311033488.0,4985.0,20.894000000000002,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1061,625162,4,7,,103169389,2726,Active,116242691.0,4986.0,11.082,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1062,625163,4,7,,103169389,2726,Active,2851402.0,4988.0,14.397,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1063,625164,1,6,,103169389,2726,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1064,625165,3,4,,103169389,2726,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1065,625166,3,4,,103169389,2726,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1066,625167,5,5,,103169389,2726,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1067,625168,4,7,,103169389,2726,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1068,625169,1,6,,103169389,2726,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1069,625170,3,4,,103169389,2726,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1070,625171,4,7,,103169389,2726,Active,7531135.0,3757.0,5.8275,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1071,625172,4,7,,103169389,2726,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1072,625173,5,5,,103169389,2726,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1073,625174,5,5,,103169389,2726,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1074,625175,5,5,,103169389,2726,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1075,625176,1,9,,103169389,2726,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1076,625177,5,5,,103169389,2726,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1077,625178,5,5,,103169389,2726,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1078,625179,1,9,,103169389,2726,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1079,625180,5,5,,103169389,2726,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1080,625181,5,5,,103169389,2726,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1081,625182,5,5,,103169389,2726,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1082,625183,5,5,,103169389,2726,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1083,625184,5,5,,103169389,2726,Active,2811086.0,1956.0,28.868000000000002,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1084,625185,5,5,,103169389,2726,Active,125370.0,2534.0,8.68,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1085,625186,5,5,,103169389,2726,Active,119533.0,2064.0,19.366,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1086,625187,5,5,,103169389,2726,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1087,625188,1,9,,103169389,2726,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1088,625189,1,7,,103169389,2726,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1089,625190,4,5,,103169389,2726,Active,,,4.685,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1090,625191,4,7,,103169389,2726,Active,112815.0,25075.0,4.041,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1091,625192,4,7,,103169389,2726,Active,543727.0,3356.0,0.00385,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1092,625193,5,5,,103169389,2726,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1093,625194,4,7,,103169389,2726,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1094,625195,4,7,,103169389,2726,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1095,625196,5,6,,103169389,2726,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1096,625197,3,4,,103169389,2726,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1097,625198,4,7,,103169389,2726,Active,1168247.0,29412.0,0.00854,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1098,625199,4,7,,103169389,2726,Active,543734.0,24173.0,0.00897,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1099,625200,4,7,,103169389,2726,Active,1168243.0,146.0,0.00399,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1100,625201,4,7,,103169389,2726,Active,1351829.0,150.0,0.35200000000000004,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1101,625202,4,7,,103169389,2726,Active,613504690.0,151.0,0.026000000000000002,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1102,625203,4,7,,103169389,2726,Active,20141211.0,152.0,0.374,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1103,625204,4,7,,103169389,2726,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1104,625205,4,7,,103169389,2726,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1105,625206,4,7,,103169389,2726,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1106,625207,4,7,,103169389,2726,Active,128616.0,6530.0,0.019,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1107,625208,5,5,,103169389,2726,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1108,625209,4,7,,103169389,2726,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1109,625210,3,4,,103169389,2726,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1110,625211,1,6,,103169389,2726,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1111,625212,3,4,,103169389,2726,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1112,625213,4,7,,103169389,2726,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1113,625214,1,9,,103169389,2726,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1114,625215,3,4,,103169389,2726,Active,,,3.214,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1115,625216,3,4,,103169389,2726,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1116,625217,4,7,,103169389,2726,Active,1168220.0,3357.0,0.126,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1117,625218,4,7,,103169389,2726,Active,112816.0,3358.0,0.00524,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1118,625219,3,4,,103169389,2726,Active,,,7.365,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1119,625220,4,7,,103169389,2726,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1120,625221,4,7,,103169389,2726,Active,1703010.0,3362.0,0.057,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1121,625222,4,7,,103169389,2726,Active,400630.0,6532.0,0.039,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1122,625223,4,7,,103169389,2726,Active,74752153.0,10280.0,0.451,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1123,625224,3,4,,103169389,2726,Active,,,2.718,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1124,625225,3,4,,103169389,2726,Active,,,2.832,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1125,625226,4,7,,103169389,2726,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1126,625227,4,7,,103169389,2726,Active,229462950.0,6865.0,27.195,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1127,625228,4,7,,103169389,2726,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1128,625229,5,5,,103169389,2726,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1129,625230,1,6,,103169389,2726,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1130,625231,4,7,,103169389,2726,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1131,625232,1,9,,103169389,2726,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1132,625233,4,7,,103169389,2726,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1133,625234,3,4,,103169389,2726,Active,,,1.527,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1134,625235,4,7,,103169389,2726,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1135,625236,5,5,,103169389,2726,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1136,625237,4,7,,103169389,2726,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1137,625238,4,7,,103169389,2726,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1138,625239,4,7,,103169389,2726,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1139,625240,1,9,,103169389,2726,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1140,625241,4,7,,103169389,2726,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1141,625242,4,7,,103169389,2726,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1142,625243,5,5,,103169389,2726,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1143,625244,5,5,,103169389,2726,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1144,625245,5,5,,103169389,2726,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1145,625246,1,9,,103169389,2726,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1146,625247,5,5,,103169389,2726,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1147,625248,5,5,,103169389,2726,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1148,625249,5,5,,103169389,2726,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1149,625250,5,5,,103169389,2726,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1150,625251,5,5,,103169389,2726,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1151,625252,4,7,,103169389,2726,Active,118228.0,1812.0,0.225,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1152,625253,4,7,,103169389,2726,Active,118206.0,1813.0,0.054000000000000006,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1153,625254,4,7,,103169389,2726,Active,1169206.0,1814.0,0.012,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1154,625255,4,7,,103169389,2726,Active,1345939.0,1815.0,1.365,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1155,625256,4,7,,103169389,2726,Active,266667.0,6531.0,2.6430000000000002,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1156,625257,4,7,,103169389,2726,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1157,625258,4,7,,103169389,2726,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1158,625259,4,7,,103169389,2726,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1159,625260,3,4,,103169389,2726,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1160,625261,3,4,,103169389,2726,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1161,625262,3,4,,103169389,2726,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1162,625263,4,7,,103169389,2726,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1163,625264,3,4,,103169389,2726,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1164,625265,1,6,,103169389,2726,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1165,625266,3,4,,103169389,2726,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1166,625267,3,4,,103169389,2726,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1167,625268,4,2,,103169389,2726,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1168,625268,4,2,,103169389,2726,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1169,625268,4,2,,103169389,2726,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1170,625268,4,2,,103169389,2726,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1171,625269,4,7,,103169389,2726,Active,547645.0,3269.0,0.017,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1172,625270,4,7,,103169389,2726,Active,123120.0,3274.0,2.6260000000000003,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1173,625271,5,5,,103169389,2726,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1174,625272,3,4,,103169389,2726,Active,,,2.6710000000000003,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1175,625273,4,6,,103169389,2726,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1176,625274,1,6,,103169389,2726,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1177,625275,3,4,,103169389,2726,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1178,625277,1,3,,103169389,2726,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
1179,625279,1,3,,103169389,2726,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
1180,625280,1,3,,103169389,2726,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
1181,625281,1,3,,103169389,2726,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
1182,625282,1,3,,103169389,2726,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
1183,625283,1,3,,103169389,2726,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
1184,625284,1,3,,103169389,2726,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
1185,625285,1,3,,103169389,2726,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
1186,625286,1,3,,103169389,2726,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
1187,625287,1,3,,103169389,2726,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
1188,625288,1,3,,103169389,2726,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
1189,625289,1,3,,103169389,2726,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
1190,625290,1,3,,103169389,2726,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
1191,625291,1,3,,103169389,2726,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
1192,625292,1,3,,103169389,2726,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
1193,637498,1,5,,103169389,2726,Active,,,0.0076,Ki,Displacement of [3H]spiperone from dopamine D2-like receptor in porcine striatal homogenates after 30 mins by scintillation counting,Confirmatory,22204903.0,
1194,639368,3,1,,103169389,2726,Unspecified,,,,,Permeability of the compound by PAMPA assay,Other,21420206.0,
1195,643383,1,6,,103169389,2726,Unspecified,,,,,Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy,Other,22122484.0,
1196,648667,3,1,,103169389,2726,Unspecified,,,,,Permeability of the compound in porcine brain lipid assessed as ratio of compound in acceptor plate to amount of compound in donor plate at 5 mg/ml after 10 hrs by PAMPA assay,Other,22341944.0,
1197,651631,4,1,,144203671,2726,Inconclusive,269849759.0,7157.0,10.5909,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1198,651632,4,1,,144203671,2726,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1199,651633,4,1,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1200,651634,4,1,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1201,651635,1,3,,11110991,2726,Inconclusive,171543895.0,6311.0,7.0795,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1202,651635,1,3,,90340916,2726,Inconclusive,171543895.0,6311.0,25.1189,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1203,651741,1,1,,124879756,2726,Inconclusive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1204,651828,1,2,,92308728,2726,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1205,651965,1,1,,124879754,2726,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1206,651965,1,1,,124879757,2726,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1207,652048,1,2,,144203671,2726,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1208,652051,1,1,,144203671,2726,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1209,652106,1,1,,90340916,2726,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1210,652106,1,1,,124879754,2726,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1211,652106,1,1,,124879757,2726,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1212,658437,2,4,,103169389,2726,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis mc2 155 after 72 hrs by MTT assay,Other,22459211.0,
1213,678712,1,8,,103169389,2726,Unspecified,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
1214,678713,1,8,,103169389,2726,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
1215,678714,1,8,,103169389,2726,Unspecified,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
1216,678715,1,8,,103169389,2726,Unspecified,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
1217,678716,1,8,,103169389,2726,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
1218,678717,1,8,,103169389,2726,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
1219,678721,1,5,,103169389,2726,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
1220,678722,1,5,,103169389,2726,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
1221,681117,3,6,,103169389,2726,Unspecified,313104181.0,6580.0,4.3,IC50,TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells,Confirmatory,12606755.0,
1222,681121,1,8,,103169389,2726,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing MDCKII cells,Other,11602674.0,
1223,681130,1,8,,103169389,2726,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells,Other,11602674.0,
1224,681139,3,6,,103169389,2726,Unspecified,262527527.0,8647.0,33.5,IC50,TP_TRANSPORTER: increase in dihydrofluorescein intracellular accumulation (dihydrofluorescein: 1 uM) in SK-E2 cells (expressing BSEP),Confirmatory,12739759.0,
1225,681155,3,6,,103169389,2726,Unspecified,262527527.0,8647.0,30.9,IC50,TP_TRANSPORTER: increase in bodipy intracellular accumulation (Bodipy: 0.2 uM) in SK-E2 cells (expressing BSEP),Confirmatory,12739759.0,
1226,681619,2,7,,103169389,2726,Unspecified,238054374.0,5243.0,27.4,Km,TP_TRANSPORTER: ATP hydrolysis in membranes from MDR1-expressing insect cells,Confirmatory,12031686.0,
1227,686970,1,2,,124879757,2726,Active,49168486.0,3417.0,15.8489,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1228,686971,1,2,,124879757,2726,Inconclusive,,,19.9526,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1229,686977,2,1,,49698686,2726,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
1230,686978,1,1,,124879752,2726,Inconclusive,79154014.0,55775.0,18.3564,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1231,686978,1,1,,124879754,2726,Inconclusive,79154014.0,55775.0,35.4813,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1232,686978,1,1,,124879757,2726,Active,79154014.0,55775.0,10.0,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1233,686978,1,1,,144203671,2726,Active,79154014.0,55775.0,23.715,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1234,686979,1,1,,124879752,2726,Inconclusive,79154014.0,55775.0,23.1093,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1235,686979,1,1,,124879754,2726,Inconclusive,79154014.0,55775.0,35.4813,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1236,686979,1,1,,124879757,2726,Active,79154014.0,55775.0,11.2202,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1237,686979,1,1,,144203671,2726,Inconclusive,79154014.0,55775.0,21.136,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1238,688495,2,2,,103169389,2726,Active,,,0.64,Kd,Binding affinity to human mBBr-labeled CaM M124C mutant by fluorescence spectroscopy,Confirmatory,22924467.0,
1239,695374,1,2,,103169389,2726,Unspecified,,,,,Selectivity ratio of Ki for human dopamine D3 receptor to Ki for human dopamine D2long receptor,Other,23018094.0,
1240,695376,3,5,,103169389,2726,Active,1169206.0,1814.0,0.0038,Ki,Displacement of [3H]-N-methylspiperone from human dopamine D3 receptor expressed in HEK293 cells after 30 mins by scintillation counting,Confirmatory,23018094.0,
1241,695377,3,5,,103169389,2726,Active,118206.0,1813.0,0.0012,Ki,Displacement of [3H]-N-methylspiperone from human dopamine D2long receptor expressed in HEK293 cells after 30 mins by scintillation counting,Confirmatory,23018094.0,
1242,695378,3,5,,103169389,2726,Inconclusive,118228.0,1812.0,,Ki,Displacement of [3H]-SCH-23390 from human dopamine D1 receptor expressed in HEK293 cells after 30 mins by scintillation counting,Confirmatory,23018094.0,
1243,695379,1,3,,103169389,2726,Active,,,0.0041,Ki,Displacement of [3H]-N-methylspiperone from dopamine D2 like receptor in pig striatal homogenates after 30 mins by scintillation counting,Confirmatory,23018094.0,
1244,695381,1,3,,103169389,2726,Inconclusive,,,,Ki,Displacement of [3H]-SCH-23390 from dopamine D1 like receptor in pig striatal homogenates after 30 mins by scintillation counting,Confirmatory,23018094.0,
1245,699539,1,7,,103169389,2726,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
1246,699540,1,7,,103169389,2726,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1247,699541,1,7,,103169389,2726,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1248,720516,2,1,,144203671,2726,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1249,720532,1,1,,11110991,2726,Active,420597.0,,7.9433,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1250,720532,1,1,,124879752,2726,Inconclusive,420597.0,,28.1838,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1251,720532,1,1,,144203671,2726,Active,420597.0,,15.8489,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1252,720533,1,1,,11110991,2726,Inconclusive,,,7.0795,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1253,720533,1,1,,124879752,2726,Inconclusive,,,35.4813,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1254,720533,1,1,,144203671,2726,Inconclusive,,,25.1189,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1255,720538,1,2,,90340916,2726,Inconclusive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
1256,720552,2,1,,144203671,2726,Active,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1257,720559,1,2,,90340916,2726,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
1258,720572,1,2,,90340916,2726,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
1259,720573,1,2,,90340916,2726,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
1260,720579,2,1,,124879752,2726,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1261,720579,2,1,,124879754,2726,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1262,720579,2,1,,124879757,2726,Inconclusive,222762.0,3707576.0,22.3872,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1263,720580,1,1,,124879752,2726,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1264,720580,1,1,,124879754,2726,Inconclusive,222762.0,3707576.0,10.0,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1265,720580,1,1,,124879757,2726,Inconclusive,222762.0,3707576.0,22.3872,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1266,720634,2,1,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1267,720635,2,1,,144203671,2726,Inconclusive,,,6.6824,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1268,720636,1,1,,124879756,2726,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1269,720637,2,1,,144203671,2726,Inconclusive,,,5.62256,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1270,720641,1,2,,92307276,2726,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
1271,720641,1,2,,92308728,2726,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
1272,720674,2,2,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1273,720675,2,2,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1274,720678,2,1,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1275,720679,2,1,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1276,720680,2,1,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1277,720681,2,1,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1278,720682,2,1,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1279,720683,2,1,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1280,720684,2,1,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1281,720685,2,1,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1282,720686,2,1,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1283,720687,2,2,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1284,720691,4,1,,144203671,2726,Inconclusive,311348376.0,2908.0,6.007000000000001,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1285,720692,3,1,,144203671,2726,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1286,720693,3,1,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1287,720717,1,3,,92124167,2726,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1288,720717,1,3,,92307276,2726,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1289,720717,1,3,,92308728,2726,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1290,720719,2,1,,144203671,2726,Inconclusive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1291,720722,1,3,,152146164,2726,Active,,,2.495,IC50_Mean,Dry powder dose  response confirmation of uHTS inhibitor hits of the mitochondrial permeability transition pore via an absorbance. Mitochondrial Swelling.,Confirmatory,,
1292,720723,1,3,,152146164,2726,Inactive,,,100.0,IC50_Mean,Dry powder dose response confirmation of uHTS inhibitor hits of the mitochondrial permeability transition pore via a fluorescent based counterscreen.  Rhodamine 123 Quenching,Confirmatory,,
1293,720725,2,1,,144203671,2726,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1294,720728,1,3,,152146164,2726,Active,,,1.97111,CRC/CRC0 at 50 microM_mean,Dry powder dose response confirmation uHTS inhibitor hits of the mitochondrial permeability transition pore via Calcium retention capacity test.,Confirmatory,,
1295,743012,3,1,,144203671,2726,Active,,,9.4392,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1296,743014,3,1,,144203671,2726,Active,,,9.4392,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1297,743015,3,1,,144203671,2726,Active,,,11.8832,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1298,743033,3,1,,144203671,2726,Inconclusive,,,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1299,743035,2,1,,144203671,2726,Inconclusive,124375976.0,367.0,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1300,743036,2,1,,144203671,2726,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1301,743040,3,1,,144203671,2726,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1302,743041,3,1,,144203671,2726,Inconclusive,,,31.21,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1303,743042,3,1,,144203671,2726,Inconclusive,124375976.0,367.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1304,743053,2,1,,144203671,2726,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1305,743054,2,1,,144203671,2726,Inconclusive,124375976.0,367.0,29.8493,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1306,743063,2,1,,144203671,2726,Inconclusive,124375976.0,367.0,26.8325,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1307,743064,3,1,,144203671,2726,Active,,,11.8832,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1308,743065,3,1,,144203671,2726,Active,399498506.0,24831.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1309,743066,3,1,,144203671,2726,Inconclusive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1310,743067,2,1,,144203671,2726,Inconclusive,399498506.0,24831.0,11.4358,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1311,743069,2,1,,144203671,2726,Inactive,348019627.0,2099.0,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1312,743074,2,1,,144203671,2726,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1313,743075,2,1,,144203671,2726,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1314,743077,2,1,,144203671,2726,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1315,743078,2,1,,144203671,2726,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1316,743079,3,1,,144203671,2726,Inconclusive,348019627.0,2099.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1317,743080,3,1,,144203671,2726,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1318,743081,3,1,,144203671,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1319,743083,3,1,,144203671,2726,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1320,743084,3,1,,144203671,2726,Inconclusive,,,26.6032,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1321,743085,3,1,,144203671,2726,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1322,743086,3,1,,144203671,2726,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1323,743091,2,1,,144203671,2726,Inconclusive,348019627.0,2099.0,29.8493,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1324,743094,3,1,,144203671,2726,Inconclusive,216409692.0,5468.0,0.4253,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1325,743122,2,1,,144203671,2726,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1326,743139,2,1,,144203671,2726,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1327,743140,2,1,,144203671,2726,Inconclusive,216409692.0,5468.0,12.4545,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1328,743191,3,1,,170465371,2726,Inconclusive,216409692.0,5468.0,26.6011,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1329,743194,3,1,,170465371,2726,Active,,,26.6011,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1330,743199,2,1,,170465371,2726,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1331,743202,4,1,,170465371,2726,Inconclusive,20149576.0,4780.0,33.4889,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1332,743203,3,1,,170465371,2726,Active,,,29.846999999999998,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1333,743205,1,1,,90340916,2726,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
1334,743205,1,1,,90340916,2726,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
1335,743206,1,1,,90340916,2726,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
1336,743206,1,1,,90340916,2726,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
1337,743207,1,1,,90340916,2726,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
1338,743207,1,1,,90340916,2726,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
1339,743209,3,1,,170465371,2726,Inconclusive,,,23.7083,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1340,743210,4,1,,170465371,2726,Inconclusive,4504517.0,3315.0,29.846999999999998,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1341,743211,3,1,,170465371,2726,Active,,,23.7083,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1342,743212,3,1,,170465371,2726,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1343,743213,3,1,,170465371,2726,Active,,,18.8322,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1344,743215,3,1,,170465371,2726,Inconclusive,216409690.0,5467.0,0.1188,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1345,743217,3,1,,170465371,2726,Active,325495553.0,9971.0,26.6011,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1346,743218,3,1,,170465371,2726,Active,,,26.6011,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1347,743219,3,1,,170465371,2726,Inconclusive,20149576.0,4780.0,29.846999999999998,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1348,743220,3,1,,170465371,2726,Inconclusive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1349,743221,3,1,,170465371,2726,Active,,,26.6011,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1350,743222,3,1,,170465371,2726,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1351,743223,3,1,,170465371,2726,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1352,743224,3,1,,170465371,2726,Inconclusive,,,10.5901,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1353,743225,3,1,,170465371,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1354,743226,2,1,,170465371,2726,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1355,743227,2,1,,170465371,2726,Inconclusive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1356,743228,3,1,,170465371,2726,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1357,743239,2,1,,170465371,2726,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1358,743240,2,1,,170465371,2726,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1359,743241,2,1,,170465371,2726,Inconclusive,216409708.0,7421.0,26.6011,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1360,743242,2,1,,170465371,2726,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1361,743244,1,1,,90340916,2726,Inconclusive,,,0.631,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1362,743244,1,1,,144203671,2726,Inconclusive,,,25.1189,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1363,745117,4,2,,103169389,2726,Active,8488960.0,3363.0,0.011000000000000001,Ki,Displacement of [3H]-LSD from 5HT7 receptor (unknown origin) expressed in CHOK1 cells,Confirmatory,23541835.0,
1364,762902,1,5,,103169389,2726,Unspecified,49037474.0,801.0,,,Binding affinity to human calmodulin expressed in Escherichia coli using T110C-mBBr fluorescent biosensor at 7.1 uM by fluorescent quenching assay,Other,23876004.0,
1365,762902,1,5,,103169389,2726,Unspecified,49037474.0,805.0,,,Binding affinity to human calmodulin expressed in Escherichia coli using T110C-mBBr fluorescent biosensor at 7.1 uM by fluorescent quenching assay,Other,23876004.0,
1366,762902,1,5,,103169389,2726,Unspecified,49037474.0,808.0,,,Binding affinity to human calmodulin expressed in Escherichia coli using T110C-mBBr fluorescent biosensor at 7.1 uM by fluorescent quenching assay,Other,23876004.0,
1367,762904,1,5,,103169389,2726,Unspecified,49037474.0,801.0,,,Binding affinity to human calmodulin expressed in Escherichia coli using M124C-mBBr fluorescent biosensor by fluorescent quenching assay,Other,23876004.0,
1368,762904,1,5,,103169389,2726,Unspecified,49037474.0,805.0,,,Binding affinity to human calmodulin expressed in Escherichia coli using M124C-mBBr fluorescent biosensor by fluorescent quenching assay,Other,23876004.0,
1369,762904,1,5,,103169389,2726,Unspecified,49037474.0,808.0,,,Binding affinity to human calmodulin expressed in Escherichia coli using M124C-mBBr fluorescent biosensor by fluorescent quenching assay,Other,23876004.0,
1370,762906,3,2,,103169389,2726,Active,49037474.0,801.0,1.24,Kd,Binding affinity to human calmodulin expressed in Escherichia coli using M124C-mBBr fluorescent biosensor by spectrofluorometer analysis,Confirmatory,23876004.0,
1371,762906,3,2,,103169389,2726,Active,49037474.0,805.0,1.24,Kd,Binding affinity to human calmodulin expressed in Escherichia coli using M124C-mBBr fluorescent biosensor by spectrofluorometer analysis,Confirmatory,23876004.0,
1372,762906,3,2,,103169389,2726,Active,49037474.0,808.0,1.24,Kd,Binding affinity to human calmodulin expressed in Escherichia coli using M124C-mBBr fluorescent biosensor by spectrofluorometer analysis,Confirmatory,23876004.0,
1373,781326,1,2,,103169389,2726,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
1374,781328,1,2,,103169389,2726,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005,Other,24249037.0,
1375,781329,1,2,,103169389,2726,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by other workers,Other,24249037.0,
1376,781330,1,2,,103169389,2726,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by potentiometric titration,Other,24249037.0,
1377,810738,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 115/9,Other,,
1378,810739,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 115/9,Other,,
1379,810740,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 115/9,Other,,
1380,810741,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 115/9,Other,,
1381,810742,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 115/9,Other,,
1382,810743,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 115/10,Other,,
1383,811062,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 635/8,Other,,
1384,811063,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 635/8,Other,,
1385,811064,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 635/8,Other,,
1386,811065,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 635/8,Other,,
1387,811066,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 635/9,Other,,
1388,811067,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 635/9,Other,,
1389,811068,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 635/9,Other,,
1390,811069,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 635/9,Other,,
1391,811070,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 635/9,Other,,
1392,811071,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 635/9,Other,,
1393,811072,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 635/9,Other,,
1394,811073,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 635/9,Other,,
1395,811074,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 635/9,Other,,
1396,811075,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 635/9,Other,,
1397,811076,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 635/9,Other,,
1398,811077,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 635/9,Other,,
1399,811078,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 635/9,Other,,
1400,811079,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 635/9,Other,,
1401,811080,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 635/9,Other,,
1402,811081,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 635/9,Other,,
1403,811082,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 635/9,Other,,
1404,811083,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 635/10,Other,,
1405,811084,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 635/10,Other,,
1406,811085,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 635/10,Other,,
1407,811086,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 635/10,Other,,
1408,811087,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 635/10,Other,,
1409,811088,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 635/10,Other,,
1410,811089,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 635/10,Other,,
1411,811090,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 635/10,Other,,
1412,811091,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 635/10,Other,,
1413,811092,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 635/10,Other,,
1414,811093,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 635/10,Other,,
1415,811094,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 635/10,Other,,
1416,811095,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 635/10,Other,,
1417,811096,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 635/10,Other,,
1418,811097,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 635/10,Other,,
1419,811098,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 635/10,Other,,
1420,811099,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 635/10,Other,,
1421,811100,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 635/11,Other,,
1422,811101,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 635/11,Other,,
1423,811102,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 635/11,Other,,
1424,811103,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 115/10,Other,,
1425,811104,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 115/10,Other,,
1426,811105,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 115/10,Other,,
1427,811106,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 115/10,Other,,
1428,811107,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 115/10,Other,,
1429,811108,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 115/10,Other,,
1430,811109,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 115/10,Other,,
1431,811110,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 115/10,Other,,
1432,811111,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 115/10,Other,,
1433,811112,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 115/10,Other,,
1434,811113,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 115/10,Other,,
1435,811114,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 115/10,Other,,
1436,811115,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 115/10,Other,,
1437,811116,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 115/10,Other,,
1438,811117,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 115/10,Other,,
1439,811118,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 115/10,Other,,
1440,811119,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 115/11,Other,,
1441,811120,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 115/11,Other,,
1442,811121,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 115/11,Other,,
1443,811122,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 115/11,Other,,
1444,811123,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 115/11,Other,,
1445,811124,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 115/11,Other,,
1446,811125,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 115/11,Other,,
1447,811126,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 115/11,Other,,
1448,811127,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 115/11,Other,,
1449,811128,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 115/11,Other,,
1450,811129,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 115/11,Other,,
1451,811130,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 115/11,Other,,
1452,811131,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 115/11,Other,,
1453,811132,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 115/11,Other,,
1454,811133,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 115/11,Other,,
1455,811134,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 115/11,Other,,
1456,811135,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 115/11,Other,,
1457,811136,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 115/12,Other,,
1458,811137,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 115/12,Other,,
1459,811138,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 115/12,Other,,
1460,811139,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 115/12,Other,,
1461,811140,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 115/12,Other,,
1462,811141,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 115/12,Other,,
1463,811142,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 115/12,Other,,
1464,811428,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 635/11,Other,,
1465,811429,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 635/11,Other,,
1466,811430,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 635/11,Other,,
1467,811431,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 635/11,Other,,
1468,811432,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 635/11,Other,,
1469,811433,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 635/11,Other,,
1470,812549,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 635/11,Other,,
1471,812550,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 635/11,Other,,
1472,812551,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 635/11,Other,,
1473,812552,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 635/11,Other,,
1474,812553,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 635/11,Other,,
1475,812554,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 635/11,Other,,
1476,812555,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 635/11,Other,,
1477,812556,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 635/11,Other,,
1478,812557,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 635/12,Other,,
1479,812558,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 635/12,Other,,
1480,812559,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 635/12,Other,,
1481,812560,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 635/12,Other,,
1482,812561,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 635/12,Other,,
1483,812562,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 635/12,Other,,
1484,812563,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 635/12,Other,,
1485,812564,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 635/12,Other,,
1486,812565,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 635/12,Other,,
1487,812566,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 635/12,Other,,
1488,812567,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 635/12,Other,,
1489,812568,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 635/12,Other,,
1490,812569,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 635/12,Other,,
1491,812570,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 635/12,Other,,
1492,812571,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 635/12,Other,,
1493,812572,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 635/12,Other,,
1494,812573,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 635/12,Other,,
1495,812584,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 115/12,Other,,
1496,812585,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 115/12,Other,,
1497,812586,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 115/12,Other,,
1498,812587,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 115/12,Other,,
1499,812588,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 115/12,Other,,
1500,812589,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 115/12,Other,,
1501,812590,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 115/12,Other,,
1502,812591,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 115/12,Other,,
1503,812592,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 115/12,Other,,
1504,812593,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 115/12,Other,,
1505,812594,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 115/13,Other,,
1506,812595,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 115/13,Other,,
1507,812596,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 115/13,Other,,
1508,812597,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 115/13,Other,,
1509,812598,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 115/13,Other,,
1510,812599,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 115/13,Other,,
1511,812600,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 115/13,Other,,
1512,812601,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 115/13,Other,,
1513,812602,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 115/13,Other,,
1514,812603,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 115/13,Other,,
1515,812604,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 115/13,Other,,
1516,812605,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 115/13,Other,,
1517,812606,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 115/13,Other,,
1518,812607,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 115/13,Other,,
1519,812608,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 115/13,Other,,
1520,812609,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 115/13,Other,,
1521,812610,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 115/13,Other,,
1522,812611,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 115/14,Other,,
1523,812612,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 115/14,Other,,
1524,812613,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 115/14,Other,,
1525,812614,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 115/14,Other,,
1526,812615,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 115/14,Other,,
1527,812616,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 115/14,Other,,
1528,812617,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 115/14,Other,,
1529,812618,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 115/14,Other,,
1530,812619,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 115/14,Other,,
1531,812620,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 115/14,Other,,
1532,812621,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 115/14,Other,,
1533,812622,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 115/14,Other,,
1534,812623,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 115/14,Other,,
1535,812624,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 115/14,Other,,
1536,812625,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 115/14,Other,,
1537,812943,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 115/14,Other,,
1538,812944,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 115/14,Other,,
1539,812945,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 115/15,Other,,
1540,812946,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 115/15,Other,,
1541,812947,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 115/15,Other,,
1542,813602,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 115/15,Other,,
1543,813603,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 115/15,Other,,
1544,813604,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 115/15,Other,,
1545,813605,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 115/15,Other,,
1546,813606,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 115/15,Other,,
1547,813607,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 115/15,Other,,
1548,813608,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 115/15,Other,,
1549,813609,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 115/15,Other,,
1550,813610,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 115/15,Other,,
1551,813611,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 115/15,Other,,
1552,813612,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 115/15,Other,,
1553,813613,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 115/15,Other,,
1554,813614,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 115/15,Other,,
1555,813615,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 115/15,Other,,
1556,813650,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 115/5,Other,,
1557,813651,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 115/5,Other,,
1558,813652,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 115/5,Other,,
1559,813653,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 115/5,Other,,
1560,813654,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 115/5,Other,,
1561,813655,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 115/5,Other,,
1562,813656,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 115/5,Other,,
1563,813657,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 115/5,Other,,
1564,813658,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 115/5,Other,,
1565,813659,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 115/5,Other,,
1566,813660,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 115/5,Other,,
1567,813932,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 115/16,Other,,
1568,813933,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 115/16,Other,,
1569,813934,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 115/16,Other,,
1570,813935,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 115/16,Other,,
1571,813936,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 115/16,Other,,
1572,813937,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 115/16,Other,,
1573,813938,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 115/16,Other,,
1574,813939,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 115/16,Other,,
1575,813940,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 115/16,Other,,
1576,813941,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 115/16,Other,,
1577,813942,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 115/16,Other,,
1578,813943,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 115/16,Other,,
1579,813944,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 115/16,Other,,
1580,813945,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 115/16,Other,,
1581,813946,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 115/16,Other,,
1582,813947,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 115/16,Other,,
1583,813948,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 115/16,Other,,
1584,813949,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 635/5,Other,,
1585,813950,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 635/5,Other,,
1586,813951,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 635/5,Other,,
1587,813952,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 635/5,Other,,
1588,813953,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 635/5,Other,,
1589,813954,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 635/5,Other,,
1590,813955,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 635/5,Other,,
1591,813956,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 635/5,Other,,
1592,813957,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 635/5,Other,,
1593,813958,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 635/5,Other,,
1594,813959,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 635/5,Other,,
1595,813960,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 635/5,Other,,
1596,813961,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 635/5,Other,,
1597,813962,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 635/5,Other,,
1598,813963,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 635/5,Other,,
1599,813964,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 635/5,Other,,
1600,813977,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 115/5,Other,,
1601,813978,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 115/5,Other,,
1602,813979,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 115/5,Other,,
1603,813980,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 115/5,Other,,
1604,813981,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 115/5,Other,,
1605,813982,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 115/5,Other,,
1606,813983,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 115/6,Other,,
1607,813984,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 115/6,Other,,
1608,813985,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 115/6,Other,,
1609,813986,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 115/6,Other,,
1610,813987,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 115/6,Other,,
1611,813988,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 115/6,Other,,
1612,813989,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 115/6,Other,,
1613,813990,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 115/6,Other,,
1614,813991,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 115/6,Other,,
1615,813992,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 115/6,Other,,
1616,813993,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 115/6,Other,,
1617,813994,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 115/6,Other,,
1618,813995,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 115/6,Other,,
1619,813996,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 115/6,Other,,
1620,813997,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 115/6,Other,,
1621,813998,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 115/6,Other,,
1622,815052,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 635/5,Other,,
1623,815053,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 635/6,Other,,
1624,815054,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 635/6,Other,,
1625,815055,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 635/6,Other,,
1626,815056,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 635/6,Other,,
1627,815085,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 115/6,Other,,
1628,815086,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 115/7,Other,,
1629,815087,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 115/7,Other,,
1630,815088,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 115/7,Other,,
1631,815089,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 115/7,Other,,
1632,815090,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 115/7,Other,,
1633,815091,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 115/7,Other,,
1634,815092,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 115/7,Other,,
1635,815093,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 115/7,Other,,
1636,815094,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 115/7,Other,,
1637,815095,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 115/7,Other,,
1638,815096,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 115/7,Other,,
1639,815097,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 115/7,Other,,
1640,815098,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 115/7,Other,,
1641,815099,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 115/7,Other,,
1642,815100,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 115/7,Other,,
1643,872339,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 115/15,Other,,
1644,872340,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 115/15,Other,,
1645,872341,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 115/15,Other,,
1646,872342,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 115/15,Other,,
1647,872343,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 115/15,Other,,
1648,872344,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 115/15,Other,,
1649,872385,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 635/10,Other,,
1650,872386,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 635/10,Other,,
1651,872387,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 635/10,Other,,
1652,872388,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 635/10,Other,,
1653,872389,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 635/11,Other,,
1654,872390,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 635/11,Other,,
1655,872391,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 635/11,Other,,
1656,872392,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 635/11,Other,,
1657,872393,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 635/11,Other,,
1658,872394,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 635/11,Other,,
1659,872395,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 635/11,Other,,
1660,872396,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 635/11,Other,,
1661,872397,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 635/11,Other,,
1662,872398,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 635/11,Other,,
1663,872399,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 635/11,Other,,
1664,872400,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 635/11,Other,,
1665,872401,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 635/11,Other,,
1666,872402,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 635/11,Other,,
1667,872403,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 635/11,Other,,
1668,872404,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 635/11,Other,,
1669,872405,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 635/11,Other,,
1670,872406,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 635/11,Other,,
1671,872407,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 635/11,Other,,
1672,872408,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 635/11,Other,,
1673,872409,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 635/11,Other,,
1674,872410,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 635/12,Other,,
1675,872411,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 635/12,Other,,
1676,872412,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 635/12,Other,,
1677,872413,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 635/12,Other,,
1678,872414,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 635/12,Other,,
1679,872415,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 635/12,Other,,
1680,872416,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 635/12,Other,,
1681,872417,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 635/12,Other,,
1682,872418,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 635/12,Other,,
1683,872419,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 635/12,Other,,
1684,872420,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 635/12,Other,,
1685,872421,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 635/12,Other,,
1686,872422,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 635/12,Other,,
1687,872423,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 635/12,Other,,
1688,872424,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 635/12,Other,,
1689,872425,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 635/12,Other,,
1690,873773,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 115/6,Other,,
1691,873774,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 115/6,Other,,
1692,873775,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 115/6,Other,,
1693,873776,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 115/6,Other,,
1694,873777,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 115/6,Other,,
1695,873778,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 115/6,Other,,
1696,873779,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 115/7,Other,,
1697,873780,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 115/7,Other,,
1698,873781,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 115/7,Other,,
1699,873782,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 115/7,Other,,
1700,873783,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 115/7,Other,,
1701,873784,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 115/7,Other,,
1702,873785,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 115/7,Other,,
1703,873786,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 115/7,Other,,
1704,873787,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 115/7,Other,,
1705,873788,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 115/7,Other,,
1706,873789,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 115/7,Other,,
1707,873790,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 115/7,Other,,
1708,873791,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 115/7,Other,,
1709,873792,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 115/7,Other,,
1710,873793,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 115/7,Other,,
1711,873794,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 115/7,Other,,
1712,873795,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 115/7,Other,,
1713,874478,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 115/7,Other,,
1714,874479,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 115/7,Other,,
1715,874480,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 115/7,Other,,
1716,874481,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 115/7,Other,,
1717,874482,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 115/8,Other,,
1718,874483,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 115/8,Other,,
1719,874484,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 115/8,Other,,
1720,874485,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 115/8,Other,,
1721,874486,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 115/8,Other,,
1722,874487,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 115/8,Other,,
1723,874488,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 115/8,Other,,
1724,874489,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 115/8,Other,,
1725,874490,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 115/8,Other,,
1726,874491,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 115/8,Other,,
1727,874492,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 115/8,Other,,
1728,874493,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 115/8,Other,,
1729,874494,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 115/8,Other,,
1730,874495,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 115/8,Other,,
1731,874496,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 115/8,Other,,
1732,874497,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 115/8,Other,,
1733,874498,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 115/8,Other,,
1734,874499,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 115/8,Other,,
1735,874500,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 115/8,Other,,
1736,874501,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 115/8,Other,,
1737,874536,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 115/15,Other,,
1738,874537,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 115/15,Other,,
1739,874538,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 115/15,Other,,
1740,874539,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 115/15,Other,,
1741,874540,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 115/15,Other,,
1742,874541,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 115/15,Other,,
1743,874542,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 115/15,Other,,
1744,874543,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 115/16,Other,,
1745,874544,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 115/16,Other,,
1746,874545,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 115/16,Other,,
1747,874546,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 115/16,Other,,
1748,874547,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 115/16,Other,,
1749,874548,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 115/16,Other,,
1750,874549,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 115/16,Other,,
1751,874550,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 115/16,Other,,
1752,874551,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 115/16,Other,,
1753,874552,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 115/16,Other,,
1754,874553,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 115/16,Other,,
1755,874554,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 115/16,Other,,
1756,874555,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 115/16,Other,,
1757,874556,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 115/16,Other,,
1758,874557,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 115/16,Other,,
1759,874558,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 115/16,Other,,
1760,874559,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 115/16,Other,,
1761,874560,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 115/16,Other,,
1762,874561,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 115/16,Other,,
1763,874562,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 115/16,Other,,
1764,874563,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 115/16,Other,,
1765,874564,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 635/5,Other,,
1766,874565,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 635/5,Other,,
1767,874566,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 635/5,Other,,
1768,874567,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 635/5,Other,,
1769,875249,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 635/5,Other,,
1770,875250,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 635/5,Other,,
1771,875251,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 635/5,Other,,
1772,875252,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 635/5,Other,,
1773,875253,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 635/5,Other,,
1774,875254,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 635/5,Other,,
1775,875255,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 635/5,Other,,
1776,875256,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 635/5,Other,,
1777,875257,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 635/5,Other,,
1778,875258,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 635/5,Other,,
1779,875259,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 635/5,Other,,
1780,875260,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 635/5,Other,,
1781,875261,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 635/5,Other,,
1782,875262,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 635/5,Other,,
1783,875263,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 635/5,Other,,
1784,875296,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 635/12,Other,,
1785,875297,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 635/12,Other,,
1786,875298,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 635/12,Other,,
1787,875299,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 635/12,Other,,
1788,875300,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 635/12,Other,,
1789,876691,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 115/8,Other,,
1790,876692,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 115/9,Other,,
1791,876693,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 115/9,Other,,
1792,876694,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 115/9,Other,,
1793,876695,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 115/9,Other,,
1794,876696,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 115/9,Other,,
1795,876697,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 115/9,Other,,
1796,876698,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 115/9,Other,,
1797,876699,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 115/9,Other,,
1798,876700,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 115/9,Other,,
1799,876701,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 115/9,Other,,
1800,876702,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 115/9,Other,,
1801,876703,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 115/9,Other,,
1802,876704,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 115/9,Other,,
1803,877388,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 115/9,Other,,
1804,877389,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 115/9,Other,,
1805,877390,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 115/9,Other,,
1806,877391,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 115/9,Other,,
1807,877392,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 115/9,Other,,
1808,877393,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 115/9,Other,,
1809,877394,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 115/9,Other,,
1810,877395,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 115/9,Other,,
1811,877396,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 115/10,Other,,
1812,877397,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 115/10,Other,,
1813,877398,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 115/10,Other,,
1814,877399,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 115/10,Other,,
1815,877400,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 115/10,Other,,
1816,877401,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 115/10,Other,,
1817,877402,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 115/10,Other,,
1818,877403,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 115/10,Other,,
1819,877404,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 115/10,Other,,
1820,877405,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 115/10,Other,,
1821,877406,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 115/10,Other,,
1822,877407,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 115/10,Other,,
1823,877408,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 115/10,Other,,
1824,877409,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 115/10,Other,,
1825,877410,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 115/10,Other,,
1826,877411,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 115/10,Other,,
1827,877412,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 115/10,Other,,
1828,877413,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 115/10,Other,,
1829,877414,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 115/10,Other,,
1830,877415,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 115/10,Other,,
1831,877416,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 115/10,Other,,
1832,877417,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 115/11,Other,,
1833,877418,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 115/11,Other,,
1834,877419,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 115/11,Other,,
1835,877420,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 115/11,Other,,
1836,877454,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 635/5,Other,,
1837,877455,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 635/5,Other,,
1838,877456,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 635/6,Other,,
1839,877457,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 635/6,Other,,
1840,877458,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 635/6,Other,,
1841,877459,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 635/6,Other,,
1842,877460,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 635/6,Other,,
1843,877461,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 635/6,Other,,
1844,877462,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 635/6,Other,,
1845,877463,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 635/6,Other,,
1846,877464,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 635/6,Other,,
1847,877465,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 635/6,Other,,
1848,877466,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 635/6,Other,,
1849,877467,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 635/6,Other,,
1850,877468,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 635/6,Other,,
1851,877469,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 635/6,Other,,
1852,877470,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 635/6,Other,,
1853,877471,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 635/6,Other,,
1854,877472,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 635/6,Other,,
1855,877473,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 635/6,Other,,
1856,877474,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 635/6,Other,,
1857,877475,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 635/6,Other,,
1858,877476,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 635/6,Other,,
1859,877477,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 635/7,Other,,
1860,877478,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 635/7,Other,,
1861,878158,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 635/7,Other,,
1862,878159,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 635/7,Other,,
1863,878160,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 635/7,Other,,
1864,878161,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 635/7,Other,,
1865,878162,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 635/7,Other,,
1866,878163,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 635/7,Other,,
1867,878164,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 635/7,Other,,
1868,878165,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 635/7,Other,,
1869,878166,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 635/7,Other,,
1870,878167,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 635/7,Other,,
1871,878168,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 635/7,Other,,
1872,878169,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 635/7,Other,,
1873,878170,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 635/7,Other,,
1874,878171,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 635/7,Other,,
1875,878172,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 635/7,Other,,
1876,878173,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 635/7,Other,,
1877,878174,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 635/7,Other,,
1878,878175,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 635/7,Other,,
1879,878176,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 635/7,Other,,
1880,878177,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 635/8,Other,,
1881,878178,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 635/8,Other,,
1882,878179,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 635/8,Other,,
1883,878180,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 635/8,Other,,
1884,879612,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 115/11,Other,,
1885,879613,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 115/11,Other,,
1886,879614,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 115/11,Other,,
1887,879615,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 115/11,Other,,
1888,879616,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 115/11,Other,,
1889,880298,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 115/11,Other,,
1890,880299,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 115/11,Other,,
1891,880300,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 115/11,Other,,
1892,880301,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 115/11,Other,,
1893,880302,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 115/11,Other,,
1894,880303,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 115/11,Other,,
1895,880304,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 115/11,Other,,
1896,880305,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 115/11,Other,,
1897,880306,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 115/11,Other,,
1898,880307,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 115/11,Other,,
1899,880308,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 115/11,Other,,
1900,880309,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 115/11,Other,,
1901,880310,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 115/12,Other,,
1902,880311,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 115/12,Other,,
1903,880312,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 115/12,Other,,
1904,880313,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 115/12,Other,,
1905,880314,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 115/12,Other,,
1906,880315,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 115/12,Other,,
1907,880316,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 115/12,Other,,
1908,880317,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 115/12,Other,,
1909,880318,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 115/12,Other,,
1910,880319,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 115/12,Other,,
1911,880320,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 115/12,Other,,
1912,880321,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 115/12,Other,,
1913,880322,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 115/12,Other,,
1914,880323,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 115/12,Other,,
1915,880324,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 115/12,Other,,
1916,880325,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 115/12,Other,,
1917,880326,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 115/12,Other,,
1918,880327,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 115/12,Other,,
1919,880328,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 115/12,Other,,
1920,880329,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 115/12,Other,,
1921,880330,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 115/12,Other,,
1922,880331,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 115/13,Other,,
1923,880332,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 115/13,Other,,
1924,880333,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 115/13,Other,,
1925,880334,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 115/13,Other,,
1926,880335,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 115/13,Other,,
1927,880336,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 115/13,Other,,
1928,880337,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 115/13,Other,,
1929,880338,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 115/13,Other,,
1930,880339,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 115/13,Other,,
1931,880372,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 635/8,Other,,
1932,880373,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 635/8,Other,,
1933,880374,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 635/8,Other,,
1934,880375,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 635/8,Other,,
1935,880376,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 635/8,Other,,
1936,880377,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 635/8,Other,,
1937,880378,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 635/8,Other,,
1938,880379,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 635/8,Other,,
1939,880380,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 635/8,Other,,
1940,880381,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 635/8,Other,,
1941,880382,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 635/8,Other,,
1942,880383,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 635/8,Other,,
1943,880384,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 635/8,Other,,
1944,880385,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 635/8,Other,,
1945,880386,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 635/8,Other,,
1946,880387,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 635/8,Other,,
1947,881068,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 635/8,Other,,
1948,881069,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 635/9,Other,,
1949,881070,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 635/9,Other,,
1950,881071,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 635/9,Other,,
1951,881072,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 635/9,Other,,
1952,881073,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 635/9,Other,,
1953,881074,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 635/9,Other,,
1954,881075,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 635/9,Other,,
1955,881076,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 635/9,Other,,
1956,881077,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 635/9,Other,,
1957,881078,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 635/9,Other,,
1958,881079,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 635/9,Other,,
1959,881080,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 635/9,Other,,
1960,881081,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 635/9,Other,,
1961,881082,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 635/9,Other,,
1962,881083,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 635/9,Other,,
1963,881084,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 635/9,Other,,
1964,881085,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 635/9,Other,,
1965,881086,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 635/9,Other,,
1966,881087,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 635/9,Other,,
1967,881088,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 635/9,Other,,
1968,881089,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 635/9,Other,,
1969,881090,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 635/10,Other,,
1970,881091,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 635/10,Other,,
1971,881092,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 635/10,Other,,
1972,881093,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 635/10,Other,,
1973,881094,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 635/10,Other,,
1974,881095,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 635/10,Other,,
1975,881096,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 635/10,Other,,
1976,881097,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 635/10,Other,,
1977,881098,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 635/10,Other,,
1978,881099,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 635/10,Other,,
1979,882463,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 115/5,Other,,
1980,882464,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 115/5,Other,,
1981,882465,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 115/5,Other,,
1982,882466,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 115/5,Other,,
1983,882467,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 115/5,Other,,
1984,882468,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 115/5,Other,,
1985,882469,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 115/5,Other,,
1986,882470,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 115/5,Other,,
1987,882471,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 115/5,Other,,
1988,882472,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 115/5,Other,,
1989,882473,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 115/5,Other,,
1990,882474,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 115/5,Other,,
1991,882475,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 115/5,Other,,
1992,882476,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 115/5,Other,,
1993,882477,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 115/5,Other,,
1994,882478,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 115/5,Other,,
1995,882479,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 115/5,Other,,
1996,882480,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 115/5,Other,,
1997,882481,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 115/5,Other,,
1998,882482,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 115/5,Other,,
1999,883165,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 115/5,Other,,
2000,883166,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 115/6,Other,,
2001,883167,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 115/6,Other,,
2002,883168,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 115/6,Other,,
2003,883169,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 115/6,Other,,
2004,883170,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 115/6,Other,,
2005,883171,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 115/6,Other,,
2006,883172,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 115/6,Other,,
2007,883173,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 115/6,Other,,
2008,883174,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 115/6,Other,,
2009,883175,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 115/6,Other,,
2010,883176,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 115/6,Other,,
2011,883177,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 115/6,Other,,
2012,883178,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 115/6,Other,,
2013,883179,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 115/6,Other,,
2014,883180,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 115/6,Other,,
2015,883214,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 115/13,Other,,
2016,883215,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 115/13,Other,,
2017,883216,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 115/13,Other,,
2018,883217,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 115/13,Other,,
2019,883218,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 115/13,Other,,
2020,883219,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 115/13,Other,,
2021,883220,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 115/13,Other,,
2022,883221,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 115/13,Other,,
2023,883222,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 115/13,Other,,
2024,883223,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 115/13,Other,,
2025,883224,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 115/13,Other,,
2026,883225,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 115/13,Other,,
2027,883226,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 115/14,Other,,
2028,883227,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 115/14,Other,,
2029,883228,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 115/14,Other,,
2030,883229,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 115/14,Other,,
2031,883230,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 115/14,Other,,
2032,883231,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 115/14,Other,,
2033,883232,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 115/14,Other,,
2034,883233,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 115/14,Other,,
2035,883234,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 115/14,Other,,
2036,883235,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 115/14,Other,,
2037,883236,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 115/14,Other,,
2038,883237,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 115/14,Other,,
2039,883238,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 115/14,Other,,
2040,883239,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 115/14,Other,,
2041,883240,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 115/14,Other,,
2042,883241,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 115/14,Other,,
2043,883242,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 115/14,Other,,
2044,883243,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 115/14,Other,,
2045,883244,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 115/14,Other,,
2046,883245,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 115/14,Other,,
2047,883246,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 115/14,Other,,
2048,883247,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 115/15,Other,,
2049,883248,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 115/15,Other,,
2050,883249,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 115/15,Other,,
2051,883250,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 115/15,Other,,
2052,883251,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 115/15,Other,,
2053,883252,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 115/15,Other,,
2054,883253,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 115/15,Other,,
2055,883254,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 115/15,Other,,
2056,883293,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 635/10,Other,,
2057,883294,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 635/10,Other,,
2058,883295,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 635/10,Other,,
2059,883296,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 635/10,Other,,
2060,883297,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 635/10,Other,,
2061,883298,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 635/10,Other,,
2062,883299,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 635/10,Other,,
2063,923349,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011016,Other,,
2064,923350,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011016,Other,,
2065,923351,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011016,Other,,
2066,923352,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011016,Other,,
2067,923353,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011016,Other,,
2068,923354,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011016,Other,,
2069,923355,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011016",Other,,
2070,923356,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011016,Other,,
2071,923357,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011016,Other,,
2072,923358,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011016,Other,,
2073,923359,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011016,Other,,
2074,923360,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011016,Other,,
2075,923361,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011016,Other,,
2076,923362,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011016,Other,,
2077,923363,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011016,Other,,
2078,923364,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011016,Other,,
2079,923365,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011016,Other,,
2080,926513,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011016,Other,,
2081,926514,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011016,Other,,
2082,926515,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011016,Other,,
2083,926516,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011016,Other,,
2084,926517,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011016,Other,,
2085,926518,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011016,Other,,
2086,926519,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011016,Other,,
2087,926520,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011016,Other,,
2088,926521,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011016,Other,,
2089,926522,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011016,Other,,
2090,926523,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011016,Other,,
2091,926524,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011016,Other,,
2092,926525,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011016,Other,,
2093,926526,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011016,Other,,
2094,928508,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011016,Other,,
2095,928509,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011016,Other,,
2096,928510,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011016,Other,,
2097,928511,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011016",Other,,
2098,928512,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011016,Other,,
2099,939903,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011016,Other,,
2100,939904,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011016,Other,,
2101,947961,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011016,Other,,
2102,947962,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011016",Other,,
2103,947963,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011016,Other,,
2104,947964,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011016,Other,,
2105,947965,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011016,Other,,
2106,947966,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011016,Other,,
2107,947967,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011016,Other,,
2108,947968,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011016,Other,,
2109,947969,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011016,Other,,
2110,947970,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011016,Other,,
2111,947971,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011016,Other,,
2112,948032,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011016,Other,,
2113,948033,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011016,Other,,
2114,948034,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011016,Other,,
2115,948035,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011016,Other,,
2116,948036,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011016,Other,,
2117,948037,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011016,Other,,
2118,948038,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011016,Other,,
2119,948039,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011016,Other,,
2120,948040,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011016,Other,,
2121,948041,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011016,Other,,
2122,948042,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011016",Other,,
2123,948043,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011016,Other,,
2124,948044,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011016,Other,,
2125,948045,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011016,Other,,
2126,948046,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011016,Other,,
2127,948047,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011016,Other,,
2128,948048,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011016,Other,,
2129,948049,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011016,Other,,
2130,948050,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011016,Other,,
2131,948098,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011016,Other,,
2132,948099,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011016,Other,,
2133,948100,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011016,Other,,
2134,948101,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011016,Other,,
2135,948102,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011016,Other,,
2136,948103,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011016,Other,,
2137,948104,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011016,Other,,
2138,948105,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011016,Other,,
2139,954784,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011016,Other,,
2140,954785,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011016,Other,,
2141,954786,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011016,Other,,
2142,954787,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011016,Other,,
2143,954788,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011016,Other,,
2144,954789,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011016,Other,,
2145,954790,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011016,Other,,
2146,954791,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011016,Other,,
2147,954792,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011016,Other,,
2148,954793,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011016,Other,,
2149,954794,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011016,Other,,
2150,954795,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011016,Other,,
2151,954796,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011016,Other,,
2152,954797,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011016,Other,,
2153,954798,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011016,Other,,
2154,954799,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011016,Other,,
2155,954800,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011016,Other,,
2156,954801,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011016,Other,,
2157,954802,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011016,Other,,
2158,959841,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011016,Other,,
2159,959842,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011016,Other,,
2160,959843,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011016,Other,,
2161,959844,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011016,Other,,
2162,959845,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011016,Other,,
2163,959846,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011016,Other,,
2164,959847,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011016,Other,,
2165,959848,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011016,Other,,
2166,959849,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011016,Other,,
2167,960244,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011016,Other,,
2168,960245,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011016,Other,,
2169,960246,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011016,Other,,
2170,960247,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011016,Other,,
2171,960248,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011016,Other,,
2172,960249,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011016,Other,,
2173,960250,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011016,Other,,
2174,960251,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011016,Other,,
2175,960252,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011016,Other,,
2176,960253,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011016,Other,,
2177,960254,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011016,Other,,
2178,960255,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011016,Other,,
2179,960256,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011016,Other,,
2180,960257,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011016,Other,,
2181,960258,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011016,Other,,
2182,960692,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011016,Other,,
2183,960693,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011016,Other,,
2184,960694,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011016,Other,,
2185,960695,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011016,Other,,
2186,961279,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011016,Other,,
2187,961280,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011016,Other,,
2188,961281,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011016,Other,,
2189,961282,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011016,Other,,
2190,961283,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011016,Other,,
2191,961284,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011016,Other,,
2192,961285,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011016,Other,,
2193,961286,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011016,Other,,
2194,961287,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011016,Other,,
2195,961288,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011016,Other,,
2196,961589,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011016,Other,,
2197,961590,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011016,Other,,
2198,961591,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011016,Other,,
2199,961592,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011016,Other,,
2200,961593,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011016,Other,,
2201,961594,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011016,Other,,
2202,961595,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011016,Other,,
2203,961596,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011016,Other,,
2204,961597,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011016,Other,,
2205,961598,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011016,Other,,
2206,961599,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011016,Other,,
2207,961600,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011016,Other,,
2208,961601,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011016,Other,,
2209,961602,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011016,Other,,
2210,961603,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011016,Other,,
2211,961604,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011016,Other,,
2212,961605,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011016,Other,,
2213,961606,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011016,Other,,
2214,961607,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011016,Other,,
2215,977599,1,1,,103169389,2726,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2216,977602,1,2,,103169389,2726,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2217,978345,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011016",Other,,
2218,978346,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
2219,978347,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2220,978348,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2221,978349,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011016",Other,,
2222,978350,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011016",Other,,
2223,982296,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011016,Other,,
2224,982297,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
2225,982298,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011016",Other,,
2226,982299,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011016",Other,,
2227,982300,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011016",Other,,
2228,982301,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2229,982302,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011016",Other,,
2230,982303,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011016",Other,,
2231,982304,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011016",Other,,
2232,982305,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011016",Other,,
2233,982306,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011016,Other,,
2234,982307,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011016",Other,,
2235,982308,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011016,Other,,
2236,982309,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011016",Other,,
2237,982310,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
2238,982311,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011016",Other,,
2239,982312,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011016",Other,,
2240,982313,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011016",Other,,
2241,982314,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
2242,982315,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011016",Other,,
2243,982316,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011016",Other,,
2244,982317,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
2245,982318,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011016",Other,,
2246,982319,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011016,Other,,
2247,982320,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
2248,982321,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011016",Other,,
2249,982322,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
2250,982323,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
2251,982324,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
2252,982325,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
2253,982326,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011016",Other,,
2254,982327,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
2255,982794,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
2256,982795,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011016",Other,,
2257,982796,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
2258,982797,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011016",Other,,
2259,982798,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011016",Other,,
2260,984321,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011016",Other,,
2261,984322,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011016,Other,,
2262,984323,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011016,Other,,
2263,984324,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011016",Other,,
2264,984325,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
2265,984326,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011016",Other,,
2266,984327,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011016",Other,,
2267,984328,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011016",Other,,
2268,984329,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011016",Other,,
2269,984330,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011016",Other,,
2270,984331,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011016,Other,,
2271,984332,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011016",Other,,
2272,984333,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
2273,984334,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
2274,984335,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2275,984336,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011016",Other,,
2276,984337,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011016,Other,,
2277,984338,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
2278,984339,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011016",Other,,
2279,984340,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011016",Other,,
2280,984341,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011016",Other,,
2281,984342,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011016",Other,,
2282,984343,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011016",Other,,
2283,984344,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2284,984345,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
2285,984346,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
2286,984347,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011016",Other,,
2287,984348,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
2288,984349,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011016",Other,,
2289,984350,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011016",Other,,
2290,984817,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011016",Other,,
2291,984818,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011016",Other,,
2292,984819,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011016",Other,,
2293,984820,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011016",Other,,
2294,984821,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011016",Other,,
2295,984822,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011016,Other,,
2296,984823,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
2297,984824,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011016",Other,,
2298,984825,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011016",Other,,
2299,984826,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011016,Other,,
2300,984827,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2301,1025775,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011016",Other,,
2302,1025776,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011016",Other,,
2303,1025777,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011016",Other,,
2304,1025778,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2305,1025779,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
2306,1025780,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011016,Other,,
2307,1025781,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011016",Other,,
2308,1025782,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011016,Other,,
2309,1025783,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011016",Other,,
2310,1025784,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
2311,1025785,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011016",Other,,
2312,1025786,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011016",Other,,
2313,1025787,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2314,1025788,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011016",Other,,
2315,1025789,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
2316,1025790,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011016",Other,,
2317,1025791,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011016",Other,,
2318,1025792,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
2319,1025793,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
2320,1025794,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011016",Other,,
2321,1025795,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
2322,1026378,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
2323,1026379,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
2324,1026380,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
2325,1026381,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011016",Other,,
2326,1026382,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
2327,1026383,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
2328,1026384,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011016",Other,,
2329,1026385,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
2330,1026386,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011016,Other,,
2331,1026387,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011016,Other,,
2332,1026388,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011016",Other,,
2333,1026389,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
2334,1026390,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
2335,1026391,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011016",Other,,
2336,1026392,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011016,Other,,
2337,1026393,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
2338,1026394,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
2339,1026395,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2340,1026396,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011016",Other,,
2341,1028267,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011016,Other,,
2342,1028268,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
2343,1028269,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011016",Other,,
2344,1028270,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011016",Other,,
2345,1028271,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
2346,1028272,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011016",Other,,
2347,1028273,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011016",Other,,
2348,1028274,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011016",Other,,
2349,1028275,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011016,Other,,
2350,1028276,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
2351,1028277,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011016",Other,,
2352,1028278,1,3,,103169389,2726,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011016,Other,,
2353,1028279,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2354,1028280,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011016",Other,,
2355,1028281,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
2356,1028282,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2357,1028869,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2358,1028870,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011016",Other,,
2359,1033815,1,3,,103169389,2726,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
2360,1049063,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 635/5,Other,,
2361,1049064,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 635/5,Other,,
2362,1049065,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 635/5,Other,,
2363,1049066,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 635/5,Other,,
2364,1049067,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 635/6,Other,,
2365,1049068,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 635/6,Other,,
2366,1049069,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 635/6,Other,,
2367,1049070,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 635/6,Other,,
2368,1049071,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 635/6,Other,,
2369,1049072,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 635/7,Other,,
2370,1049845,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 635/7,Other,,
2371,1049846,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 635/7,Other,,
2372,1049847,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 635/7,Other,,
2373,1049848,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 635/7,Other,,
2374,1049849,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 635/8,Other,,
2375,1049850,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 635/8,Other,,
2376,1049851,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 635/8,Other,,
2377,1049852,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 635/8,Other,,
2378,1049853,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 635/8,Other,,
2379,1049854,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 635/9,Other,,
2380,1049855,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 635/9,Other,,
2381,1049856,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 635/9,Other,,
2382,1049857,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 635/9,Other,,
2383,1049858,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 635/9,Other,,
2384,1049859,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 635/10,Other,,
2385,1049860,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 635/10,Other,,
2386,1049861,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 635/10,Other,,
2387,1049862,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 635/10,Other,,
2388,1049863,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 635/10,Other,,
2389,1049864,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 635/11,Other,,
2390,1049865,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 635/11,Other,,
2391,1049866,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 635/11,Other,,
2392,1049867,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 635/11,Other,,
2393,1049868,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 635/11,Other,,
2394,1049869,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 635/12,Other,,
2395,1049870,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 635/12,Other,,
2396,1049871,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 635/12,Other,,
2397,1049872,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 635/12,Other,,
2398,1049873,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 635/12,Other,,
2399,1051928,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 115/5,Other,,
2400,1051929,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 115/5,Other,,
2401,1051930,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 115/5,Other,,
2402,1051931,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 115/5,Other,,
2403,1051932,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 115/5,Other,,
2404,1051933,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 115/6,Other,,
2405,1051934,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 115/6,Other,,
2406,1051935,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 115/6,Other,,
2407,1051936,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 115/6,Other,,
2408,1051937,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 115/6,Other,,
2409,1051938,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 115/7,Other,,
2410,1051939,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 115/7,Other,,
2411,1051940,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 115/7,Other,,
2412,1051941,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 115/7,Other,,
2413,1051942,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 115/7,Other,,
2414,1051943,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 115/8,Other,,
2415,1051944,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 115/8,Other,,
2416,1051945,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 115/8,Other,,
2417,1051946,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 115/8,Other,,
2418,1051947,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 115/8,Other,,
2419,1051948,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 115/9,Other,,
2420,1051949,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 115/9,Other,,
2421,1051950,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 115/9,Other,,
2422,1051951,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 115/9,Other,,
2423,1051952,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 115/9,Other,,
2424,1052890,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 115/10,Other,,
2425,1052891,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 115/10,Other,,
2426,1052892,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 115/10,Other,,
2427,1052893,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 115/10,Other,,
2428,1052894,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 115/10,Other,,
2429,1052895,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 115/11,Other,,
2430,1052896,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 115/11,Other,,
2431,1052897,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 115/11,Other,,
2432,1052898,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 115/11,Other,,
2433,1052899,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 115/11,Other,,
2434,1052900,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 115/12,Other,,
2435,1052901,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 115/12,Other,,
2436,1052902,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 115/12,Other,,
2437,1052903,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 115/12,Other,,
2438,1052904,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 115/12,Other,,
2439,1052905,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 115/13,Other,,
2440,1052906,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 115/13,Other,,
2441,1052907,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 115/13,Other,,
2442,1052908,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 115/13,Other,,
2443,1052909,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 115/13,Other,,
2444,1052910,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 115/14,Other,,
2445,1052911,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 115/14,Other,,
2446,1052912,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 115/14,Other,,
2447,1052913,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 115/14,Other,,
2448,1052914,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 115/14,Other,,
2449,1052915,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 115/15,Other,,
2450,1052916,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 115/15,Other,,
2451,1052917,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 115/15,Other,,
2452,1052918,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 115/15,Other,,
2453,1052919,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 115/15,Other,,
2454,1052920,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 115/16,Other,,
2455,1052921,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 115/16,Other,,
2456,1052922,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 115/16,Other,,
2457,1052923,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 115/16,Other,,
2458,1052924,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 115/16,Other,,
2459,1052925,1,2,,103169389,2726,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 635/5,Other,,
2460,1054118,2,3,,103169389,2726,Active,400630.0,6532.0,0.12,IC50,Binding affinity to SERT (unknown origin) by radioligand binding assay,Confirmatory,23919353.0,
2461,1054119,2,3,,103169389,2726,Active,543727.0,3356.0,0.0034,IC50,Binding affinity to 5HT2A receptor (unknown origin) by radioligand binding assay,Confirmatory,23919353.0,
2462,1054120,2,3,,103169389,2726,Active,118206.0,1813.0,0.012,IC50,Binding affinity to dopamine D2 receptor (unknown origin) by radioligand binding assay,Confirmatory,23919353.0,
2463,1054121,2,3,,103169389,2726,Active,547645.0,3269.0,0.012,IC50,Binding affinity to histamine H1 receptor (unknown origin) by radioligand binding assay,Confirmatory,23919353.0,
2464,1055208,1,1,,103169389,2726,Unspecified,,,,,Effective permeability of the compound at 5 mg/mL after 10 hrs by PAMPA,Other,24160297.0,
2465,1056992,1,1,,103169389,2726,Unspecified,,,,,Permeability of the compound by PAMPA,Other,24128814.0,
2466,1056993,1,1,,103169389,2726,Unspecified,,,,,Permeability of the compound at 100 mg/mL after 10 hrs by PAMPA,Other,24128814.0,
2467,1063795,4,2,,103169389,2726,Active,1345939.0,1815.0,0.03162,Ki,Displacement of [3H]N-Methylspiperone from dopamine D4 receptor (unknown origin),Confirmatory,24365159.0,
2468,1063797,4,2,,103169389,2726,Active,1169206.0,1814.0,0.00331,Ki,Displacement of [3H]N-Methylspiperone from dopamine D3 receptor (unknown origin),Confirmatory,24365159.0,
2469,1063799,4,2,,103169389,2726,Active,1703010.0,3362.0,0.06026,Ki,Displacement of [3H]LSD from 5-HT6 receptor (unknown origin),Confirmatory,24365159.0,
2470,1063800,4,2,,103169389,2726,Active,8488960.0,3363.0,0.12022999999999999,Ki,Displacement of [3H]LSD from 5-HT7 receptor (unknown origin),Confirmatory,24365159.0,
2471,1063803,4,2,,103169389,2726,Active,112816.0,3358.0,0.0302,Ki,Displacement of [3H]Mesulergine from 5-HT2C receptor (unknown origin),Confirmatory,24365159.0,
2472,1063804,4,2,,103169389,2726,Active,543727.0,3356.0,0.00589,Ki,Displacement of [3H]Ketanserin from 5-HT2A receptor (unknown origin),Confirmatory,24365159.0,
2473,1079931,1,1,,103169389,2726,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
2474,1079932,1,1,,103169389,2726,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
2475,1079933,1,1,,103169389,2726,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
2476,1079934,1,1,,103169389,2726,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
2477,1079935,1,1,,103169389,2726,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
2478,1079936,1,1,,103169389,2726,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
2479,1079937,1,1,,103169389,2726,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
2480,1079938,1,1,,103169389,2726,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
2481,1079939,1,1,,103169389,2726,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
2482,1079940,1,1,,103169389,2726,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
2483,1079941,1,1,,103169389,2726,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
2484,1079942,1,1,,103169389,2726,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
2485,1079943,1,1,,103169389,2726,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
2486,1079944,1,1,,103169389,2726,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
2487,1079945,1,1,,103169389,2726,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
2488,1079946,1,1,,103169389,2726,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
2489,1079947,1,1,,103169389,2726,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
2490,1079948,1,1,,103169389,2726,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
2491,1079949,1,1,,103169389,2726,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
2492,1097336,1,3,,103169389,2726,Unspecified,,,,,Drug level in Homo sapiens (human) whole blood assessed as retention time by UPLC-TOF-MS analysis,Other,,
2493,1108823,1,2,,103169389,2726,Unspecified,,,,,Displacement of [3H]alpha-BGT from nAChR in Torpedo nobiliana electric organs membranes at 1000 uM by scintillation counting method,Other,,
2494,1108836,2,1,,103169389,2726,Unspecified,,,1000.0,IC50,Displacement of [3H]alpha-BGT from nAChR in Torpedo nobiliana electric organs membranes by scintillation counting method,Confirmatory,,
2495,1108837,2,1,,103169389,2726,Active,,,1.28,IC50,Displacement of [3H]PCP from nAChR in Torpedo nobiliana electric organs membranes in presence of 100 uM carbachol by scintillation counting method,Confirmatory,,
2496,1108838,2,1,,103169389,2726,Active,,,16.4,IC50,Displacement of [3H]PCP from nAChR in Torpedo nobiliana electric organs membranes by scintillation counting method,Confirmatory,,
2497,1108844,1,3,,103169389,2726,Unspecified,,,151.0,IC50,Displacement of [3H]alpha-BGT from nAChR in Apis mellifera (honeybee) head homogenates,Confirmatory,,
2498,1108845,1,3,,103169389,2726,Active,,,5.8,IC50,Displacement of [3H]PCP from nAChR in Apis mellifera (honeybee0 head homogenates,Confirmatory,,
2499,1117298,1,2,,170465371,2726,Inactive,,,39.8107,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
2500,1117301,1,2,,170465371,2726,Active,,,10.0,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
2501,1117302,1,2,,170465371,2726,Inactive,,,12.5893,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
2502,1117303,1,2,,170465371,2726,Inactive,,,10.0,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
2503,1117304,1,2,,170465371,2726,Active,,,14.1254,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
2504,1117305,1,2,,170465371,2726,Active,,,3.9811,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
2505,1117310,1,1,,170465371,2726,Inactive,,,39.8107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
2506,1117311,1,1,,170465371,2726,Inactive,,,10.0,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
2507,1117312,1,1,,170465371,2726,Active,,,3.98107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
2508,1117314,1,1,,170465371,2726,Inactive,,,14.1254,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
2509,1117315,1,1,,170465371,2726,Inactive,,,12.5893,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
2510,1117318,1,1,,170465371,2726,Active,,,10.0,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
2511,1117324,1,1,,170465371,2726,Inactive,,,10.0,IC50,VEGF stimulated ADSC/ECFC co-culture nuclear area decrease (viability)-IC50,Confirmatory,,
2512,1117326,1,1,,170465371,2726,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
2513,1117329,1,1,,170465371,2726,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
2514,1117336,1,1,,170465371,2726,Active,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
2515,1117337,1,1,,170465371,2726,Inactive,,,10.0,IC50,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-IC50,Confirmatory,,
2516,1117340,1,1,,170465371,2726,Active,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
2517,1117341,1,1,,170465371,2726,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
2518,1117342,1,1,,170465371,2726,Active,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
2519,1117343,1,1,,170465371,2726,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
2520,1117346,1,1,,170465371,2726,Active,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
2521,1122478,1,1,,103169389,2726,Unspecified,,,,,Antimycobacterial against Mycobacterium smegmatis in presence of 25-desacetylrifampicin,Other,,
2522,1122479,1,1,,103169389,2726,Unspecified,,,,,Antimycobacterial against Mycobacterium smegmatis in presence of ciprofloxacin,Other,,
2523,1122480,1,1,,103169389,2726,Unspecified,,,,,Antimycobacterial against Mycobacterium smegmatis in presence of TMC207,Other,,
2524,1122481,1,1,,103169389,2726,Unspecified,,,,,Antimycobacterial against Mycobacterium smegmatis in presence of spectinomycin,Other,,
2525,1122482,1,1,,103169389,2726,Unspecified,,,,,Antimycobacterial against Mycobacterium smegmatis in presence of streptomycin,Other,,
2526,1122483,1,1,,103169389,2726,Unspecified,,,,,Antimycobacterial against Mycobacterium smegmatis in presence of kanamycin,Other,,
2527,1122484,1,1,,103169389,2726,Unspecified,,,,,Antimycobacterial against Mycobacterium smegmatis in presence of rifampicin,Other,,
2528,1122485,1,1,,103169389,2726,Unspecified,,,,,Antimycobacterial against Mycobacterium smegmatis,Other,,
2529,1123418,1,1,,103169389,2726,Unspecified,,,,,Induction of muscle relaxation/sedation in po dosed mouse by inclined screen test,Other,34039.0,
2530,1123419,1,1,,103169389,2726,Unspecified,,,,,Induction of taming effect in po dosed mouse by foot shock method,Other,34039.0,
2531,1123420,1,1,,103169389,2726,Unspecified,,,,,Muscle relaxing activity in po dosed cat,Other,34039.0,
2532,1123421,1,1,,103169389,2726,Unspecified,,,,,Anticonvulsant activity in po dosed mouse assessed as reduction of pentylenetetrazole-induced seizures,Other,34039.0,
2533,1123422,1,1,,103169389,2726,Unspecified,,,,,Anticonvulsant activity in po dosed mouse assessed as reduction of maximal electroshock-induced seizures,Other,34039.0,
2534,1123423,1,1,,103169389,2726,Unspecified,,,,,Anticonvulsant activity in po dosed mouse assessed as reduction of minimal electroshock-induced seizures,Other,34039.0,
2535,1123424,1,1,,103169389,2726,Unspecified,,,,,Toxicity in mouse assessed as effect on central nervous system,Other,34039.0,
2536,1123508,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in STD-ddy mouse assessed as inhibition of locomotion at 100 mg/kg, po measured for 3 mins",Other,37336.0,
2537,1123509,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in STD-ddy mouse assessed as inhibition of locomotion at 10 mg/kg, po measured for 3 mins",Other,37336.0,
2538,1123510,1,1,,103169389,2726,Active,,,,,"Neuroleptic activity in STD-ddy mouse assessed as muscle relaxation at 100 mg/kg, po after 20 mins",Other,37336.0,
2539,1123511,1,1,,103169389,2726,Active,,,,,"Neuroleptic activity in STD-ddy mouse assessed as catalepsy at 100 mg/kg, po measured up to 30 secs",Other,37336.0,
2540,1123513,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in Wistar HLA rat assessed as inhibition of methamphetamine-induced stereotyped behavior at 2 mg/kg, ip administered 20 mins before methamphetamine challenge measured every 30 mins for 3 hrs followed by every 1 hr for further 3 hrs",Other,37336.0,
2541,1123514,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in Wistar HLA rat assessed as inhibition of methamphetamine-induced stereotyped behavior at 5 mg/kg, ip administered 20 mins before methamphetamine challenge measured every 30 mins for 3 hrs followed by every 1 hr for further 3 hrs",Other,37336.0,
2542,1123515,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in Wistar HLA rat assessed as inhibition of methamphetamine-induced stereotyped behavior at 10 mg/kg, ip administered 20 mins before methamphetamine challenge measured every 30 mins for 3 hrs followed by every 1 hr for further 3 hrs",Other,37336.0,
2543,1123519,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in po dosed STD-ddy mouse assessed as inhibition of methamphetamine-induced stereotyped behavior administered 100 mins before methamphetamine challenge measured for 20 mins,Other,37336.0,
2544,1123520,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in sc dosed Wistar HLA rat assessed as inhibition of apomorphine-induced gnawing administered 1 hr before apomorphine challenge measured 5 to 20 mins,Other,37336.0,
2545,1123521,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in po dosed STD-ddy mouse assessed as inhibition of locomotion measured for 3 mins,Other,37336.0,
2546,1123522,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in po dosed STD-ddy mouse assessed as catalepsy measured up to 30 secs,Other,37336.0,
2547,1123523,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in po dosed STD-ddy mouse assessed as inhibition of active avoidance,Other,37336.0,
2548,1123524,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in po dosed Wistar HLA rat assessed as inhibition of intracranial self-stimulation measured for 1 to 24 hrs,Other,37336.0,
2549,1123525,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in ip dosed Wistar HLA rat assessed as inhibition of intracranial self-stimulation measured for 1 to 24 hrs,Other,37336.0,
2550,1123529,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in po dosed rat assessed as concentration required to cause 50% reduction of motor activity,Other,37338.0,
2551,1123530,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in po dosed mouse assessed as inhibition of d-amphetamine sulfate-induced lethality administered for 0.5 hrs followed by d-amphetamine sulfate challenge measured after 24 hrs,Other,37338.0,
2552,1123533,1,1,,103169389,2726,Inactive,,,,,"Antidepressant activity in mouse assessed as inhibition of tetrabenazine hexamate-induced depression at 25 mg/kg, po administered 1 hr followed by tetrabenazine hexamate challenge measured after 30 mins",Other,37338.0,
2553,1123535,1,1,,103169389,2726,Unspecified,,,,,Induction of catalepsy in po dosed rat measured for 0.5 to 18 hrs,Other,37338.0,
2554,1133173,1,1,,103169389,2726,Unspecified,,,794.328,Ki,Inhibition of mouse brain synaptosomal Lysophosphatidylcholine acyltransferase using substrate [32P]lysophosphatidylcholine and oleoyl-CoA,Confirmatory,722729.0,
2555,1133174,1,1,,103169389,2726,Unspecified,,,,,Antihemolytic potency against hypotonic lysis-induced erythrocytes (unknown origin) assessed as stabilization,Other,722729.0,
2556,1133175,3,1,,103169389,2726,Unspecified,,,,,"Molar volume, Vm of the compound at zero temperature",Other,722729.0,
2557,1134064,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in ip dosed mouse assessed as inhibition of amphetamine-induced mortality,Other,853506.0,
2558,1134065,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in ip dosed rat assessed as drug required for blocking discriminated jump-out avoidance behavior in after 1 hr,Other,853506.0,
2559,1135128,1,1,,103169389,2726,Unspecified,,,,,Antipsychotic activity in ip dosed rat assessed as reduction in avoidance responding by Sidman avoidance test,Other,15111.0,
2560,1135928,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in ip dosed ICR-DUB mouse assessed as survival administered 1 hr prior to d-amphetamine challenge measured after 24 hrs,Other,22753.0,
2561,1135930,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in ip dosed ICR-DUB mouse assessed as survival administered 16 hrs prior to d-amphetamine challenge measured after 24 hrs,Other,22753.0,
2562,1135931,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in ip dosed ICR-DUB mouse assessed as survival administered 2 days prior to d-amphetamine challenge measured after 24 hrs,Other,22753.0,
2563,1135932,1,1,,103169389,2726,Active,,,,,Neuroleptic activity in ip dosed ICR-DUB mouse assessed as survival administered 3 days prior to d-amphetamine challenge measured after 24 hrs,Other,22753.0,
2564,1135944,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in mouse assessed as suppression of conditioned avoidance behavior by measuring mean correct responses level at 10 mg/kg, ip administered immediately prior to electric shock challenge",Other,22753.0,
2565,1135945,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in mouse assessed as suppression of conditioned avoidance behavior by measuring mean correct responses level at 10 mg/kg, ip administered 1 hr prior to electric shock challenge",Other,22753.0,
2566,1135946,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in mouse assessed as suppression of conditioned avoidance behavior by measuring mean correct responses level at 10 mg/kg, ip administered 2 hrs prior to electric shock challenge",Other,22753.0,
2567,1135947,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in mouse assessed as suppression of conditioned avoidance behavior by measuring mean correct responses level at 10 mg/kg, ip administered 8 hrs prior to electric shock challenge",Other,22753.0,
2568,1135948,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in mouse assessed as suppression of conditioned avoidance behavior by measuring mean correct responses level at 10 mg/kg, ip administered 1 day prior to electric shock challenge",Other,22753.0,
2569,1135949,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in mouse assessed as suppression of conditioned avoidance behavior by measuring mean correct responses level at 10 mg/kg, ip administered 2 days prior to electric shock challenge",Other,22753.0,
2570,1135954,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in mouse assessed as suppression of conditioned avoidance behavior by measuring mean correct responses level at 10 mg/kg, ip administered 4 hrs prior to electric shock challenge",Other,22753.0,
2571,1136082,3,1,,103169389,2726,Active,,,2.5,IC50,Displacement of [3H]-DA from dopamine receptor in calf caudate membranes after 15 mins by liquid scintillation counting analysis,Confirmatory,25967.0,
2572,1136083,3,1,,103169389,2726,Active,,,0.034,IC50,Displacement of [3H]-HALO from dopamine receptor in calf caudate membranes after 10 mins by liquid scintillation counting analysis,Confirmatory,25967.0,
2573,1136084,1,1,,103169389,2726,Unspecified,,,,,Ratio of IC50 for displacement of [3H]-DA from dopamine receptor in calf caudate membranes to IC50 for displacement of [3H]-HALO from dopamine receptor in calf caudate membranes,Other,25967.0,
2574,1136085,1,1,,103169389,2726,Unspecified,,,,,Antipsychotic activity in ip dosed HAM/ICR mouse assessed as protection against d-amphetamine-induced lethality administered 30 mins followed by d-amphetamine challenge measured after 30 mins,Other,25967.0,
2575,1136088,1,1,,103169389,2726,Unspecified,,,,,"Antipsychotic activity in HAM/ICR mouse assessed as blockade of conditioned avoidance response at 2 mg/kg, ip measured after 30 mins relative to control",Other,25967.0,
2576,1136138,1,1,,103169389,2726,Unspecified,,,,,Ratio of MED for inhibition of amphetamine-induced stereotyped-behavior in ip dosed Sprague-Dawley rat to ED50 for suppression of conditioned avoidance response in ip dosed Sprague-Dawley rat,Other,27637.0,
2577,1136346,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in ip dosed Sprague-Dawley rat assessed as inhibition of Sidman avoidance measured for 4 to 6 hrs,Other,31478.0,
2578,1136347,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in po dosed Sprague-Dawley rat assessed as inhibition of Sidman avoidance measured for 4 to 6 hrs,Other,31478.0,
2579,1136350,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in ip dosed Long-Evans rat assessed as inhibition of pole-climb avoidance,Other,31478.0,
2580,1136351,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in ip dosed Long-Evans rat assessed as increase in escape failure,Other,31478.0,
2581,1136355,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in squirrel monkey assessed as inhibition of Sidman avoidance at 2.5 mg/kg, po measured for 4 hrs",Other,31478.0,
2582,1136358,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in squirrel monkey assessed as inhibition of Sidman avoidance at 5 mg/kg, po measured for 4 hrs",Other,31478.0,
2583,1136362,1,1,,103169389,2726,Unspecified,,,,,Non-specific toxicity in po dosed Beagle dog assessed as inhibition of apomorphine hydrochloride-induced emesis,Other,31478.0,
2584,1136364,1,1,,103169389,2726,Unspecified,,,,,Non-specific toxicity in ip dosed Wistar rat assessed as inhibition of amphetamine-induced circling administered 60 mins prior to amphetamine challenge,Other,31478.0,
2585,1136368,1,1,,103169389,2726,Unspecified,,,,,Non-specific toxicity in sc dosed Wistar rat assessed as inhibition of apomorphine hydrochloride-induced stereotypy administered 1 hr prior to apomorphine hydrochloride challenge measured after 5 to 20 mins,Other,31478.0,
2586,1136369,1,1,,103169389,2726,Unspecified,,,,,Non-specific toxicity in ip dosed Wistar rat assessed as inhibition of d-amphetamine sulfate-induced stereotypy administered 1 hr prior to d-amphetamine sulfate challenge measured after 55 to 65 mins,Other,31478.0,
2587,1136414,1,1,,103169389,2726,Active,,,,,"Antipsychotic activity in mouse assessed as protection against amphetamine-induced lethality at 5 mg/kg, ip treated 30 mins before amphetamine challenge",Other,31487.0,
2588,1136415,1,1,,103169389,2726,Active,,,,,"Antipsychotic activity in mouse assessed as protection against amphetamine-induced lethality at 50 mg/kg, ip treated 30 mins before amphetamine challenge",Other,31487.0,
2589,1136418,1,1,,103169389,2726,Active,,,,,"Antipsychotic activity in mouse assessed as increase in brain dopamine turnover at 25 to 30 mg/kg, ip pretreated with 200 mg/kg, ip alpha-methyl-p-tyrosine tyrosine hydroxylase inhibitor",Other,31487.0,
2590,1137410,1,1,,103169389,2726,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against pentylenetetrazole-induced clonic convulsions,Other,42799.0,
2591,1137411,1,1,,103169389,2726,Unspecified,,,,,Hypothermic activity in ip dosed albino CF1 mouse assessed as effect on body temperature measured after 45 mins,Other,42799.0,
2592,1137412,1,1,,103169389,2726,Unspecified,,,,,Inhibition of apomorphine-induced cage climbing in ip dosed albino CF1 mouse compound administered prior to challenge measured for 5 mins after 5 mins of challenge,Other,42799.0,
2593,1137413,1,1,,103169389,2726,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF1 mouse assessed as inhibition of bicucullin-induced tonic extensor convulsions,Other,42799.0,
2594,1137414,1,1,,103169389,2726,Unspecified,,,,,Antidepressant activity in ip dosed albino CF1 mouse assessed as potentiation of gamma-butyrolactone-induced sleep,Other,42799.0,
2595,1137415,1,1,,103169389,2726,Unspecified,,,,,Reduction of hypoxic stress in ip dosed albino CF1 mouse assessed as prolongation of hypoxic survival time,Other,42799.0,
2596,1137416,1,1,,103169389,2726,Unspecified,,,,,Inhibition of amphetamine aggregation toxicity in ip dosed albino CF1 mouse compound administered 1 hr prior to challenge measured after 2 hrs,Other,42799.0,
2597,1137417,1,1,,103169389,2726,Unspecified,,,,,Potentiation of yohimbine toxicity in ip dosed aggregated albino CF1 mouse,Other,42799.0,
2598,1137418,1,1,,103169389,2726,Unspecified,,,,,Inhibition of oxotremorine-induced hypothermia in ip dosed albino CF1 mouse,Other,42799.0,
2599,1137419,1,1,,103169389,2726,Unspecified,,,,,Potentiation of apomorphine-induced gnawing in ip dosed albino CF1 mouse,Other,42799.0,
2600,1142394,1,3,,103169389,2726,Active,118206.0,1813.0,0.0061,Ki,Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells,Confirmatory,24779610.0,
2601,1146455,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in ip dosed mouse assessed as blockade of righting reflex by measuring failure to right to normal position measured for 30 secs,Other,29124.0,
2602,1146456,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in ip dosed mouse assessed as blockade of traction reflex by measuring failure to grasp wire with hind paws measured for 5 secs,Other,29124.0,
2603,1146457,1,1,,103169389,2726,Unspecified,,,,,Neuroleptic activity in ip dosed mouse assessed as blockade of prehensile reflex by measuring failure to hang measured for 5 secs,Other,29124.0,
2604,1146458,1,2,,103169389,2726,Unspecified,,,,,Neuroleptic activity in ip dosed mouse assessed as blockade of corneal reflex by measuring failure to blink,Other,29124.0,
2605,1146463,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in gerbil assessed as escape latency time at 2 mg/kg, ip measured up to 50 mins by sidman avoidance test relative to control",Other,29124.0,
2606,1146473,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in gerbil assessed as escape latency time at 0.5 mg/kg, ip measured up to 50 mins by sidman avoidance test relative to control",Other,29124.0,
2607,1146474,1,1,,103169389,2726,Unspecified,,,,,"Neuroleptic activity in gerbil assessed as escape latency time at 1 mg/kg, ip measured up to 50 mins by sidman avoidance test relative to control",Other,29124.0,
2608,1146482,1,1,,103169389,2726,Active,,,,,"Neuroleptic activity in wild fox assessed as taming effect at 4 mg/kg, ip",Other,29124.0,
2609,1146485,1,1,,103169389,2726,Unspecified,,,,,"Toxicity in wild fox assessed as ataxia at 4 mg/kg, ip",Other,29124.0,
2610,1147087,1,1,,103169389,2726,Inactive,,,,,"Antidepressant activity in Swiss-Webster mouse assessed as prevention of reserpine-induced ptosis at 1 to 50 mg/kg, ip",Other,403284.0,
2611,1147091,1,1,,103169389,2726,Unspecified,,,,,"Antipsychotic activity in po dosed Sprague-Dawley rat assessed as prevention of d-amphetamine-induced stereotyped behavior measured for 1 min after 90, 100, and 110 mins injection of amphetamine",Other,403284.0,
2612,1148003,1,1,,103169389,2726,Unspecified,,,,,"Dissociation constant, pKa of the compound by UV-visible spectrophotometer analysis",Other,576620.0,
2613,1148004,1,1,,103169389,2726,Unspecified,,,,,"Oleyl alcohol-water partition coefficient, Rm of the compound measured at 0% methanol by reverse-phase thin layer chromatography",Other,576620.0,
2614,1148005,2,1,,103169389,2726,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,576620.0,
2615,1148006,1,3,,103169389,2726,Unspecified,1351907.0,280717.0,,,Binding affinity to bovine serum albumin by circular dichroic probe technique,Other,576620.0,
2616,1148007,1,3,,103169389,2726,Unspecified,1351907.0,280717.0,,,Binding affinity to bovine serum albumin,Other,576620.0,
2617,1148008,1,3,,103169389,2726,Unspecified,1351907.0,280717.0,,,Binding affinity to bovine serum albumin assessed as intrinsic binding constant,Other,576620.0,
2618,1149103,1,1,,103169389,2726,Unspecified,,,,,Analgesic activity in po dosed mouse assessed as inhibition of acetic acid-induced writhing administered 30 mins prior to acetic acid challenge measured after 5 mins for 20 mins,Other,817021.0,
2619,1149108,1,1,,103169389,2726,Unspecified,,,,,"Analgesic activity in Sprague-Dawley rat assessed as increase in pain threshold at 20 mg/kg, po after 15 to 90 mins by tail flick test",Other,817021.0,
2620,1149116,1,1,,103169389,2726,Unspecified,,,,,"Antianxiety activity in albino BALB/cJ mouse assessed as reduction in footshock-induced fighting behavior at 5 mg/kg, po after 30 to 90 mins",Other,817021.0,
2621,1149120,1,1,,103169389,2726,Unspecified,,,,,"Antianxiety activity in Long-Evans rat assessed as reduction in motor activity at 10 mg/kg, po after 2 hrs relative to vehicle-treated control",Other,817021.0,
2622,1149132,1,1,,103169389,2726,Unspecified,,,,,"Antipsychotic activity in rat assessed as reduction of methamphetamine-induced hyperactivity at 5 mg/kg, po administered prior to methamphetamine challenge relative to vehicle-treated control",Other,817021.0,
2623,1149133,1,1,,103169389,2726,Unspecified,,,,,"Antipsychotic activity in rat assessed as reduction of methamphetamine-induced hyperactivity at 10 mg/kg, po administered prior to methamphetamine challenge relative to vehicle-treated control",Other,817021.0,
2624,1149137,1,1,,103169389,2726,Unspecified,,,,,"Antipsychotic activity in rat assessed as reduction of methamphetamine-induced hyperactivity at 20 mg/kg, po administered prior to methamphetamine challenge relative to vehicle-treated control",Other,817021.0,
2625,1152675,1,3,,103169389,2726,Active,118206.0,1813.0,,,Antagonist activity at human recombinant D2 receptor expressed in CHO-K1 cells assessed as inhibition of apomorphine-induced response treated 15 to 30 mins before agonist challenge by luminescence analysis,Other,24805037.0,
2626,1159387,1,2,,103169389,2726,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
2627,1159388,1,2,,103169389,2726,Unspecified,,,,,"ASTRAZENECA: Solubility in pH7.4 buffer using solid starting material using the method described in J. Assoc. Lab. Autom. 2011, 16, 276-284. Experimental range 0.10 to 1500 uM",Other,,
2628,1159389,1,2,,103169389,2726,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
2629,1159390,1,2,,103169389,2726,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
2630,1159394,1,2,,103169389,2726,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
2631,1159395,1,2,,103169389,2726,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in rat hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736",Other,,
2632,1159396,1,2,,103169389,2726,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
2633,1159509,1,1,,170465371,2726,Inconclusive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2634,1159515,1,1,,170465371,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2635,1159516,1,1,,170465371,2726,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2636,1159517,1,1,,170465371,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2637,1159518,1,1,,170465371,2726,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2638,1159519,1,1,,170465371,2726,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2639,1159520,1,1,,170465371,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2640,1159521,1,1,,170465371,2726,Inconclusive,15928672.0,19885.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2641,1159523,1,1,,170465371,2726,Inconclusive,15928672.0,19885.0,26.6032,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2642,1159524,1,1,,124879752,2726,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2643,1159525,1,1,,170465371,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2644,1159526,1,1,,170465371,2726,Inconclusive,119627033.0,3725.0,11.9856,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2645,1159527,1,1,,170465371,2726,Inconclusive,325495497.0,6256.0,6.74,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2646,1159528,1,1,,170465371,2726,Active,119627033.0,3725.0,9.16208,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2647,1159529,1,1,,170465371,2726,Inconclusive,,,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2648,1159531,1,1,,170465371,2726,Inconclusive,325495497.0,6256.0,17.5925,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2649,1159550,3,1,,252402355,2726,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
2650,1159551,1,1,,170465371,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2651,1159552,1,1,,170465371,2726,Active,325495463.0,5914.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2652,1159553,2,1,,170465371,2726,Inconclusive,325495463.0,5914.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2653,1159555,1,1,,170465371,2726,Active,325495463.0,5914.0,27.644000000000002,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2654,1159580,2,1,,268735291,2726,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
2655,1159580,2,1,,273002747,2726,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
2656,1159607,2,1,,312309757,2726,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
2657,1159614,1,2,,170465371,2726,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
2658,1159620,1,1,,103169389,2726,Active,,,,,Summary of drug indications.,Other,,
2659,1161115,1,1,,103169389,2726,Active,,,10.0,IC50,Inhibition of Mycobacterium tuberculosis NDH2,Confirmatory,25150092.0,
2660,1161117,1,1,,103169389,2726,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Ra after 5 days by serial macrobroth dilution method,Other,25150092.0,
2661,1167550,1,1,,103169389,2726,Unspecified,,,,,Permeability of the compound in 70:30 PBS:EtOH by PAMPA-BBB assay,Other,25282266.0,
2662,1169140,1,1,,103169389,2726,Unspecified,,,,,Retention time of the compound by EPSA supercritical fluid chromatography,Other,25313332.0,
2663,1182131,1,1,,103169389,2726,Unspecified,,,,,Antitubercular activity against Mycobacterium smegmatis by checkerboard assay,Other,24997576.0,
2664,1182132,1,1,,103169389,2726,Unspecified,,,,,Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of rifampicin,Other,24997576.0,
2665,1182133,1,1,,103169389,2726,Active,,,,,Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of 25-desacetylrifampicin,Other,24997576.0,
2666,1182134,1,1,,103169389,2726,Unspecified,,,,,Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of kanamycin,Other,24997576.0,
2667,1182135,1,1,,103169389,2726,Active,,,,,Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of spectinomycin,Other,24997576.0,
2668,1182140,1,1,,103169389,2726,Active,,,,,Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of 7-hydroxy chlorpromazine,Other,24997576.0,
2669,1182146,1,1,,103169389,2726,Unspecified,,,,,Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of rifampicin,Other,24997576.0,
2670,1182148,1,1,,103169389,2726,Unspecified,,,,,Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of 25-desacetylrifampicin,Other,24997576.0,
2671,1182149,1,1,,103169389,2726,Unspecified,,,,,Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of kanamycin,Other,24997576.0,
2672,1182150,1,1,,103169389,2726,Unspecified,,,,,Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of spectinomycin,Other,24997576.0,
2673,1182151,1,1,,103169389,2726,Unspecified,,,,,Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of 7-hydroxy chlorpromazine,Other,24997576.0,
2674,1189129,1,1,,103169389,2726,Active,,,17.15,IC50,"DNDI: Chagas in Vitro, 96 hour",Confirmatory,,
2675,1189130,1,1,,103169389,2726,Active,,,12.32,IC50,"DNDI: Cytotoxicity in Vitro, 72 hour, in rat skeletal myoblast cells",Confirmatory,,
2676,1189131,1,1,,103169389,2726,Active,,,31.36,IC50,"DNDI: Cytotoxicity in Vitro, 96 hour, in mouse macrophages (infected-amastigotes)",Confirmatory,,
2677,1189133,1,1,,103169389,2726,Active,,,1.25,IC50,"DNDI: HAT in Vitro, 72 hour",Confirmatory,,
2678,1189134,1,1,,103169389,2726,Active,,,48.45,IC50,"DNDI: Leish (axenic) in Vitro, 72 hour",Confirmatory,,
2679,1189135,1,1,,103169389,2726,Unspecified,,,9.41,IC50,"DNDI: Leish (macro) in Vitro, 96 hour",Confirmatory,,
2680,1189136,1,1,,103169389,2726,Active,,,3.03,IC50,"DNDI: Malaria in Vitro, 72 hour",Confirmatory,,
2681,1196324,2,1,,103169389,2726,Active,118206.0,1813.0,0.001,IC50,Antagonist activity at human dopamine D2 receptor expressed in CHOK1 cells assessed as inhibition of apomorphine-induced calcium mobilization by radiometric and luminescence plate counting method,Confirmatory,25557493.0,
2682,1196374,1,2,,103169389,2726,Active,118206.0,1813.0,0.001,IC50,Antagonist activity against human recombinant dopmaine D2L receptor expressed in CHOK1 cells assessed as reduction in apomorphine-induced increase in intracellular Ca2+ levels by aequorin based radiometric and luminescence plate counting method,Confirmatory,25557493.0,
2683,1201570,1,1,,103169389,2726,Unspecified,,,,,"Toxicity in NMRI mouse assessed as induction of hypoactivity at 10 mg/kg, ip",Other,25793650.0,
2684,1201571,1,1,,103169389,2726,Unspecified,,,,,"Toxicity in NMRI mouse assessed as induction of ataxia at 10 mg/kg, ip",Other,25793650.0,
2685,1201572,1,1,,103169389,2726,Unspecified,,,,,"Toxicity in NMRI mouse assessed as induction of sleep at 10 mg/kg, ip",Other,25793650.0,
2686,1201746,1,1,,103169389,2726,Unspecified,,,,,Permeability of the compound after 16 hrs by PAMPA,Other,25812965.0,
2687,1201747,1,1,,103169389,2726,Unspecified,,,,,Permeability of the compound by PAMPA,Other,25812965.0,
2688,1207150,1,1,,103169389,2726,Active,,,4.3,IC50,Inhibition of Na channel (species unknown),Confirmatory,21300721.0,
2689,1207209,1,1,,103169389,2726,Active,,,1.47,IC50,Inhibition of hERG K channel,Confirmatory,21300721.0,
2690,1207240,1,2,,103169389,2726,Active,,,,,Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range),Other,21300721.0,
2691,1207730,1,1,,103169389,2726,Active,,,3.4,IC50,"Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits",Confirmatory,23812503.0,
2692,1209455,1,2,,103169389,2726,Unspecified,262527527.0,8647.0,147.6,IC50,Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
2693,1209456,1,2,,103169389,2726,Unspecified,12585136.0,83569.0,122.3,IC50,Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
2694,1209457,1,1,,103169389,2726,Active,,,,,Unbound Cmax in human plasma,Other,21965623.0,
2695,1210069,1,2,,103169389,2726,Active,21264413.0,1573.0,24.4,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
2696,1210070,1,2,,103169389,2726,Active,84028191.0,1565.0,1.49,IC50,Inhibition of CYP2D6 in human liver microsomes using bufuralol substrate by LC-MS/MS method,Confirmatory,23033255.0,
2697,1210071,1,2,,103169389,2726,Active,116241312.0,1576.0,23.3,IC50,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,Confirmatory,23033255.0,
2698,1210072,1,2,,103169389,2726,Unspecified,6686268.0,1559.0,50.0,IC50,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,Confirmatory,23033255.0,
2699,1210073,1,2,,103169389,2726,Active,60416369.0,1557.0,34.1,IC50,Inhibition of CYP2C19 in human liver microsomes using omeprazole substrate by LC-MS/MS method,Confirmatory,23033255.0,
2700,1210074,1,2,,103169389,2726,Active,117144.0,1544.0,4.14,IC50,Inhibition of CYP1A2 in human liver microsomes using phenacetin substrate by LC-MS/MS method,Confirmatory,23033255.0,
2701,1210791,1,2,,103169389,2726,Active,215273968.0,316.0,0.62,Ki,Competitive inhibition of human liver cytosolic aldehyde oxidase using DACA as substrate assessed as free enzyme by Lineweaver-Burk plot analysis,Confirmatory,22996261.0,
2702,1210792,1,2,,103169389,2726,Inconclusive,215273968.0,316.0,,Ki,Uncompetitive inhibition of human liver cytosolic aldehyde oxidase using DACA as substrate assessed as enzyme-substrate complex by Lineweaver-Burk plot analysis,Confirmatory,22996261.0,
2703,1210793,1,2,,103169389,2726,Inconclusive,215273968.0,316.0,,,Ratio of Ki for uncompetitive inhibition of human liver cytosolic aldehyde oxidase to Ki for competitive inhibition of human liver cytosolic aldehyde oxidase,Other,22996261.0,
2704,1211791,1,1,,103169389,2726,Unspecified,,,,,Fraction unbound in human hepatocytes,Other,21998403.0,
2705,1211792,1,1,,103169389,2726,Unspecified,,,,,Hepatic clearance in human,Other,21998403.0,
2706,1211794,1,2,,103169389,2726,Unspecified,,,,,Fraction unbound in blood (not specified),Other,21998403.0,
2707,1211795,1,1,,103169389,2726,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21998403.0,
2708,1211796,1,1,,103169389,2726,Unspecified,,,,,Intrinsic clearance in cryopreserved human HepaRG cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
2709,1211797,1,1,,103169389,2726,Unspecified,,,,,Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
2710,1211798,1,1,,103169389,2726,Unspecified,,,,,Intrinsic clearance in human using well stirred liver model by LC-MS/MS method,Other,21998403.0,
2711,1215120,1,1,,103169389,2726,Active,,,0.184,Kd,Binding affinity to Wistar rat brain lipid by TRANSIL assay,Confirmatory,21071520.0,
2712,1215121,1,2,,103169389,2726,Unspecified,,,,,Fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method,Other,21071520.0,
2713,1215122,1,1,,103169389,2726,Unspecified,,,,,Fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay,Other,21071520.0,
2714,1215123,1,2,,103169389,2726,Active,124028612.0,24186.0,11.7,Kd,Binding affinity to Wistar rat serum albumin,Confirmatory,21071520.0,
2715,1215124,1,1,,103169389,2726,Unspecified,,,,,Binding affinity to Wistar rat brain lipid assessed as fraction unbound by TRANSIL assay,Other,21071520.0,
2716,1215127,1,2,,103169389,2726,Unspecified,,,,,Ratio of fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay to fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method,Other,21071520.0,
2717,1220554,1,2,,103169389,2726,Unspecified,,,,,Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
2718,1220555,1,2,,103169389,2726,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
2719,1220556,1,2,,103169389,2726,Unspecified,,,,,Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
2720,1220557,1,2,,103169389,2726,Unspecified,,,,,Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
2721,1220558,1,2,,103169389,2726,Unspecified,,,,,Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
2722,1220559,1,2,,103169389,2726,Unspecified,,,,,Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
2723,1220560,1,1,,103169389,2726,Unspecified,,,,,Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
2724,1222774,1,1,,103169389,2726,Unspecified,,,,,"Unbound hepatobiliary clearance in healthy human at 10 mg, iv bolus dose and 25, 50 and 100 mg, po",Other,23454828.0,
2725,1222775,1,1,,103169389,2726,Unspecified,,,,,"Unbound renal clearance in healthy human at 10 mg, iv bolus dose and 25, 50 and 100 mg, po",Other,23454828.0,
2726,1222776,1,1,,103169389,2726,Unspecified,,,,,"Systemic clearance in healthy human at 10 mg, iv bolus dose and 25, 50 and 100 mg, po",Other,23454828.0,
2727,1222777,1,1,,103169389,2726,Unspecified,,,,,"Fraction unbound in healthy human at 10 mg, iv bolus dose and 25, 50 and 100 mg, po",Other,23454828.0,
2728,1222793,1,1,,103169389,2726,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,23454828.0,
2729,1224834,3,1,,170465371,2726,Active,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
2730,1224835,1,1,,170465371,2726,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
2731,1224836,1,1,,170465371,2726,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2732,1224837,1,1,,170465371,2726,Inconclusive,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2733,1224838,1,1,,170465371,2726,Inconclusive,66775687.0,9970.0,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2734,1224839,1,1,,170465371,2726,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2735,1224840,3,1,,170465371,2726,Active,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
2736,1224841,3,1,,170465371,2726,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2737,1224842,3,1,,170465371,2726,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2738,1224843,1,1,,170465371,2726,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2739,1224844,1,1,,170465371,2726,Inconclusive,,,15.089,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
2740,1224845,1,1,,170465371,2726,Inconclusive,344243002.0,100757539.0,61.9315,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
2741,1224846,1,1,,170465371,2726,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
2742,1224847,1,1,,170465371,2726,Active,,,55.1965,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
2743,1224848,3,1,,170465371,2726,Inconclusive,325495545.0,2101.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2744,1224849,3,1,,170465371,2726,Inactive,325495545.0,2101.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2745,1224857,2,1,,170465371,2726,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
2746,1224859,2,1,,90340916,2726,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
2747,1224859,2,1,,170465371,2726,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
2748,1224863,1,1,,176484022,2726,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
2749,1224863,1,1,,176484866,2726,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
2750,1224863,1,1,,316919411,2726,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
2751,1224867,1,1,,170465371,2726,Active,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
2752,1224868,1,1,,170465371,2726,Active,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
2753,1224869,1,1,,170465371,2726,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
2754,1224870,1,1,,170465371,2726,Active,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
2755,1224871,1,1,,170465371,2726,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
2756,1224872,1,1,,170465371,2726,Active,,,21.3138,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
2757,1224873,1,1,,170465371,2726,Inconclusive,,,21.3138,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
2758,1224874,1,1,,170465371,2726,Active,,,21.3138,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
2759,1224875,1,1,,170465371,2726,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
2760,1224876,1,1,,170465371,2726,Active,,,21.3138,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
2761,1224877,1,1,,170465371,2726,Active,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
2762,1224878,1,1,,170465371,2726,Active,,,21.3138,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
2763,1224879,1,1,,170465371,2726,Active,,,21.3138,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
2764,1224880,1,1,,170465371,2726,Inconclusive,,,16.9301,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
2765,1224881,1,1,,170465371,2726,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
2766,1224882,1,1,,170465371,2726,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
2767,1224883,1,1,,170465371,2726,Active,,,23.9145,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
2768,1224884,1,1,,170465371,2726,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
2769,1224885,1,1,,170465371,2726,Active,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
2770,1224886,1,1,,170465371,2726,Active,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
2771,1224887,1,1,,170465371,2726,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
2772,1224888,1,1,,170465371,2726,Active,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
2773,1224889,1,1,,170465371,2726,Inconclusive,,,18.9959,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
2774,1224890,1,1,,170465371,2726,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
2775,1224892,1,1,,170465371,2726,Inconclusive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2776,1224893,1,1,,170465371,2726,Inconclusive,66775687.0,9970.0,28.7255,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2777,1224894,1,1,,170465371,2726,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
2778,1224895,1,1,,170465371,2726,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2779,1224896,1,1,,170465371,2726,Inconclusive,344243002.0,100757539.0,58.4671,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
2780,1224905,2,1,,92308728,2726,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
2781,1224905,2,1,,92308728,2726,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
2782,1224905,2,1,,252566369,2726,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
2783,1224905,2,1,,252566369,2726,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
2784,1245889,1,1,,103169389,2726,Active,,,30.3,GI50,Cytotoxicity against human NCI-H1650 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,26372073.0,
2785,1247107,1,1,,103169389,2726,Active,,,21.0,IC50,Displacement of [3H]MK-801 from NMDA receptor in Wistar rat brain membranes by scintillation counting analysis,Confirmatory,26296478.0,
2786,1259241,1,1,,170465371,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
2787,1259242,1,1,,170465371,2726,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
2788,1259243,1,1,,170465371,2726,Active,124375976.0,367.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
2789,1259244,1,1,,170465371,2726,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
2790,1259247,1,1,,170465371,2726,Inconclusive,124375976.0,367.0,29.8493,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
2791,1259248,1,1,,170465371,2726,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
2792,1259310,1,1,,332876302,2726,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
2793,1259325,1,2,,336954197,2726,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
2794,1259344,1,1,,144203671,2726,Active,,,3.1623,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
2795,1259355,1,1,,26751621,2726,Inconclusive,,,35.4813,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
2796,1259356,1,1,,144203671,2726,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
2797,1259364,1,1,,170465371,2726,Inconclusive,1013403374.0,9734.0,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
2798,1259365,1,1,,170465371,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
2799,1259366,1,1,,170465371,2726,Active,,,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2800,1259367,1,1,,170465371,2726,Inconclusive,,,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2801,1259368,1,1,,170465371,2726,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2802,1259369,1,1,,170465371,2726,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2803,1259377,1,1,,170465371,2726,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2804,1259378,1,1,,170465371,2726,Active,54288833.0,2100.0,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2805,1259379,1,1,,170465371,2726,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2806,1259380,1,1,,170465371,2726,Active,,,16.7855,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2807,1259381,1,1,,170465371,2726,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
2808,1259382,1,1,,170465371,2726,Active,,,18.8336,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2809,1259383,1,1,,170465371,2726,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
2810,1259384,1,1,,170465371,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
2811,1259385,1,1,,170465371,2726,Active,119601739.0,7253.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2812,1259386,1,1,,170465371,2726,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2813,1259387,1,1,,170465371,2726,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
2814,1259388,1,1,,170465371,2726,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
2815,1259389,1,1,,124637878,2726,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
2816,1259390,1,1,,170465371,2726,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2817,1259391,1,1,,170465371,2726,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
2818,1259392,1,1,,170465371,2726,Inconclusive,109731339.0,2737.0,5.0111099999999995,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2819,1259393,1,1,,170465371,2726,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
2820,1259394,1,1,,170465371,2726,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2821,1259395,1,1,,170465371,2726,Active,119601739.0,7253.0,26.6032,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2822,1259396,1,1,,170465371,2726,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2823,1259400,1,1,,170465371,2726,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
2824,1259401,1,1,,170465371,2726,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2825,1259402,1,1,,170465371,2726,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2826,1259403,1,1,,170465371,2726,Inconclusive,325495545.0,2101.0,29.8493,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2827,1259404,1,1,,170465371,2726,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2828,1259407,1,1,,363901661,2726,Inactive,,,,,CCRIS mutagenicity studies,Other,,
2829,1259408,1,1,,363894764,2726,Unspecified,,,,,GENE-TOX mutagenicity studies,Other,,
2830,1259410,1,1,,363901661,2726,Unspecified,,,,,CCRIS tumor promotion studies,Other,,
2831,1259416,1,2,,340079697,2726,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
2832,1259416,1,2,,375177964,2726,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
2833,1259419,1,1,,135650088,2726,Active,260099679.0,3356.0,,,Human 5-HT2A receptor (5-Hydroxytryptamine receptors),Other,12629531.0,
2834,1259421,1,1,,340079697,2726,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
2835,1259421,1,1,,375177964,2726,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
2836,1259423,1,2,,354779417,2726,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
2837,1259423,1,2,,354809238,2726,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
2838,1259423,1,2,,354938931,2726,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
2839,1259423,1,2,,354965022,2726,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
2840,1259423,1,2,,355010249,2726,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
